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Abstract 
 
Abnormal regulation of various posttranslational modifications (PTMs) of microtubule-
associated protein tau induce its self-aggregation, which is a hallmark pathophysiological 
process of neurodegenerative diseases (NDDs) collectively called as tauopathies including 
Alzheimer’s disease (AD) and frontotemporal dementia. Increased tau phosphorylation is 
a key PTM in conversion of tau into more toxic species in cells, which is regulated by 
interactions of various protein kinases and phosphatases. However, the exact 
mechanism(s) of how various combinatory PTMs affect aggregation and cell-to-cell 
propagation of tau are poorly understood. We developed a novel live cell reporter system 
based on protein-fragment complementation assay (PCA) and studied dynamic protein-
protein interactions of tau in native cellular environment. The PCA was further validated 
on investigating cellular secretion and uptake of tau in live cells. A proof-of-concept 
screen was performed using PCA platform revealed several GABAA receptor activators 
that altered the interaction of tau-Pin1. Pin1 act as a critical facilitator of tau 
dephosphorylation by catalyzing the isomerization of cis/trans peptidyl-prolyl bond at 
phosphorylated Thr231-Pro motif of tau. Additionally, we showed that screen-identified 
GABAA receptor modulators increased tau phosphorylation at the AT8 phosphoepitope in 
cultures of mature primary cortical neurons and remained at elevated level 24 h after 
washout of the drugs. Mechanistic studies suggested that enhanced GABAA receptor-
induced tau phosphorylation was associated with decreased interaction of tau and protein 
phosphatase 2A (PP2A) without any reduction in enzymatic activity of PP2A and 
involved CDK5 kinase. Furthermore, the assessment of expression and splicing status of 
late-onset AD (LOAD) susceptibility genes in our neuropathologically validated AD 
cohort of post mortem brain samples revealed increased expression of MS4A6A and 
decreased expression of FRMD4A in regards to increased AD-related neurofibrillary 
pathology according to Braak staging. Moreover, the expression level of FRMD4A was 
functionally associated with amyloidogenic APP processing and increased tau 
phosphorylation in vitro. FRMD4A expression levels also correlated with cellular tau 
secretion assessed by PCA-based assay platform using siRNA-mediated gene silencing. 
Subsequent mechanistic studies on secretion showed a more general involvement of cell 
polarity complex signaling including Par3/Par6/aPKC? complex-induced activation of 
Arf6 via cytohesins. These novel connections of altered FRMD4A expression level in AD 
brain and its impact on cellular tau secretion further corroborate the suggested role of 
FRMD4A in LOAD pathogenesis and pathophysiology. Here, for the first time, we 
assessed a functional association between LOAD-related susceptibility gene and cell-to-
cell propagation of tau, and also showed the decreased expression of FRMD4A related to 
increasing disease severity according to Braak staging.             
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1 Introduction  
 
Plethora of molecular interactions governs the functions and eventually determines the 
fate of the cell in a highly complex cellular environment. In particular, the functionality of 
the cell is regulated by dynamic protein interaction network predominantly via formation 
of multi-protein complexes. Despite of the vast investigation effort, the majority of the 
protein interaction patterns are poorly understood, which is due to the immense amount of 
protein pathways that encompass the physiological function of the cell. Aberrations in 
cellular protein-protein interactions are, however, widely recognized and typically closely 
associated with various pathological disorders. Hence, more profound understanding of 
both physiological and pathophysiological protein-protein interactions maintaining the 
cellular integrity would provide novel insight and possible therapeutic strategies on 
addressing these interactions contributing to cellular dysfunction (Arkin & Wells 2004).         
 Protein misfolding and subsequent aggregation in the central nervous system (CNS) is 
a characteristic pathological feature of numerous neurodegenerative disorders (NDDs) 
(Lee et al., 2001; Ballatore et al., 2007). Cerebral accumulation of microtubule-associated 
protein tau (MAPT) defines a group of NDDs referred as tauopathies, in which 
intracellular tau formations called neurofibrillary tangles (NFTs) are the most prominent 
neuropathological hallmark inclusions. Specifically, the formation of these filamentous 
depositions is driven by disequilibrium of multiple posttranslational modifications (PTMs) 
of tau such as aberrant phosphorylation, which is the most studied and disease-associated 
PTM of tau in tauopathies including e.g. Alzheimer’s disease (AD) and frontotemporal 
dementia. Importantly, although tau pathology occurs in various NDDs with additional 
pathologies, toxic gain-of-functions and loss of normal microtubule stabilizing function 
are alone sufficient to cause tau-driven neurodegeneration independently of involvement 
of possible concomitant pathologies.  
 The increased knowledge of the genetic landscape of sporadic, late-onset AD (LOAD) 
that represent more than 95% of all AD cases, has been mainly provided by genome-wide 
association studies (GWAS) (e.g. Karch & Goate 2015; Chouraki & Seshadri 2014; 
Lambert et al., 2013b). Given that causative factors underlying LOAD pathogenesis are 
mainly currently unknown, the emergence of large number of LOAD-associated 
susceptibility genes within the past few years have critically broaden the understanding of 
possible genes contributing to disease pathogenesis besides APOE, which is the strongest 
known risk factor after aging. However, the functional association of identified LOAD 
susceptibility genes with established AD-related pathophysiological pathways and the 
specific expression and splicing profiles during the disease progression remains largely 
elusive. Accordingly, several single-nucleotide polymorphisms (SNPs) are located either 
in non-coding or intergenic regions of the identified loci, and, the subtle effect of each 
individual gene conferring the LOAD risk are both significantly hindering the 
investigation of these genes in existing disease models. Nonetheless, GWAS-induced 
acceleration of studying the genetics of LOAD has generated a tremendous amount of 
opportunities for variable approaches towards targeting the pathophysiological pathways 
underlying the disease pathogenesis.  
 Accumulating evidence on prion-like spreading of various disease-specific proteins 
implicate an existence of a common mechanism for spreading of pathology in NDDs 
(Brettschneider et al., 2015; Guo & Lee 2014). A prion paradigm -hypothesis suggest that 
 2 
amyloidogenic non-prion proteins, including e.g. amyloid-? (A?), ?-synuclein, TDP-43 
and superoxidase dismutase 1, huntingtin and tau in AD, Parkinson’s disease, 
Huntington’s disease, amyotrophic lateral sclerosis and tauopathies, respectively, may 
share a common or similar mechanism with prions for cell-to-cell transmission of 
pathology between distinct brain regions. In prion disease, such as Creutzfeldt-Jacob 
disease (CJD), normal cellular prion protein converts into conformationally altered 
misfolded protein, which is further capable of recruiting and inducing the conformational 
switch of their normal counterparts, a perpetual process referred as seeding fibrillization 
(Prusiner 1982; Aguzzi 2009; Aguzzi et al., 2008). Upon growth of prion aggregates they 
also fragment and spread thereby generating a loop of subsequent seeding of 
conformationally distinct variants, or strains. This has been also suggested to be the 
mechanism in non-prion proteinopathies, such as tauopathies. However, the exact 
molecular mechanism(s) of how and which protein species are actively secreted from the 
cell to extracellular space and how these protein species, or strains, are internalized by 
adjacent cells are poorly understood. 
 Demographic aging, particularly in developed societies generates increasing socio-
economical burden within the next few decades caused by dementias and other NDDs. 
Therefore, it is of high importance to address the investigation effort towards elucidation 
of molecular mechanisms of pathophysiological pathways of NDDs. Since the 
development of novel therapeutics is expensive and time consuming and early diagnosis 
of NDDs in patients is highly challenging, it is essential to try to focus the research to 
early aberrant disease-specific protein-protein interactions. Furthermore, according to AD 
and related tauopathies, it is fundamental to characterize the multiple cascade-event 
eventually leading to tau-mediated neurodegeneration. Specifically, to investigate the 
contribution of expression and splicing status of currently identified LOAD susceptibility 
genes to disease pathogenesis and progression, and study how these genes may be 
functionally associated with cell-to-cell propagation of tau pathology could reveal novel 
therapeutic targets in treatment of these disorders.       
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2 Review of literature – Biology of microtubule-associated protein tau  
2.1 Structure and functions 
 
Microtubules (MTs) are components that maintain the structure of cytoskeleton 
organization in cells (e.g. Meraz-Rios et al., 2010). This is essential to formation of axons 
and dendrites that are both highly important in intracellular cargo trafficking of various 
molecules such as proteins, and also play a crucial role in transsynaptic signalling. 
Microtubule-associated protein tau (MAPT) is a major cytoskeletal-associated protein, 
encoded by MAPT gene that is located on chromosome 17q21 (Neve et al., 1986). MAPT 
contains 16 exons, from which 13 are included in the primary transcript due to an 
exclusion of exons 4a, 6 and 8 in the human brain (figure 2.1) (Buee et al., 2000). 
However, exons 4a, 6 and 8 are specific for peripheral tau expression. Constitutive tau 
exons 1,4, 5, 7, 9, 11, 12 and 13 are transcribed and translated into a protein unlike exons  
-1 (part of the promoter region) and 14, which are only transcribed but not translated 
(Goedert et al., 1989a). 
 Tau is a member of neuronal microtubule-binding protein (MAP) family with other 
proteins such as MAP1 and MAP2 (Iqbal et al., 2005). Tau is functionally the major MT-
associated protein in neurons where its main functions are to stabilize and promote the 
assembly and disassembly of MTs (Weingarten et al., 1975). Tau binds to MTs via 
microtubule binding repeats that are located in the microtubule-binding repeat domain 
(MBRD) at the C-terminal part of tau (Lee et al., 1989). Microtubule-binding repeats are 
encoded by exons 9, 10, 11 and 12. MBRD can also be further diveded in two regions, 
including microtubule-binding region and acidic region, which covers the most C-teminal 
part of MBRD (e.g. Meraz-Rios et al., 2010; Wang & Liu 2008). The microtubule-binding 
region of the MBRD consists of either three (3R-tau, repeats R1, R3, R4) or four (4R-tau, 
repeats R1, R2, R3, R4) similar but not identical repetitive sequences of 31 or 32 amino 
acids (aa) residues (Lee et al., 1989; Iqbal et al., 2009). These two isoforms are due to 
alternative splicing of exon 10 encoding the R2-repeat (Andreadis et al., 1992; Hernandez 
& Avila 2007).  
 Alternative splicing of exons 2, 3 and 10 in tau mRNA results in six tau isoforms in the 
human brain (Andreadis et al., 1992; Goedert et al., 1989a). Exon 3 is exon 2 dependent, 
i.e. exon 3 is never included in the final protein if the exon 2 is absent, whereas expression 
of exon 2 is independent of exon 3 (Andreadis et al., 1995). These six human tau isoforms 
resulting from the presence or absence of alternatively spliced exons 2, 3 and 10 differ in 
length ranging from 351 to 441 aa (Goedert et al., 1989a; Kosik et al., 1989; Goedert et 
al., 1989b).  
 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. A schematic representation of the MAPT gene, primary transcript and 
domain structure of six human tau isoforms expressed in the central nervous system. 
The human MAPT gene encoding tau protein is located on chromosome 17q21. From the 
16 exons of the MAPT gene (upper panel), 13 exons are transcribed in the primary 
transcript (exons 4A, 6 and 8 are specific for peripheral tau and are not present in the 
human brain mRNA) (middle panel). Exon -1, which is part of the promoter, and exon 14 
are both transcribed but not translated into a protein. Six tau isoforms are found in the 
human brain produced by constitutive exons 1, 4, 5, 7, 9, 11, 12 and 13, and alternative 
splicing of exons 2, 3 and 10 (lower panel). Differences between the isoforms are due to 
presence or absence of one or two amino-terminal inserts of 29 amino acids (0N, 1N, 2N) 
encoded by exons 2 and 3 combined with carboxy-terminal inserts of either 3 (R1, R3 and 
R4) or 4 (R1-R4) repeat-regions. R2 repeat-region is encoded by exon 10. These six tau 
isoforms vary in lenght including 352, 381, 383, 410, 412 or 441 amino acids (with exon 
combinations of 2-3-10-; 2+3-10-; 2-3-10+; 2+3+10-; 2+3-10+; 2+3+10+, respectively). 
All tau isoforms have been found in the adult human brain, but only the shortest isoform 
0N/3R, is expressed in fetal human brain. Tau protein can be divided into N-terminal 
acidic region, proline-rich region, microtubule-binding repeat domain (MBRD) or repeat 
region and C-terminus. Modified from Gendron & Petrucelli et al., 2009. 
 
 
Two structurally distinct domains called projection domain and microtubule-binding 
repeat domain exist in tau (e.g. Meraz-Rios et al., 2010; Wang & Liu 2008). The N-
terminally located projection domain is reported to project from the surface of 
microtubules (Hirokawa et al., 1988). Tau projection domain can be further divided into 
two separate regions (e.g. Meraz-Rios et al., 2010; Wang & Liu 2008), from which the C-
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terminal proline rich region is positively charged. Conversely, the N-terminal projection 
domain region consists of predominantly acidic residues resulting in negatively charged 
region. Exons 2 and 3 encode 29 aa long sequences in the N-terminal projection domain, 
which can exist in variable patterns, i.e. the N-terminus can contain either two, one or zero 
29 aa insertions (namely 2N, 1N and 0N respectively). Another region of the projection 
domain, called proline-rich region, modulates the length of N-terminal part of projection 
domain hence modifying the overall length of the protein (Buee et al., 2000). The exact 
function(s) of the projection domain is yet to be elucidated but it is known to interact with 
other cytoskeleton related proteins such as neurofilaments and plasma membrane (Brandt 
et al., 1995; Hirokawa et al., 1988). Furthermore, phosphorylation-dependent interaction 
between tau and MTs is suggested to occur via regulation of the proline-rich region (Lee 
et al., 2004). 
 All six tau isoforms are expressed in the adult human brain whereas only the shortest 
0N/3R is found in the fetal human brain (Kosik et al., 1989; Goedert et al., 1989b). 2R-
repeat in the 4R-tau and the presence of either one or both of the N-terminal inserts 
increase the microtubule-binding affinity of tau potentiating the longest 2N/4R isoform to 
be the most efficient in promoting MT-assembly (e.g. Lu & Kosik 2001; Alonso et al., 
2001b). Besides the R2 repeat, a specific peptide sequence located at the interregion of 
repeats R1 and R2 is suggested as a region that most efficiently induces the MT 
polymerization (Goode & Feinstein 1994). 
 Tau has been reported to have physiological functions outside of regulation of MT 
dynamics. First, nuclear tau localization, where tau is found to exist in less soluble form, 
suggests that tau is specifically modified either posttranslationally or via interaction with 
other proteins (Brady et al., 1995). Secondly, induction of paired helical filament (PHF) 
formation is activated by binding of tau to RNA through MBRD (Kampers et al., 1996). 
Thirdly, tau interferes with binding of kinesin and kinesin-like proteins to MTs, which 
further disrupts axonal cargo transport (Tatebayashi et al., 2004) and participates in cell 
viability maintenance by antagonizing apoptosis (Li et al., 2007). Although tau is 
predominantly considered to be an axonal protein, additional role of tau in dendrites has 
been reported suggesting that tau mediates A?-toxicity in AD (Ittner et al., 2010). 
Specifically, Src-family tyrosine kinase Fyn interacts with tau via its projection domain. 
In tau knockout mice, the postsynaptic targeting of Fyn was found to be diminished, 
which resulted in decreased N-methyl-D-aspartate (NMDA) receptor phosphorylation that 
mitigated NMDA receptor-mediated excitotoxicity. This reduction of excitotoxicity 
subsequently decreases toxicity of A? (Ittner et al., 2010). 
2.2 Regulation of tau phosphorylation and dephosphorylation 
 
Like all other phosphoproteins, the biological activity of tau is also regulated by its 
phosphorylation status (e.g. Alonso et al., 1994; Kopke et al., 1993). In addition to tau 
expression, also its phosphorylation is developmentally regulated; e.g. the shortest isoform 
(0N/3R) in fetal and postnatal human brain has high phosphorylation status whereas in 
healthy adult brain it is markedly reduced (Goedert et al., 1993). Furhermore, increase in 
tau phosphorylation in mitotic stage of cell cycle has been observed indicating that tau 
phosphorylation is also functionally regulated (Delobel et al., 2002). Thus, these data 
implicate that both developmental and functional regulation of tau phosphorylation are 
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essential in modulation of MT stabilization and dynamics during normal neurite formation 
and other MT-associated functions (Wang & Liu 2008). Moreover, upon hypo- or 
hyperphosphorylation tau loses its ability to bind MTs, which indicates the importance of 
phosphorylation at specific sites in order to maintain high affinity to bind MTs and 
properly function as a MT stabilizing protein (Garcia de Ancos et al., 1993). Conversely, 
phosphorylation at certain sites may decrease or even prevent MT binding and stabilizing 
capacity of tau further inducing its self-aggregation.  
 Multiple protein kinases, each of which has a preference toward specific region or site, 
catalyze tau phosphorylation (e.g. Liu et al., 2007). Of these kinases, more than ten have 
been shown to phosphorylate serine (Ser) and threonine (Thr) residues in vitro. The 
protein kinases that participate in tau phosphorylation can be divided in two distinct 
groups according to their motif-specifity: proline-directed protein kinases and non-
proline-directed protein kinases (e.g. Meraz-Rios et al., 2010; Wang & Liu 2008). The 
proline-directed protein kinases -group includes kinases such as DYRK1A, MAP-kinases, 
ERK1/2, CDK5 and GSK-3?, from which the latter is the most strongly associated with 
tau hyperphosphorylation in AD pathogenesis (e.g. Gong et al., 2005; Wang & Liu 2008; 
Grimes & Jope 2001). Kinases such as PKA, PKC and CaMKII are included in the non-
proline-directed protein kinases. Conversely to phosphorylation, all the major protein 
phosphatases (PPs), with the exception of PP2C, are capable of dephosphorylating tau 
(Liu et al., 2005). Of these PPs including PP1, PP2A, PP2B and PP5, PP2A has the 
highest efficacy in tau dephosphorylation. Additionally to role of PPs and kinases in 
regulation of tau phosphorylation, the conformational state of tau strongly affects the rate 
and extent of phosphorylation (Alonso Adel et al., 2004). The changes in conformational 
state of tau may promote phosphorylation in two ways: tau may become a more suitable 
substrate for protein kinases and/or a specific conformation may reduce the efficacy of 
dephosphorylation by making tau less favourable substrate to PPs (Iqbal et al., 2005). 
Moreover, a process called tau priming phosphorylation by certain protein kinases 
significantly promotes the subsequent proline-directed protein kinase phosphorylation 
which may further promote hyperphosphorylation (Liu et al., 2004).  
 In the longest human brain tau isoform (2N/4R, 441 aa) there are at least 80 putative 
phosphorylated Ser and Thr residues (Gong et al., 2005; Wang & Liu 2008). More than 30 
of these sites have been identified in PHF-tau in AD brain. The localization of these sites 
is predominantly concentrated in the proline-rich region (residues 172-251, numbering 
according to the longest isoform 2N/4R) and C-terminal region (residues 368-441), which 
is flanking the MBRD (Gong et al., 2005; Wang & Liu 2008; Liu et al., 2007). 
Additionally, some of the sites are localized in MBRD, including Ser262 (R1), Ser285 
(R1-R2 inter-repeat), Ser305 (R3-R4 inter-repeat), Ser324 (R3), Ser352 (R4) and Ser356 
(R4). Compared to hyperphosphorylation in other regions or sites of tau, 
hyperphosphorylation at sites that are located with the MBRD is suggested to have more 
severe effect on impairing MT stabilizing and assembly promoting function of tau, which 
is likely due to its diminished affinity to bind MT.  
 Disturbed balance between phosphorylation and dephosphorylation may result in tau 
hyperphosphorylation via either increased kinase activity or downregulation of PP enzyme 
activity or both (Gong et al., 2005). However, the sites that are essential in promoting the 
development of AD pathophysiology are yet poorly understood. This has lead to a debate 
whether tau hyperphosphorylation per se is sufficient alone to induce neurotoxicity and 
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neurofibrillary pathology observed in tauopathies. Accordingly, the combined 
phosphorylation of sites Thr212, Thr231 and Ser262 is reported to drive tau aggregation, 
disrupt MT-integrity, induce neurotoxicity and concomitant apoptosis in vitro (Alonso et 
al., 2010). These data provide a connection between tau hyperphosphorylation and 
neurofibrillary degeneration at least in vitro, and also identifies sites at which 
hyperphosphorylation may facilitate the conversion of tau to toxic species, which can no 
longer maintain its physiological functions. In addition to the above mentioned 
phosphorylation sites that may convert tau into toxic species, sites Ser199, Ser202, 
Thr205, Ser235, Ser356, Ser396, Ser404 and Ser422 have been proposed to have similar 
effect (Alonso Adel et al., 2004).  
2.2.1 Kinases 
2.2.1.1 GSK-3 
 
Glycogen synthase kinase-3 (GSK-3) is a proline-directed Ser/Thr protein kinase, i.e. Ser 
or Thr preceding Pro, encoded by two distinct genes GSK3A and GSK3B resulting in two 
protein isoforms, GSK-3? and GSK-3?, respectively, which are abundantly expressed in 
the brain (Woodgett 1990). Although these two isoforms share significant sequence 
homology with each other, there are differences in their N- and C-terminal regions (e.g. 
Avila et al., 2010). GSK-3 is an essential regulatory enzyme with multiple cellular 
functions mediated by substrate phosphorylation, e.g. regulation of numerous 
physiological functions including glycogen metabolism and signal transduction (Grimes & 
Jope 2001).  
 Phosphorylation status of N-terminal serine residues 21 and 9 in GSK-3? and GSK-3?, 
respectively, modulate the enzymatic activity of GSK-3 kinases (Jope & Johnson 2004). 
GSK-3 activity is reduced by phosphorylation of these Ser residues by phopshorylation 
mediated by priming kinases, such as protein kinase A (PKA) (Fang et al., 2000) and Akt 
(Cross et al., 1995). These kinases are a part of a rather large kinase group capable of 
phosphorylation of these serines thereby contributing to reduction of GSK-3 activity. 
Conversely, the enzymatic GSK-3 activity is increased upon phosphorylation of tyrosine 
residues 279 and 216 in GSK-3? and GSK-3?, respectively. Additionally, several GSK-3 
substrates require priming (pre-phosphorylation of neighboring sites) to be further 
phosphorylated by GSK-3 resulting in bidirectional GSK-3 activity regulation, i.e. the 
phosphorylation status of the substrate may dictate the possible subsequent 
phosphorylation by GSK-3. Besides the state of its specific intramolecular 
phosphorylation, enzymatic activity of GSK-3 kinases is modulated by their interaction 
with other proteins and protein complexes (Avila et al., 2010), and the subcellular 
localization of GSK-3 since its compartmentalization is widely distributed throughout the 
cell (Grimes & Jope 2001).  
 GSK-3, especially the GSK-3? isoform, phosphorylates multiple sites on tau and is 
frequently reported as one of the main kinases regulating tau phosphorylation (Ishiguro et 
al., 1993; Grimes & Jope 2001). It participates in regulation of phosphorylation 
equilibrium of tau under normal physiological conditions and strongly contributes to 
hyperphosphorylation in pathophysiological conditions thereby rendering the possible 
subsequent dissociation of tau from the MTs, which further results in disruption of the MT 
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network. Interestingly, the phosphorylation of GSK-3? primed tau sites seems to more 
strongly affect its interaction with MTs as compared with non-primed sites (Cho & 
Johnson 2003). Moreover, Ser9-phosphorylated GSK-3?, regardless of its reduced 
enzymatic activity, is suggested to be able to phosphorylate tau via a mechanism that is 
yet to be elucidated (Yuan et al., 2004). 
2.2.1.2  CDK5 
 
In addition to GSK-3, cyclin-dependent kinase 5 (CDK5) is considered as another main 
kinase that contributes to regulation of tau phosphorylation status (Cruz & Tsai 2004a). 
CDK5 plays an essential role in development and maintenance of CNS by 
phosphorylation of a vast array of substrates. Association with its non-catalytic regulatory 
subunits p35 and p39 is fundamental for CDK5 to obtain enzymatic activity and further 
maintain its normal cellular functions. Since these CDK5 activators p35 and 39 are mainly 
expressed in post-mitotic neurons, the CDK5 activity is predominantly enriched in CNS 
(Lew et al., 1994).  
 CDK5 deregulation induced neurotoxicity contributes to pathogenesis of several 
NDDs, including AD (Cruz & Tsai 2004b). Under various neurotoxic conditions induced 
by e.g. oxidative stress or A?-mediated toxicity, the CDK5 regulatory activators p35 and 
p39 are cleaved by calpain resulting in truncated forms p25 and p29, respectively (Patzke 
& Tsai 2002; Kusakawa et al., 2000). Importantly, compared to non-cleaved forms, these 
calpain-cleaved activators p25 and p29 are more stable in the p25/p29-CDK5 heterodimer, 
which prolongs its kinase activity. Moreover, both the subcellular localization between 
complexes p25-CDK5 and p35-CDK5 (Cruz & Tsai 2004b) and substrate specificity is 
altered (Patrick et al., 1999). Furthermore, tau hyperphosphorylation, induction of 
cytoskeletal disruption and increased neuronal apoptosis are all possible consequences of 
increased p25 generation and accumulation (Patrick et al., 1999). Interestingly, p25 may 
also bind and activate GSK-3? (Chow et al., 2014).  
2.2.1.3 DYRK1A 
 
Dual-specificity tyrosine (Y)-phosphorylation-related kinase 1A (DYRK1A) is a 
multifaceted enzyme related to Ser/Thr phosphorylation of tau (e.g. Ryoo et al., 2007). In 
addition to phosphorylation of its several protein substrates, proline-directed protein 
kinase DYRK1A has dual substrate specificity: Tyr321 located in the activation loop of 
the catalytic domain is autophosphorylated for its self-activation (Himpel et al., 2001) and 
phosphorylation is targeted to Ser/Thr residues of multiple proteins (Himpel et al., 2000). 
Interestingly, DYRK1A is suggested to prime numerous substrates such as tau to be 
further phosphorylated by GSK-3 (Woods et al., 2001). Yet interesting aspect connecting 
DYRK1A and AD is the chromosomal location of the gene that encodes DYRK1A kinase: 
in humans it is located on chromosome 21, which full or partial trisomy causes Down 
syndrome (DS) (e.g. Wiseman et al., 2009). Due to additional copy caused by 
chromosome 21 trisomy, the overexpression of many genes that are located there, such as 
gene encoding amyloid precursor protein, lead to different developmental deficits, such as 
impaired learning and memory and mental retardation in which DYRK1A is suggested to 
play an important role (Ahn et al., 2006). This is tightly connected to the fact that almost 
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all DS patients develop AD-like dementia and pathophysiology by the age of 40 (Park et 
al., 2009). Furthermore, besides its function as a tau kinase, DYRK1A is known to 
phosphorylate APP at Thr668 and presenilin-1, which could result in increased A? 
production and aggregation (Ryoo et al., 2008; Ryu et al., 2010). 
2.2.1.4  Other proline-directed protein kinases 
 
Mitogen-activated protein kinases (MAPKs) are a family of proline-directed Ser/Thr 
protein kinases, which participate in several cellular functions (e.g Munoz & Ammit 2010; 
Kim & Choi 2010). MAPK induced signal transduction cascades typically involve a 
minimum of three consecutive kinases, such as MAPK3, MAPK2 and MAPK, which 
subsequentally lead to phosphorylation of large number of diverse MAPK substrates. The 
MAPK signalling pathways can be activated either via interaction of two kinase 
components or formation of multiple kinase complex that is regulated by specific 
scaffolding proteins such as JNK-interacting proteins (Kim & Choi 2010).  The most 
studied MAPK family members include extracellular signal-regulated kinase (ERK), c-
Jun NH2-terminal kinase (JNK, also known as stress activated protein kinase) and p38, 
which all exists in several isoforms (Schaeffer & Weber 1999). These kinases are 
involved in multiple cellular functions, including cell growth and differentiation, 
apoptosis and modulation of inflammation and other stress responses. Furthermore, 
MAPK mediated signalling pathways are known to contribute to pathogenesis of several 
disorders with highly diverse pathophysiological characteristics, such as cancer and NDDs 
like AD, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) (Kim & Choi 2010). 
Regarding to AD pathogenesis, MAPKs are reported play an essential role in several 
distinct AD related processes, such as regulation of ?- and ?-secretases, induction of 
neuronal apoptosis and phosphorylation of both APP and tau (Munoz & Ammit 2010; 
Kim & Choi 2010). Moreover, other MAPKs (JNK, ERK and p38) are all associated with 
abnormal tau phosphorylation in AD (e.g. Churcher 2006). Co-localization of 
phosphorylation-activated p38 and tau accumulations are found in both hippocampal and 
cortical AD brain slices (Zhu et al., 2000) and in transgenic mice overexpressing human 
tau (Kelleher et al., 2007).  
2.2.1.5  Non-proline-directed protein kinases  
 
PKA (cAMP-dependent protein kinase) is a multisubstrate non-proline-directed protein 
kinase that is involved in several crucial cellular signaling pathways (Walsh & Van Patten 
1994). Activation of PKA-catalyzed transduction pathways requires elevation of 
intracellular cAMP concentration and the co-localization of PKA holoenzyme with its 
specific substrates. Consistently with other tau kinases, PKA has been intensively studied 
in vitro and also reported to phosphorylate tau in vivo (Liu et al., 2004). Importantly, PKA 
serves as a priming kinase that prephosphorylates its substrates at specific Ser/Thr sites 
hence facilitating the subsequent phosphorylation by proline-directed protein kinases, 
such as GSK-3 and CDK5 (Wang et al., 2007; Liu et al., 2004). Moreover, PKA-mediated 
tau phosphorylation alone that precedes the possible sequential phosphorylation by other 
kinases, is suggested to result in AD -like aberrant tau phosphorylation. This 
phosphorylation is suggested to be duration-dependent, i.e. only the transient activation 
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with specific PKA-activator is capable of inducing abnormal AD -like 
hyperphosphorylation of tau (Wang et al., 2007; Zhang et al., 2006). Other non-proline-
directed protein kinases that are implicated in regulation of tau phosphorylation include 
various casein kinases (CK), calcium- and calmodulin-dependent protein kinase II 
(CaMKII) and protein kinase C (PKC) (Kuret et al., 1997; Yamamoto et al., 2002; Liu et 
al., 2003).  
2.2.1.6 Fyn 
 
Fyn is a tyrosine (Tyr) kinase that belongs to the src tyrosine kinase family with various 
biological functions, such as cell adhesion signalling and regulation of neuronal function 
(Resh 1998). With regards to tau phosphorylation, Fyn mediated Tyr phosphorylation of 
tau is reported to occur after A?-exposure (Williamson et al., 2002) and also during the 
development of neurodegeneration (Lee et al., 2004). However, Tyr phosphorylation of 
tau may not significantly alter its MT binding properties. Interestingly, Tyr 
phosphorylation of Tau has been implicated to contribute to various MT-independent 
mechanisms in the regulation of tau, such as functioning as an indicator of tau 
relocalization into cellular compartments where activated kinases are abundant. 
Alternatively, Tyr phosphorylation of tau may serve as an indicator for activation of src 
family kinases that can subsequently facilitate the activation of tau phosphorylation by 
various Ser/Thr kinases. Importantly, additional role of Fyn in neurodegeneration has been 
reported. Specifically, it has been suggested that Fyn transport to dendritic postsynapse is 
mediated by tau, which is predominantly considered as an axonal protein, and thereby 
contributes to A?-driven synaptotoxicity via the NMDA receptor in an AD mouse model 
(Ittner et al., 2010). Interestingly, it was shown that postsynaptic Fyn targeting was 
disrupted in tau deficient mice and in mice expressing truncated tau resulting in decreased 
A? toxicity.  
2.2.2 Protein phosphatases and dephosphorylation  
 
Protein phosphatases (PPs) are responsible for dephosphorylation of tau and other 
substrates after phosphorylation by various kinases (Liu et al., 2005). The regulation of PP 
activity occurs via numerous mechanisms, such as phosphorylation of PP regulatory 
subunits, subcellular localization of PPs and its potential substrates and calcium (Tian & 
Wang 2002). In mammals, brain expression of five Ser/Thr PPs is observed, including 
PP1, PP2A, PP2B, PP2C and PP5 (Liu et al., 2005). Of these phosphatases, all except 
PP2C dephosphorylate tau at same specific sites (at least) in vitro with varying efficacy 
toward each specific site. The total tau dephosphorylation activity in human brain is 
unevenly divided between PPs 1, 2A, 2b and 5 with proportions of approximately 11%, 
71%, 7% and 10%, respectively. Hence, taken together the partial PP contributions and 
the observed decrease of PP2A activity in AD brain, PP2A is suggested to be 
pathophysiologically the most important tau PP. Moreover, PP2A not only 
dephosphorylates tau but additionally regulates several kinases that are involved in tau 
phosphorylation via activation or inactivation of these kinases (Tanimukai et al., 2005).  
 Intracellular PP2A activity is regulated by two endogenous inhibitors I1PP2A and I2PP2A 
(Tanimukai et al., 2005). I1PP2A mediated inhibition of PP2A occurs via its catalytic 
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subunit PP2Ac. I2PP2A, which is mainly located in the nucleus in neurons, is cleaved into 
two fragments and further translocated into cytoplasm where it interacts with catalytic 
PP2A subunit and co-localizes with tau aggregates in specific regions of AD brain. 
Moreover, the expression level of these endogenous inhibitors of PP2A is inceased 
approximately 20% in AD brain, which may directly result to tau hyperphosphorylation. 
Interestingly, NMDA -receptor antagonist memantine, which is clinically used to treat the 
symptoms of AD, is reported to enhance the activity of PP2A thereby inhibiting or at least 
diminishing hyperphosphorylation of tau and neurofibrillary degeneration (Li et al., 2004). 
Additionally, compromised PP2A activity due to its increased demethylation may further 
reduce the ability of PP2A to dephosphorylate tau (Zhou et al., 2008). Intriguingly, 
sodium selenate was reported as a specific PP2A activator that decreases tau 
phosphorylation and mitigates functional deficits and tau driven pathology without any 
neurotoxic effects (van Eersel et al., 2010; Corcoran et al., 2010). Since the expression 
level and activity of PP2A are both significantly reduced in AD brain (Tanimukai et al., 
2005; Vogelsberg-Ragaglia et al., 2001) PP2A is a potential target for drug development 
for AD (Liu et al., 2005; Tian & Wang 2002).   
2.2.3 Tau hyperphosphorylation and neurofibrillary degeneration 
 
The major factor that contributes to tau dysfunction and neurofibrillary degeneration in 
AD and related tauopathies is tau hyperphosphorylation (Iqbal et al., 2009; Alonso et al., 
1994; Grundke-Iqbal et al., 1986). Conversely to normal, physiological tau 
phosphorylation in which tau contains 2-3 mole of phosphate per mole of tau, the 
phosphate level in hyperphosphorylated tau in AD brain is increased 3-4 fold (Kopke et 
al., 1993). There are several factors, such as disturbed phosphorylation/dephosphorylation 
equilibrium, altered brain glucose metabolism and A?-mediated pathways (although the 
role of A? is still controversial) that may contribute tau hyperphosphorylation (Gong & 
Iqbal 2008). The exact mechanism of hyperphosphorylated tau-induced neurofibrillary 
degeneration is yet to be partly elucidated regardless of the intensive investigation efforts 
toward the subject (e.g. Wang & Liu 2008). Nevertheless, it most probably involves both: 
loss of normal tau function and gain of toxic function.  
 Upon hyperphosphorylation tau detaches from the MTs and accumulates into two 
different intraneuronal tangle formations called paired helical filaments (PHFs) and 
straight filaments (SFs) (figure 2.2) (Iqbal et al., 1989; Alonso et al., 2001a; Grundke-
Iqbal et al., 1986). In both tangle formations, tau is the predominant protein component. 
Formation of PHFs and SFs almost invariably results in the generation of neurofibrillary 
tangles (NFTs), intracellular structures detected in neuropathological analysis of AD and 
tauopathy brains. Besides the self-assembly process of all the six human tau isoforms into 
highly stable PHF/NFT aggregates, the cytosolic non-fibrillar form of 
hyperphosphorylated tau sequesters other MAPs (MAP1 and MAP2) and tau that is not 
hyperphosphorylated (Alonso et al., 1994; Alonso et al., 1997; Kopke et al., 1993). 
Subsequently, this toxic gain-of-function results in disruption of MT assembly and 
stabilization. The affinity of AD-like hyperphosphorylated tau (AD-like p-tau) to bind and 
sequester different tau isoforms varies (2N/4R > 1N/4R > 0N/4R and 2N/3R > 1N/3R > 
0N/3R, and also 2N/4R > 2N/3R) (Alonso et al., 2001b). Thus, whereas 4R-isoforms are 
preferentially sequestered by AD-like p-tau, the lack of N-terminal fragments and the 
 12 
absence of fourth additional MT-binding repeat R2 indicate a protective role of the 
shortest fetal human tau isoform against neurofibrillary degeneration. Moreover, AD-like 
p-tau is reported to inhibit proteasome function in cells and PHF-tau is found to be 
polyubiquitynated (Cripps et al., 2006), which emphasize the importance of degradation 
and clearance mechanisms of AD-like p-tau to prevent further accumulation of misfolded 
proteins and NFT formation. Importantly, AD-like p-tau disrupts axonal transport by 
interfering with the kinesin-like motor protein and by destabilizing MTs, which are highly 
important tracks in axonal transport of various cellular organelles and proteins 
(Tatebayashi et al., 2004). Considering the highly polarized morphology of neurons, 
functionality of axonal transport system is crucial for neuronal viability. 
 
 
 
Figure 2.2. Tau phosphorylation and filament formation. Normal physiological 
phosphorylation and dephosphorylation cycle of tau is regulated by protein kinases and 
protein phosphatases (1) by either attaching a free phosphate or detaching a phosphate 
from tau, respectively. Tau hyperphosphorylation is a result of increased kinase activity 
and/or decreased phosphatase activity (2). Upon tau hyperphosphorylation and possible 
contribution of other posttranslational modifications (PTM), such as acetylation and 
truncation (3), tau typically detaches from microtubules and becomes more prone to form 
straight filaments (SFs)/paired helical filaments (PHFs) or prefibrils (4) subsequently 
leading to formation of insoluble intracellular fibrils, aggregates and neurofibrillary 
tangles (NFTs) (5). Normal tau phosphorylation and hyperphosphorylation are reversible 
processes hence hyperphosphorylation does not necessarily lead to formation of 
PHFs/prefibrils. Conversely, if PHFs are abundantly present in the cytosol the subsequent 
formation of NFTs is almost invariable.    
 
 
Protein kinases are naturally the key molecules driving tau toward its 
hyperphosphorylated form. Indeed, phosphorylation of tau by several kinases, such as 
PKA, CaMKII, GSK-3? and CDK5, and by using different combinations and sequential 
treatments with recombinant protein kinases, “normal” tau is reported to 
hyperphosphorylate and self-assemble into PHFs (Wang et al., 2007). PP2A is capable of 
dephosphorylating all the essential sites required for self-assembly of AD-like p-tau, 
which further verifies its role as the major tau phosphatase. Interestingly, after 
dephosphorylation of AD-like p-tau by PP2A, rephosphorylation is found to occur via 
various kinase combinations, which can restore the self-assembling property to form 
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PHFs/NFTs. These results strongly implicate the reversible nature of tau 
hyperphosphorylation and the involvement of multiple kinases. Besides the sequential 
phosphorylation by specific kinase combination at certain sites, the sequential pattern of 
AD-associated tau phosphorylation sites has been studied in primary neurons (Bertrand et 
al., 2010). Similar to priming phosphorylation of tau by various kinases, the sequence of 
phosphorylation at specific AD-related sites could have an impact on the overall status of 
tau phosphorylation mediated by differential cascades. The AT8 epitope of tau, which 
consists of sites Ser199, Ser202 and Thr205, is considered a central mediator of various 
cascades regulating the priming and feedback processes and is one of the most intensively 
studied tau phosphorylation epitope. 
2.3 Other proteins interacting with tau 
2.3.1 ?-Tubulin 
 
MTs are crucial cellular elements that are involved in vast array of vital functions (Chau et 
al., 1998). These essential MT functions including e.g. cell motility, cell division and cell 
morphology, are collectively regulated by microtubule-associated proteins via 
stabilization of the MT structure and regulation of their assembly and disassembly 
dynamics. MTs are non-covalent polarized cytoskeletal polymers, which are assembled 
from ?- and ?-tubulin monomer subunits that form a dynamic heterodimer and require 
additional molecules to stabilize their structure (Kar et al., 2003). Binding of tau to ?-
tubulin subunits within the MT occurs via the repeat-region sequences located in the 
MBRD of tau (Amos 2004; Lee et al., 1989; Chau et al., 1998). Aberrant tau 
phosphorylation results in reduced ability of tau to regulate MT-dynamics, which can 
further lead to disruption of the MT-network and compromise axonal transport of proteins 
and various cellular organelles in neurons. Interestingly, ?-III-tubulin, which is the 
predominant neuronal tubulin isoform, is also found to be hyperphosphorylated in AD 
brain probably due to decreased PP2A activity and/or expression (Vijayan et al., 2001). 
Although this process may not have a large impact in healthy human brain, the additional 
effect rendered by ?-tubulin hyperphosphorylation to already disturbed MT-dynamics 
may be significant in AD brain.  
2.3.2 14-3-3? 
 
The 14-3-3 protein family comprises a family of small acidic regulatory molecules that 
interact with a large number of signaling proteins and regulate numerous cellular 
processes via binding to their target proteins (Fu et al., 2000). By binding to their target 
proteins, 14-3-3 proteins modulate and stabilize enzymatic activity and conformation of 
their ligands, and, function as mediators of protein-protein interactions and subcellular 
protein localization. Due to their abundant brain expression and wide range of ligands, 14-
3-3 proteins are crucial regulators of many vital cellular functions, such as cell cycle, 
signal transduction and apoptosis (Fu et al., 2000; van Hemert et al., 2001). In eukaryotes, 
seven distinct 14-3-3 isoforms (?, ?, ?, ?, ?, ? and ?) are all encoded by indivudual genes, 
which are translated to highly conserved phosphoserine-binding proteins, which 
predominantly exist as dimers (both homo- and heterodimers) (van Hemert et al., 2001; 
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Yuan et al., 2004). Large diversity of mechanisms, including cellular expression level, 
posttranslational modifications and isoform specificity, contribute to the stringent 
regulation of the 14-3-3 -ligand interactions (Fu et al., 2000).  
 In 14-3-3?, the phosphorylation status of Ser58 residue (located in the dimer interface) 
determines whether the 14-3-3? is in monomeric or dimeric form (Woodcock et al., 2003). 
This single site has been shown to be phosphorylated by various protein kinases including 
Akt (protein kinase B) in vitro (Powell et al., 2002) and sphingosine-dependent kinase in 
vitro and in vivo (Woodcock et al., 2003). Intriguingly, the disruption of the 14-3-3? 
dimer mediated by phosphorylation of Ser58 residue does not completely inhibit its 
capability to bind ligands although the dimeric structure of 14-3-3? strongly facilitates its 
cellular functions. 
 14-3-3 proteins are known to interact with multiple molecules associated with 
pathways that contribute to abnormal phosphorylation of tau (Hernandez et al., 2004; Kim 
et al., 2004; Agarwal-Mawal et al., 2003). Importantly, a multiprotein complex containing 
tau, GSK-3? and 14-3-3? co-immunoprecipitates from brain extracts (Agarwal-Mawal et 
al., 2003). The exact mechanism how tau and GSK-3? are connected within the complex 
by 14-3-3? is not completely understood. Interestingly, 14-3-3? is suggested to mediate 
the interaction of tau and Ser9-phosphorylated GSK-3? thereby stimulating the GSK-3? 
mediated tau phosphorylation, although the 14-3-3?- Ser9-GSK-3? interaction does not 
seem to require the presence of tau (Yuan et al., 2004). However, these data have not been 
further confirmed. Furthermore, tau phosphorylation at Ser214 by Akt kinase is shown to 
significantly increase the affinity of 14-3-3? to bind tau resulting in reduced tau 
aggregation and fibril formation in vitro (Sadik et al., 2009). Additionally, it has been 
reported that 14-3-3? increases DYRK1A activity via stabilizing the active dimer structure 
of 14-3-3? (Kim et al., 2004) and that 14-3-3? regulates PKA-mediated tau 
phosphorylation (Hashiguchi et al., 2000). Due to the overlapping binding region in tau, it 
has been suggested that 14-3-3? and tubulin may compete in tau binding under specific 
conditions.       
2.3.3 Pin1 
 
Peptidyl-prolyl isomerases are molecules that function as a conformational switch 
catalyzing the cis/trans isomerization of peptidyl-prolyl bonds (figure 2.3) (e.g. Zhou et 
al., 1999; Yaffe 1997). Peptidyl-prolyl isomerases can be divided into three families: 
cyclophilins, FK506 binding proteins (FKBPs) and parvulins (Lu et al., 1996; Lu et al., 
2002a). Of these highly conserved peptidyl-prolyl isomerase -families, Pin1 is a member 
of parvulins, although being the only peptidyl-prolyl isomerase capable of recognizing 
and subsequently isomerizing phosphorylated serine/threonine-proline sequences 
(pSer/Thr-Pro) (Yaffe 1997).  
Pin1 (protein interacting with NIMA (never in mitosis A) 1) is a ubiquitously expressed 
enzyme that has strong substrate specificity for phosphoproteins (Zhou et al., 1999). The 
two Pin1 structural domains have distinct functions: the N-terminal phospho-specific WW 
domain modulates Pin1 binding to its substrates and the C-terminal peptidyl-prolyl 
isomerase domain catalyzes the conformational cis/trans isomerization of the substrates 
(Lu et al., 1996; Lu et al., 2002a; Yaffe 1997). Phosphorylation of Pin1 at Ser16 residue 
located at pSer/Thr-Pro-binding pocket regulates the substrate binding activity by 
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inhibiting the WW domain-pSer/Thr-Pro motif interaction (Lu et al., 2002b). Moreover, 
Pin1 function is regulated by its subcellular localization, which is dependent on substrate 
availability. Thus, because the WW domain is required for substrate binding, the 
phosphorylation status of Ser16 of pSer/Thr-Pro motif affects the subcellular localization. 
Pin function is additionally modulated by its expression level, which is regulated by cell 
division cycle (Liou et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Peptidyl-prolyl cis/trans isomerization. Proline residues exist in two distinct 
isoforms potentially providing a peptidyl-prolyl bond switch in the polypeptide chain 
backbone, which is controlled by cis/trans isomerization (a). To avoid the rate limitations 
in the protein folding and refolding due to rather slow intrinsic spontaneous conversion 
between the two isomers, the conversion is catalyzed by ubiquitous peptidyl-prolyl 
cis/trans isomerases. Based on their substrate specificity, three families of peptidyl-prolyl 
cis/trans isomerases are characterized: cyclophilins, FK506 binding proteins (FKBPs) and 
parvulins. Parvulins are further divided into subfamilies of parvulin-type and Pin1-type 
peptidyl-prolyl cis/trans isomerases, from which Pin1 and Pin1-type peptidyl-prolyl 
cis/trans isomerases specifically isomerize phosphorylated Ser/Thr-Pro bonds (b). 
Isomerization of both phosphorylated and nonphosphorylated Ser/Thr-Pro motifs is 
essential due to a conformational specifity of numerous protein kinases and phosphatases, 
which phosphorylate and dephosphorylate predominantly the trans-form of proline bond 
of proteins. PPIases, peptidyl-prolyl cis/trans isomerases; S, serine; P, proline. Modified 
from Lu et al., 2002. 
 
Pin1 is involved in several cellular processes, including regulation of cellular signaling 
and cell cycle progression, modulation of transcription and RNA processing, and, 
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contributes to neuronal survival, DNA damage response and cellular stress (Lu et al., 
2002a; Lu 2004). The participation of Pin1 in a such wide array of diverse cellular 
processes can be at least partly explained by the vast number of its substrates. Pin1 
regulation is highly stringent under normal physiological conditions and its deregulation is 
coherently associated with a number of human diseases with most implications in cancer 
and AD (Lu 2004). Importantly, the discovery of Pin1 to specifically recognize and 
further catalyze the pSer/Thr-Pro bond isomerization resulting in conformational change 
in motifs in question, introduced a novel mechanism of protein signaling and modification 
occurring after phosphorylation (Ranganathan et al., 1997; Yaffe 1997; Lu 2004).  
 Both AD hallmark proteins, tau and APP, are substrates of Pin1 (Liou et al., 2003). 
With regards to APP, phosphorylated Thr668-Pro motif in cis conformation is suggested 
to promote amyloidogenic APP processing and subsequent A? production whereas trans 
conformation seems to drive the non-amyloidogenic pathway (Pastorino et al., 2006). 
Furthermore, inhibition of GSK-3? by Pin1 is reported to decrease amyloidogenic APP 
processing (Ma et al., 2012). Specifically, Pin1 binds to phospho-Thr330-Pro motif in 
GSK-3? thereby inhibiting its kinase activity that results in decreased GSK-3?-mediated 
phosphorylation of Thr668 and APP turnover rate both in vitro and in vivo. Additionally, 
loss of Pin1 function is associated with altered intracellular APP localization and 
processing (Pastorino et al., 2012). These data implicate that upon decreased total APP 
levels mediated by increased protein turnover, Pin1 facilitated inhibition of GSK-3? may 
provide a novel mechanism in alleviating A?-driven AD pathophysiology.  
 Pin1 binds to and catalyzes the cis/trans isomerization of tau phosphorylated at the 
Thr231-Pro motif (Lu et al., 1999). Importantly, PP2A is a Pro-directed conformation-
specific phosphatase that is only capable of interacting with the trans isomer of pSer/Thr-
Pro motif (Zhou et al., 2000). Hence, this binding specifity of PP2A underlines the 
importance of Pin1-mediated conversion of cis to trans isomer of the tau Thr231-Pro 
motif enabling PP2A to dephosphorylate tau, which may further restore the ability of tau 
to bind and stabilize MTs (Lu et al., 1999; Zhou et al., 2000). In the case of complete Pin1 
depletion or merely its reduced activity, which is seen in AD, cis form of pThr231-Pro 
motif is the prevalent isomer resulting in elevated tau hyperphosphorylation and 
subsequent NFT formation. Interestingly, simultaneous dephosphorylation at sites Ser16 
in Pin1 and Thr231 in tau have been reported to be induced by A?42 in vitro (Bulbarelli et 
al., 2009). Specifically, A?42 induced increase in Pin1 activity was suggested to reduce or 
even prevent tau hyperphosphorylation. Considering the essential role of Pin1 in 
modulation of both APP and tau it provides a remarkable candidate target for novel AD 
therapies (Liou et al., 2003). 
2.4 Other posttranslational modifications of tau 
 
Tau protein can undergo a wide range of posttranslational modifications (PTMs) in 
addition to phosphorylation (Gong et al., 2005). These various mechanisms that modify 
tau posttranslationally include glycosylation, glycation, ubiquitination, polyamination, 
truncation, nitration (Gong et al., 2005), acetylation (Min et al., 2010) and methylation 
(Thomas et al., 2012). PTMs of tau under physiological and pathophysiological conditions 
are pivotal mechanisms in facilitating the conversion of functional tau into dysfunctional 
protein and inducing PHF/SF -formation, which promotes neurofibrillary degeneration in 
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AD and other tauopathies (Gong et al., 2005; Wang & Liu 2008). However, regardless of 
the crucial contribution of PTMs to tau in various NDDs, many of them are much less 
studied compared to tau phosphorylation.  
 The covalent linking of oligosaccharides to protein side chains is a process called 
glycosylation that is facilitated by different enzymes like glycotransferases (Gong et al., 
2005; Wang & Liu 2008). The two types of glycosylation, O- and N-linked glycosylation, 
have a difference in the form of the glycosidic bond. N-glycosylation, in which 
oligosaccharides are covalently linked to the amino groups of asparagine side chains, 
usually occurs in rough endoplasmic reticulum and in Golgi apparatus (e.g. Gong et al., 
2005). Furthermore, N-glycosylation is found to be enhanced in PHF-tau compared to 
normally functioning non-self-aggregated tau (Liu et al., 2002b). Additionally, abnormal 
glycosylation has been reported to promote hyperphosphorylation of tau via specific 
protein kinase pathways involving e.g. PKA, CDK5 and GSK-3? and due to decreased tau 
dephosphorylation by inhibition of PP2A and PP5 (Liu et al., 2002a). Importantly, 
aberrant glycosylation precedes hyperphosphorylation of tau and the impact of 
glycosylation to phosphorylation is site-specific (Gong et al., 2005; Liu et al., 2002a).  
 In O-glycosylation, oligosaccharides are covalently bound to Ser or Thr residues that 
are localized in close proximity with Pro residues (Gong et al., 2005; Wang & Liu 2008). 
Particularly, O-linked monosaccharide ?-N-acetylglucosamine (O-GlcNAc) addition to 
tau Ser/Thr residues has been studied and the reduction of O-GlcNAcylation in AD brain 
has been reported (Liu et al., 2004; Arnold et al., 1996). This reduced O-GlcNAcylation in 
AD can be at least partially explained by the notion that O-GlcNAcylation and 
phosphorylation of tau take place in the same residues implicating that there may be a site-
specific competition between these two PTMs (Liu et al., 2004). Moreover, it has been 
reported that increased amount of O-GlcNAc due to chemically inhibited glycoside 
hydrolase (O-GlcNAcase), a hydrolase that removes the O-GlcNAc from the tau Ser/Thr 
residues results in motor neuron loss in transgenic mouse model (JNPL3) expressing 
human FTDP-17 tau P301L mutant (Yuzwa et al., 2012). Intriguingly, no alterations in 
phosphorylation status of tau upon O-GlcNAcylation modification were found suggesting 
a phosphorylation-independent mechanism. In addition, the role of O-GlcNAcylation at a 
specific tau site was shown to significantly contribute to a reduction of tau fibrillization. 
However, until to date, only one O-GlcNAc site (Ser400) is identified in endogenous tau 
(Wang et al., 2010) and recently the protective role of O-GlcNAcylation against tau 
hyperphosphorylation has been questioned (Morris et al., 2015). O-GlcNAcylation is 
negatively regulated by compromised glucose metabolism in the brain, which may further 
induce tau hyperphosphorylation (Liu et al., 2004). Accordingly, reduced O-
GlcNAcylation introduces an additional mechanism connecting impaired brain glucose 
metabolism and AD pathogenesis (Gong et al., 2005). Regardless of its role as one of the 
most common PTM of tau, the exact molecular mechanism(s) of glycosylation is not 
completely understood.  
 Unlike the enzymatic glycosylation, glycation is a process of nonenzymatic bonding of 
reducing saccharides to polypeptide amino side chains (Gong et al., 2005; Yan et al., 
1994). Protein glycation-oxidation results in heterogenous and complex formations called 
advanced glycation end products (AGE), which have been observed to be present in 
PHFs/NFTs (Sasaki et al., 1998; Yan et al., 1994). Glycation of tau is also reported to be 
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induced by oxidative stress in neuronal cells (Yan et al., 1994) and suggested to contribute 
to the PHF -formation (Kuhla et al., 2007).  
 Tau that is located in PHFs and NFTs is polyubiquitinated in AD, unlike normal and 
soluble hyperphosphorylated tau (Perry et al., 1987). Ubiquitin-conjugation of damaged or 
misfolded proteins under normal physiological conditions directs these non-functional 
proteins to degradation by ATP-dependent ubiquitin-proteasome pathway (Hershko & 
Ciechanover 1992). Nonetheless, significant reduction of polyubiquitinated PHF-tau 
degradation is observed in AD, which is suggested to be at least partly due to diminished 
proteasome function that may lead to concomitant tau aggregation and NFT -formation 
(Keller et al., 2000). Besides polyubiquination, polyamination affects the rate of tau 
degradation (Tucholski et al., 1999). The reaction in which polyamines are added to tau is 
catalyzed by tissue transglutaminase. Although polyamination of tau does not have an 
impact on its MT -binding affinity based on in situ experiments, it aggravates the calpain 
protease-mediated tau cleavage and degradation in vitro. 
 Caspases and some other proteases execute the C-terminal truncation of tau leading to 
conformational changes within the protein (Yin & Kuret 2006). C-terminal cleavage of tau 
enhances its propensity to aggregate into PHFs/NFTs compared to full-length tau. 
Truncation of tau is proposed to occur at early stages of disease pathogenesis and it may 
be capable of inducing fibrillization of tau even in low concentrations, i.e. C-terminal 
truncation lowers the critical concentration of tau self-aggregation.  
 Tau nitration, which is shown to be site-specific toward tyrosine residues 18, 29, 197 
and 394 (Reynolds et al., 2005), contributes to tau filament formation and is found to 
localize with NFTs before the maturation of tau inclusions in AD brain (Horiguchi et al., 
2003). Tau nitrated at Tyr29 is reported to be the most affected nitration site in AD and 
hence suggested to contribute to pathogenesis of AD (Reynolds et al., 2006). Furthermore, 
nitration at Tyr29 is reported to age-dependently increase in the insoluble fraction of 
rTg4510 mice brain, a mouse model expressing human P301L FTDP-17 mutation that 
develops NFT-like pathology (Song et al., 2015).  
 Upon acetylation, the ubiquitin-mediated protein degradation of hyperphosphorylated 
tau has been reported to be inhibited (Min et al., 2010). In this study, histone 
acetyltransferase p300 was shown to promote tau acetylation whereas SIRT1 reverted this 
process by inducing deacetylation of tau. Additionally, depletion of protein deacetylase 
SIRT1, the expression level of which is shown to be reduced in AD (Julien et al., 2009), 
was suggested to induce hyperacetylation of tau leading to subsequent tau 
hyperphosphorylation and consequent neurofibrillary degeneration (Min et al., 2010). 
Importantly, this effect of hyperacetylation-driven tau hyperphosphorylation was shown to 
be abrogated by inducing tau deacetylation.   
 Since the identification of reversible tau acetylation, it has been the interest of multiple 
follow-up studies and has mounted further evidence on molecular mechanism of 
acetylation and its importance on tau function. Foremost, lysine residue 280 (K280), 
which is located within in the MT-binding region of tau, is pinpointed as a predominant 
acetylation target site that may play a pivotal role in AD pathology and other tauopathies 
(Cohen et al., 2011). At least partly due to its localization, tau acetylated at K280, disturb 
the primary function of tau by hindering its ability to bind MTs resulting in compromised 
MT-assembly and stabilization (Irwin et al., 2012; Cohen et al., 2011). Besides losing its 
normal function in modulating MTs, the toxic gain-of-function, including increased tau 
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fibrillization and the incremental amount of oligomerization-prone soluble tau that may 
lead to PHF/NFT-formation emerges due to acetylation (Irwin et al., 2012; Cohen et al., 
2011). Both loss of normal function and gain of toxic function further collectively 
contribute to tau-mediated neurodegeneration. However, there have been some 
contradicting reports according on how and if tau acetylation increases tau-driven 
neurodegeneration, and, that which and where different deacetylases and 
acetyltransferases are capable of modulating tau acetylation (Noack et al., 2014; Cook et 
al., 2014; Cohen et al., 2011; Min et al., 2010). Recently, tau acetylation in KXGS motifs 
located in the MT-binding region of tau was reported to inhibit phosphorylation of these 
motifs and tau aggregation (Cook et al., 2014). Furthermore, the deacetylation of the 
KXGS motifs was reported to be driven by histone deacetylase 6 (HDAC6) (Cook et al., 
2014) given that increase in its expression level correlates with increased tau burden 
whereas reduced HDAC6 activity was suggested to induce tau clearance (Cook et al., 
2012). Additionally, the presence of HDAC6 in oligodendrocytes is reported where its 
inhibition contributes to tau phosphorylation and decreases its MT-binding properties 
(Noack et al., 2014), and, also impairs autophagic clearance of tau (Leyk et al., 2015). 
Hence, these data strongly implicate an important role for HDAC6 in regulation of tau 
acetylation although its impact on tau-mediated neurodegeneration is yet incompletely 
understood. 
 There is an ongoing debate about the exact roles and sites of various acetyltransferases 
(e.g. p300 and CREB binding protein) and deacetylases (e.g. HDAC6, SIRT1) that govern 
the acetylation/deacetylation equilibrium of tau (e.g. Cook et al., 2014; Cohen et al., 2011; 
Min et al., 2010). It has been also suggested that tau possesses an intrinsic 
acetyltransferase activity capable of self-acetylation without exogenous enzymatic 
activity, but this finding is yet to be further replicated and confirmed (Cohen et al., 2013). 
Taken together and regardless of the discrepancies of various reports, further investigation 
is needed to identify the site-specificity and the dynamics between acetylation and 
phosphorylation. This may reveal a novel targets for drug development for many 
tauopathies, except for argyrophilic grain disease, in which tau acetylation is not observed 
(Grinberg et al., 2013). 
 Methylation of tau at lysine residues was quite recently reported (Thomas et al., 2012). 
By using mass spectrometry approach, monomethylation of seven distinct lysine sites 
were identified from immunopurified PHFs of AD brain. Additionally, it has been 
reported that at least 11 lysine sites are either mono- or dimethylated in cognitively 
normal healthy human brain and that the methylated lysines are mainly located in the 
MBRD (Funk et al., 2014). Moreover, some lysine residues overlap with residues that are 
also acetylated and ubiquitinated suggesting a competition between different PTMs 
toward these sites. These findings have been verified recently in a report investigating tau 
PTMs by comparing endogenous tau isolated from both wild-type and hAPP mice by 
utilizing mass spectrometry (Morris et al., 2015). Given that not many differences in tau 
PTMs were detected between wild-type and human APP mice, it was suggested that tau-
related neuronal dysfunction in hAPP mice is mediated by physiological tau forms. 
However, the enzymes that catalyze the methylation and dimethylation of tau are yet to be 
elucidated.   
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2.5 Role of tau in neurodegenerative diseases 
 
The pathological ‘umbrella’ entity frontotemporal lobar degeneration (FTLD) is a group 
of disorders that are highly heterogenous clinically, genetically and pathologically, and 
share a common and prominent feature of rather specific degeneration of frontal and 
temporal lobes (Neary et al., 1998). The neuropathological classification of FTLDs is 
currently based on five distinct major subgroups, from which three are characterized by 
proteinaceous inclusions or deposits of specific proteins that include 43 kDa transactive 
response DNA-binding protein (TDP-43) in FTLD-TDP, fused in sarcoma (FTLD-FUS) 
and tau in FTLD-tau, a group of NDDs commonly called as tauopathies (Lashley et al., 
2015).       
 Frontotemporal dementia (FTD), on the other hand, is a clinical term used to describe a 
group of dementias with early onset (under the age of 65 years) comprising the second 
most common cause of all dementias with the estimated prevalence of 15-22/100 000 
(Onyike & Diehl-Schmid 2013). Clinical presentation of patients with FTD can be either 
one of the three commonly established clinical syndromes: behavioral variant FTD 
(bvFTD) or language variant FTD (lvFTD), which is usually divided into semantic 
dementia and progressive nonfluent aphasia (PNFA) (Lashley et al., 2015). In general, 
approximately 30-50% of all FTD cases show a positive family history (Rohrer et al., 
2009). Hence, the hereditary component in FTD is rather strong. 10-20% of all FTD cases 
are due to mutations in three genes including MAPT (encoding tau), progranulin (PGRN 
or Granulin (GRN); both have been used in the literature) and chromosome 9 open 
reading frame 72 (C9orf72), which encompass most of the familial cases (Rohrer et al., 
2015; Rohrer et al., 2009).  
 The clinical symptoms between different FTD-subtypes present considerable variation. 
In bvFTD, symptoms are characterized by a set of behavioural alterations such as apathy, 
disinhibition, loss of empathy and obsessive-compulsive behaviour (Lashley et al., 2015). 
In addition, cognitive impairment in different cognitive domains is also developed as the 
disease progresses. In patients with PNFA, the symptoms usually include agrammatism, 
which is a form of aphasia in which the patient is not capable of speaking grammatically 
correctly, and/or apraxia of speech, which refers to a loss of speech level previously 
acquired before the disease onset. In the FTD variant of semantic dementia, anomia, i.e. 
difficulty to recall names or find words, is developed in addition to inability to 
comprehend single words.     
2.5.1 Tauopathies 
 
The predominant constituent in PHFs and SFs is hyperphosphorylated tau, which further, 
upon the subsequent formation of NFTs, manifest an additional neuropathological 
hallmark lesion in AD besides amyloid plaques (Iqbal et al., 1989; Grundke-Iqbal et al., 
1986). However, the observed aggregates composed of mainly hyperphosphorylated tau 
subunits are not disease-specific to AD but are widely recognized in several age-related 
NDDs that are collectively referred as tauopathies, all of which are characterized by 
development of neurofibrillary degeneration associated with dementia (e.g. Buee et al., 
2000; Iqbal et al., 2005). Furthermore, the mechanisms which may promote any 
alterations in tau metabolism that further result in NFT-formation include different PTMs, 
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missense mutations and altered expression of various tau isoforms or change in the total 
tau expression (Hernandez & Avila 2007). Importantly, the identified missense mutations 
in MAPT gene that were discovered to co-segregate with frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17), unambiguously indicate the disease-
causative feature of tau, i.e. abnormalities of tau per se are capable to result in 
neurofibrillary degeneration (Spillantini et al., 1998b; Hutton et al., 1998). 
 Tauopathies are typically divided in primary and secondary tauopathies depending 
whether the tau inclusions are the most predominant pathological protein depositions or if 
there are some other proteins that are involved in the pathogenesis of a disease (Kovacs 
2015). The primary tauopathy phenotypes include e.g. progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), Pick’s disease 
(PiD), primary age-related tauopathy (previously also known as (neurofibrillary) tangle-
only dementia) (PART), FTDP-17 and globular glial tauopathy (GGT), which was 
characterized recently (table 2.1). Besides AD, other secondary tauopathies include e.g. 
Down syndrome (DS) and Niemann-Pick type C disease (Buee et al., 2000). Notably, the 
used nomenclature for classically identified phenotypes that are associated with primary 
tauopathies are overlapping with the renewed classification of frontotemporal lobar 
degeneration (FTLD), which is a term comprising a group of several NDDs that are 
characterized by atrophy and disruption of predominantly frontal and temporal lobes of 
the brain (Cairns et al., 2007).  
 The neuropathological phenotypes of tauopathies, which are morphologically, 
biochemically and clinically heterogeneous NDDs, can be distinguished based on the 
differential involvement of various cell types, anatomical areas and the presence and/or 
absence of specific tau isoforms included in pathological tau deposits (Kovacs 2015). 
Moreover, tau filaments in different tauopathies are variably composed of either 4R- or 
3R-tau or both, which further underlines the biochemical heterogeneity of tauopathies and 
currently provides the basis for post mortem molecular classification of specific disease by 
tau compositions, i.e. the major patterns of insoluble tau that can be observed from the 
brain samples of a specific tauopathy by Western blotting (Sergeant et al., 2005). Given 
that the ratio of 4R-tau to 3R-tau is normally in healthy human brain approximately 1:1 
(Hong 1998), it has been suggested that it is the altered ratio of the isoforms rather than 
the isoform-specific toxicity that may drive the neurofibrillary degeneration of tauopathies 
(Wang & Liu 2008).   
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2.5.1.1 Braak staging 
 
AD is referred as a secondary tauopathy due to the preceding amyloid plaque pathology in 
the disease pathogenesis. In AD, although NFTs that are composed of both 4R- and 3R-
tau are primarily observed in the entorhinal cortex and hippocampus, many additional 
cortical and subcortical regions are also affected (Arnold et al., 1991; Braak & Braak 
1991). More specifically, the sequential anatomical spreading of tau pathology between 
distinct brain regions during the disease progression has been established; the spreading of 
NFT pathology is divided into seven stages (0-VI) that is called Braak staging, which is 
relative to severity and affected brain areas (figure 2.4) (Braak & Braak 1991). Initially, 
tau aggregates are detected in locus coeruleus followed by transentorhinal cortex and 
anteromedial temporal lobe (Braak & Del Tredici 2011). Subsequently, tau inclusions 
become prominent in other areas of temporal lobe such as various hippocampal and 
entorhinal cortex areas and further in the basal temporal lobe and insular cortex (Braak et 
al., 2006; Braak & Braak 1991). Eventually, the lesions start to develop in various 
neocortical areas. Moreover, NFT-affected areas in AD brain have been suggested to be 
increased in the amount 4R-tau compared to 3R-tau (Yasojima et al., 1999). Although AD 
is the most common and most widely studied sporadic (secondary) tauopathy, it is still 
incompletely understood how tau hyperphosphorylation, filament formation and 
subsequent formation of NFTs and tau deposition impact on the impairment of cognition, 
learning and memory deficits (Wang & Liu 2008). 
2.5.1.2 4R-tauopathies 
 
In the majority of primary tauopathies 4R-tau is the predominant tau isoform observed in 
tau inclusions. 4R-tauopathy phenotypes include corticobasal degeneration (CBD), 
progressive supranuclear palsy (PSP), argyrophilic grain disease (AGD) and globular glial 
tauopathy (GGT) (Kovacs 2015). Upon the first description of CBD and PSP they were 
initially classified, both clinically and pathologically, as separate disorders (Steele et al., 
1964; Rebeiz et al., 1968). Currently, due to the overlapping pathological, clinical, genetic 
and biochemical features, there is a consensus that CBD and PSP may comprise a disease 
spectrum (Kouri et al., 2011). 
 CBD is characterized as a rare, sporadic and clinically heterogenous progressive NDD 
with age of onset ranging from early fifties to late seventies with average disease duration 
being 7 years (Kouri et al., 2011). The wide variety of clinical presentation, including 
sensory, motor, cognitive and behavioural symptoms, highly complicate the diagnosis of 
CBD in living patients hence underlying the importance of neuropathological examination 
for definitive diagnosis (Litvan et al., 1997). Although the aetiology and epidemiology of 
CBD remain incompletely understood, neuronal and glial (astrocytes and 
oligodendrocytes) 4R-tau depositions are highly prominent (Kouri et al., 2011). More 
specifically, neuropathological diagnostic criteria of CBD include the presence of tau-
positive neuropil threads predominantly in the forebrain structures, such as gray and white 
matter of cortex, basal ganglia, diencephalon and rostral brainstem, and ballooned neurons 
(Dickson et al., 2002; Dickson 1999). Additionally, astrocytic plaques are the 
pathognomonic, i.e. a specific or even defining feature of particular disease, lesion in 
CBD (Feany & Dickson 1995). Interestingly, it was recently discovered that tau mutation 
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N410H in exon 13 cause CBD (Kouri et al., 2014). Moreover, the case of CBD caused by 
N410H had identical neuropathology with sporadic CBD in a study conducted with a 
cohort of autopsy-verified cases. Furthermore, an inherited tau H1 haplotype, or H1/H1 
genotype in addition to H1c subhaplotype, all confer the risk for CBD (Dickson et al., 
2007; Kouri et al., 2011).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Braak staging. By examining hundreds of post mortem Alzheimer’s disease 
brains it is possible to follow the average longitudinal progression of the disease. 
Accumulation of neurofibrillary tangle (NFT) pathology typically begins in the locus 
coeruleus and transentorhinal area (Braak stages I and II), subsequently progressing into 
limbic areas in Braak stages III and IV, and eventually reaching the neocortical and 
primary sensory areas in stages V and VI. NFTs were stained by using 
immunohistochemistry with an antibody against hyperphopshorylated tau. In the lower 
panel, increasing density of shading indicates increasing tau pathology over time (t). 
White arrows indicate the direction of NFT progression in the brain. Modified from 
Boutillier et al., 2007; Jucker & Walker 2011. 
 
 
In CBD, the pathology is predominantly focused on circumscribed cortical atrophy and 
variable subcortical areas (Kouri et al., 2011). Hence, individual presentation of CBD 
pathology may vary significantly between numerous clinically distinct syndromes. 
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Generally in NDDs, the clinical syndrome represents the topography of the specific lesion 
whereas it is not inevitably the nature of the pathology underlying the disease. Owing to 
the heterogenous pathology, wide range of clinical syndromes can be exhibited in patients 
with CBD, including corticobasal syndrome (CBS), Richardson syndrome, which is the 
main clinical presentation of PSP, bvFTD, posterior cortical atrophy, progressive aphasia 
and AD-like dementia (Raggi et al., 2007; Josephs et al., 2006; Gorno-Tempini et al., 
2004; Kertesz et al., 2000; Grimes et al., 1999; Murray et al., 2007; Bergeron et al., 1996; 
Williams et al., 2005; Bergeron et al., 1998). Furthermore, many NDDs present CBD 
mimicry, i.e. diseases resembling CBD although having different underlying pathologies, 
including e.g. Parkinson’s disease (PD), PSP, multiple system atrophy (MSA) and AD 
(Kouri et al., 2011). The main features of CBS include the classical motor presentation of 
CBD, parkinsonism that is unresponsive to levodopa, asymmetric rigidity and akinesia 
along with other basal ganglia and cortical dysfunctions such as cortical sensory deficits 
and myoclonus, i.e. involuntary muscle twitching (Riley et al., 1990). Severe postural 
instability, which can lead to unexpected falls very early after the onset of the disease 
characterize Richardson syndrome, with additional symptoms such as dysarthria (motor 
speech disorder), dysphagia (difficulty to swallow), frontal cognitive defects, a lurching 
gait (commonly described as patient is resembling a drunken sailor or a dancing bear) and 
vertical supranuclear gaze palsy (Williams et al., 2005; Steele et al., 1964). Patients with 
primary progressive aphasia exhibit dementia disorder in which the progressive language 
impairment is the main disruption (Mesulam 2001).  
 Unlike in CBD, in which most of the tau pathology is prominent in the forebrain areas, 
tau pathology in PSP is predominantly present in midbrain and hindbrain structures 
(Dickson 1999). More specifically, NFTs, neuropil threads, tufted star-shaped astrocytes 
and oligodendroglial coiled bodies are the hallmark tau-related lesions that are present 
mainly in brain regions such as brainstem, diencephalon and basal ganglia (subthalamic 
nucleus, substantia nigra and globus pallidus) but also in cortical areas and in dentate 
nucleus of cerebellum (Dickson 1999; Williams & Lees 2009). Although PSP is a 
sporadic disorder, some cases with gene mutations are associated with PSP, including e.g. 
S305S, G303V, R5L, intron 10 +16 and deletion N296 (Stanford et al., 2000; Morris et 
al., 2003; Ros et al., 2005a; Ros et al., 2005b; Pastor et al., 2001; Morris et al., 2002; 
Williams et al., 2007b; Poorkaj et al., 2002). Moreover, similar to CBD, MAPT H1 
haplotype and H1c subhaplotype are also associated with the risk of PSP (Dickson et al., 
2007; Kouri et al., 2011). Macroscopically, the atrophy is normally seen in midbrain 
areas. 
 Supranuclear palsy, postural instability and mild dementia are the main characteristics 
of PSP syndrome, which has the disease duration and age of onset highly similar to CBD 
(Williams & Lees 2009). However, substantial variety is exhibited in different clinical 
syndromes that are associated with PSP. These various clinical phenotypes are commonly 
divided into typical and atypical PSP syndromes. The typical syndrome, referred as PSP-S 
(also known as Richardson’s syndrome, PSP-RS) is the most common clinical syndrome 
that present PSP (Josephs 2015). However, it was shown in a recent study of 100 autopsy-
confirmed PSP cases, that only 24% of all patients manifested the typical PSP-S 
(Respondek et al., 2014). The atypical syndromes presenting PSP include corticobasal 
syndrome (PSP-CBS), PD-like syndrome (PSP-P), progressive (or pure) akinesia with gait 
freezing (PSP-PAGF), behavioural variant frontotemporal dementia (PSP-bvFTD), 
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cerebellar ataxia (PSP-C) and with apraxia of speech, i.e. an oral motor disorder with 
difficulty to translate speech into motor plans, with or without aphasia (PSP-AOS) 
(Josephs 2015). Hence, upon comparison of the PSP syndromes to syndromes that are 
associated with CBD, there is a significant overlap between the clinical presentations of 
these diseases. The early clinical manifestations in PSP-P include limb bradykinesia, 
rigidity and occasional tremor (Williams & Lees 2009). In PSP-P patients, similar to PD, 
there is usually moderate or even good responsiveness to initiation of levodopa treatment 
especially addressing bradykinesia and rigidity (Williams et al., 2005), although the effect 
wears off commonly after a few years from starting the therapy (Birdi et al., 2002). PSP-
PAGF is a syndrome characterized by symptoms such as progressive onset of gait 
disturbances (start hesitation) followed by freezing of either gait, speech or writing and 
unresponsiveness to levodopa (Williams et al., 2007a). Additionally, the lack of tremor, 
rigidity, dementia and abnormalities in the eye movement in the first 5 years since the 
disease onset are typical for PSP-PAGF.  
 The definite diagnosis is highly challenging even in autopsy, and misdiagnosis is not 
rare due to the significant clinical heterogeneity between different PSP-related syndromes 
(Williams & Lees 2009). Due to the complete lack of any therapeutics available for PSP 
as well as for CBD, there is an urgent need for improved biomarkers and neuroimaging 
techniques for earlier diagnosis, and, perhaps some novel insights for future treatment 
strategies as well (Josephs 2015). Intriguingly, a recent study, which is the first GWAS-
based study in CBD, identified genes MAPT (SNP rs393152) and MOBP (SNP 
rs1768208) as genetic risk factors for both CBD and PSP (Kouri et al., 2015). Strikingly, 
in a separate report that was published virtually at the same time, the SNP rs1768208 was 
associated with elevated levels of appoptosin, which is a protein that correlates with 
caspase 3 activity hence affecting the caspase 3-mediated tau cleavage (Zhao et al., 
2015a). Moreover, it was suggested that upregulation of appoptosin induces tau cleavage 
by caspase 3 resulting in PSP-associated impaired motor function and aggravated 
neuropathology, implicating a novel mechanism for PSP pathogenesis.      
 Argyrophilic grain disease (AGD) is a fairly common sporadic 4R-tauopathy with 
usually a very late age of onset, average being 75-80 years (Braak & Braak 1998). The 
characterization of AGD is based on the presence of argyrophilic grains (AGs), which are 
the most important pathological hallmark inclusion in AGD, pre-tangle neurons, coiled 
bodies in oligodendrocytes and tau-containing astrocytes. Small AGs, which are either 
spindle-shaped, round, button- or rod-like bodies predominantly localized in dendrites and 
their branches (Ikeda et al., 1995; Tolnay et al., 1998), although they have been also 
observed in axons (Tolnay & Clavaguera 2004). AGs most likely originate from pre-
tangle neurons of the transentorhinal and entorhinal cortices, hippocampus (CA1 area), 
dentate gyrus, presubiculum, adjacent temporal cortex and some other cortical areas, 
amygdala (basolateral nuclei) and lateral tuberal nucleus of thalamus (Tolnay et al., 1998; 
Tolnay & Clavaguera 2004). In AGD, pre-tangle neurons are constantly observed with 
similar or identical distribution with AGs and show positive staining with the same 
phospho-specific tau antibodies that detect AGs (Ferrer et al., 2003; Tolnay & Clavaguera 
2004). Pre-tangle neurons observed in AGD are highly similar and difficult to distinguish 
from the ones that are present in early tau depositions in AD (Bancher et al., 1989; Braak 
et al., 1994). Oligodendroglial coiled bodies are also constantly detected in AGD although 
they are highly similar to coiled bodies observed in various other tauopathies hence being 
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unspecific to AGD (Ikeda et al., 1998; Komori 1999; Tolnay & Clavaguera 2004). Unlike 
PSP-like tufted astrocytes, in AGD astrocytic tau is present more as bush-like astrocytes 
with thin tau immunoreactive processes, which usually are observed in clusters 
resembling astrocytic plaque formations of CBD (Ferrer et al., 2008). These bush-like 
astrocytes along with thin astrocytic plaque-like formations are prominent mainly in 
amygdala and temporal lobe white matter. Furthermore, ballooned neurons are frequently 
observed in AGD, particularly in the amygdala but also in some neocortical areas (Tolnay 
& Probst 1998). Moreover, NFTs and neuropil threads are variably present in AGD 
mostly localizing within the same areas as AGs and pre-tangle neurons and usually 
represent NFT pathology in the Braak stages I-III (Braak & Braak 1991; Kovacs 2015). 
Macroscopically, the brains of patients with AGD are normally either almost unchanged 
with no apparent atrophy as compared with age-matched individuals or may show minor 
atrophy in the frontotemporal cortex (Tolnay & Clavaguera 2004). However, in AGD 
cases in which the patient is demented, there is severe atrophy of the ambient gyrus, which 
is the junction combining amygdala and temporal lobe (Saito et al., 2002). 
Neuropathologically, AGD can be divided in three (or four) stages according to 
anatomical distribution of AGs in the brain (Saito et al., 2004; Ferrer et al., 2008).  
 Although the cause of AGD is currently unknown and there are no identified risk 
factors beside aging, the disease pathogenesis has been suggested to include the essential 
involvement of oxidative stress-driven activation of stress-activated tau-kinases, which 
further result in tau hyperphosphorylation and subsequent tau aggregation and 
ubiquitination of AGs in pre-tangles and NFTs (Ferrer et al., 2008). Moreover, upon 
incorporation of mutated ubiquitin (UBB+1), which is shown to be present in AG and NFT 
containing neurons in AGD (Fischer et al., 2003), tau degradation is inhibited resulting in 
structures that sequester active tau kinases leading to increased tau phosphorylation in 
AGs and NFTs (Ferrer et al., 2008).  
 Clinical symptoms of AGD typically include dementia and cognitive decline (Togo et 
al., 2002; Saito et al., 2002; Tolnay & Clavaguera 2004), although changes in personality, 
behavioural disturbances, imbalance of mood and emotions, aggression and ill temper and 
loss of episodic memory are occasionally observed (Ikeda et al., 2000; Braak & Braak 
1998). In older AGD patients, additional symptoms including amnesia, irritability, 
delusions and apathy have been also reported (Togo et al., 2005). Interestingly, in study 
conducted with a rather small set of deceased elderly one third of cognitively normal aged 
(approximately 85 years old) individuals was found to have argyrophilic grain pathology 
(Knopman et al., 2003). Hence, it has been suggested that the presence of AG pathology 
in non-demented elderly may predispose or at least increase the probability for developing 
dementia (Josephs et al., 2008).  
 Globular glial tauopathies (GGTs) are a recently defined family of 4R-tauopathies 
presenting various combinations of different clinical features (Ahmed et al., 2013). 
Neuropathologically, GGTs are characterized by the presence of two distinct globular 
glial inclusions (GGIs, hence the name GGT): argyrophilic 4R-tau immunoreactive 
globular oligodendroglial inclusions (GOIs) and 4R-tau immunoreactive globular 
astroglial inclusions (GAIs), which are non-argyrophilic indicating that tau is in non-fully 
fibrillar form. Moreover, tau pathology in neurons usually exhibits as diffuse cytoplasmic 
inclusions, which are either globular or small (pre)tangle-like deposits (Ahmed et al., 
2013; Kovacs 2015). GGTs are chararacterized as a rare sporadic tauopathies with almost 
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all autopsy confirmed cases showed homozygous for H1-haplotype (Tacik et al., 2015; 
Kovacs et al., 2008; Ahmed et al., 2011). Interestingly, a very recent study reported a 
novel tau mutation in a single individual associated with GGT (Tacik et al., 2015). It was 
shown that tau mutation K317N may directly cause GGT, and the pathogenic nature of 
this mutation was further showed by using K317N recombinant tau in a set of 
experiments, which showed decreased tubulin polymerization-promoting activity and 
increase in 4R-tau filament formation. Overall, at the molecular level, the formation of 
unconvential non-fully fibrillar tau inclusions specifically in GGTs is currently 
incompletely understood.  
 In general, brain atrophy in GGT cases is predominantly observed in temporal and 
frontal lobes or precentral gyrus (Ahmed et al., 2013; Tacik et al., 2015; Kovacs 2015). 
However, brain atrophy may differ significantly between patients ranging from very mild 
to significant. According to recent consensus recommendations, GGTs are classified into 
three subtypes, all of which present different clinical manifestations (Ahmed et al., 2013). 
However, there is a significant overlap in neuropathological manifestations between 
different types of GGTs. In type I, there is a predominant involvement of frontotemporal 
areas with presence of GOIs in the white matter. In cases with type II, the anatomical 
distribution of both GOIs and GAIs is more concentrated in motor cortex and 
corticospinal tract. In addition to areas in type II, frontotemporal areas are also affected in 
type III with an abundance of GAIs present in cortical areas together with GOIs. 
Noteworthy, the anatomical distribution of tau pathology (GGIs) in GGTs has strong 
correlation with predominating clinical symptoms (Fu et al., 2010; Kovacs et al., 2008; 
Ahmed et al., 2011). Importantly, GGTs may be often misdiagnosed depending on the 
subtype of the disease due to a significant similarities in clinical features: PiD or FTD in 
type I, PSP, CBD, motor neuron disease (MND) or primary lateral sclerosis (PLS) in type 
II and PSP, CBD or MND in type III (Ahmed et al., 2013).     
2.5.1.3 3R-tauopathies 
 
The only identified primary 3R-tauopathy to date is Pick’s disease (PiD) (also called 
FTLD-tau with Pick bodies), in which the most characteristic features include neuronal 
cytoplasmic argyrophilic Pick bodies (PBs) immunoreactive for 3R-tau, circumscribed 
brain atrophy of the frontal and temporal lobes and widespread white matter degeneration 
(Mackenzie et al., 2009; Delacourte et al., 1996). Spherical or globular tau-positive PBs 
are predominantly present in the granule cells of the dentate gyrus, hippocampal 
pyramidal neurons and in temporal and/or frontal cortical regions but can be also observed 
in subcortical areas (Kovacs 2015). Furthermore, some of the remaining cortical neurons 
that exhibit ballooned shape are called Pick cells. Interestingly, it has been suggested that 
in PiD significant portion of 4R-tau pathology is also present (Zhukareva et al., 2002). 
This is, however, most likely explained either by the presence of 4R-tau in NFTs or 
sometimes rarely the coexisting AGD (Kovacs et al., 2013). The clinical symptoms of PiD 
usually manifest as FTD and progressive aphasia (Piguet et al., 2011; Kovacs et al., 2013). 
The age of onset is typically at early sixties and disease duration is approximately 10 
years. Both the age at onset and duration of the disease shows substantial variability 
ranging from 42-70 years and 2-31 years, respectively, suggesting that Pick’s disease may 
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also affect elderly. Particularly, it has been reported that disease duration may be 
significantly longer in patients presenting lvFTD than with bvFTD (Piguet et al., 2011).     
Another disorder in which 3R-tau is the predominant isoform related to NFT-pathology 
is Down syndrome, where the increased ratio of 3R-tau to 4R-tau is suggested to be driven 
by the overexpression of DYRK1A-kinase due to the chromosome 21 trisomy (Wegiel et 
al., 2011; Shi et al., 2008).  
2.5.1.4 Mixed 4R- and 3R-tauopathies  
 
Primary age-related tauopathy (PART), which was formerly known also as neurofibrillary 
tangle-only dementia, is a primary tauopathy in which NFTs are composed of both 4R- 
and 3R-tau (Crary et al., 2014). NFTs observed in the brains of PART patients are 
identical to the NFTs seen in AD, i.e flame-shaped NFTs localized in neuronal cell bodies 
and apical dendrites. However, PART neuropathology is lacking amyloid plaques. The 
anatomical localization of NFTs in PART is mainly restricted in the structures in medial 
temporal lobe, basal forebrain, brainstem and olfactory structures. Clinical symptoms 
include changes in cognition ranging from normal to amnestic and only a small fraction of 
cases exhibit severe cognitive impairment. Furthermore, especially in cases with amnestic 
cognitive changes, disorientation, depression and paranoia may exist (Jellinger & Attems 
2007). Moreover, the disease duration is usually shorter and the age of onset is higher as 
compared to AD (Janocko et al., 2012). Although it has been implicated that PART, 
especially the rare severe cases, can be associated with age-related memory impairment 
(Nelson et al., 2009; Ikeda et al., 1999), the full clinicopathological spectrum of PART is 
yet to be established given that the PART term and classification were only recently 
introduced (Crary et al., 2014).    
2.5.1.5 Frontotemporal dementia with parkinsonism linked to chromosome 17  
  
Unlike sporadic FTLDs, frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17) is caused by mutations in two genes on chromosome 17, 
MAPT and Progranulin (PGRN), and by using this criteria FTDP-17 has been subdivided 
into FTDP-17 MAPT and FTDP-17 PGRN (Boeve & Hutton 2008). Since the discovery of 
first mutations in MAPT that were all associated with dementia syndrome with signs of 
parkinsonism in some affected individuals (Poorkaj et al., 1998; Spillantini et al., 1998b; 
Hutton et al., 1998), numerous additional mutations have been identified. These findings 
have further underlined the established disease-causative role of tau abnormalities to 
directly result in neurofibrillary degeneration.  
 Hereditary autosomal-dominant FTDP-17 MAPT affect both sexes equally with the 
avarage age at onset of symptoms being 49 years (Ghetti et al., 2015). The average age of 
disease onset is very similar to sporadic FTLDs together with the large range of possible 
appearance of various initial symptoms that may start either as early as in early twenties or 
in late seventies. There is a substantial divergence in life expectancy ranging from 1,5 to 
26 years average being 8,5 years after the onset of symptoms (Wszolek et al., 2003; Reed 
et al., 2001). Intriguingly, clinical disease phenotype may vary significantly between or 
within families carrying the different mutations or even in individuals and families 
carrying the same mutation (Forman 2004; Bugiani et al., 1999). These observations 
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suggest that epigenetics in concert with environmental factors induce variability of 
phenotype manifestation.  
 Clinically, individuals that present fully developed syndrome normally exhibit at least 
two out of three main symptoms: personality and behavioural disturbances, cognitive 
impairment together or without motor dysfunction (Ghetti et al., 2015). The cognitive 
symptoms and behavioural and personality alterations in FTDP-17 MAPT usually fulfill 
the criteria for bvFTD presenting symptoms such as apathy, disinhibition, loss of 
empathy, hyperorality including e.g. excessive use of alcohol or drugs as well as the 
cognitive early stage symptoms including inattention, disorganization, impaired 
judgement and decision making and difficulty in initiating and completing tasks (Neary et 
al., 1998). In the early disease stage the orientation and memory are relatively unaffected. 
Also, an adynamic aphasia syndrome is often seen resulting in reduced speech that is 
normally caused by loss of aspects of language generation. As the disease progresses, the 
memory and visuaspatial function along with orientation are deteriorating eventually 
leading to a progressive dementia covering most of the cognitive aspects and often 
patients entirely lose their ability to speak (Ghetti et al., 2015). Parkinsonism is the most 
predominant motor symptom although in some families motor signs are completely absent 
or may become prominent very late in the disease progression. In case parkinsonism 
exhibits, in FTDP-17 MAPT it is characterized by postural instability, bradykinesia, 
absence of resting tremor and only minor or no responsiveness to levodopa treatment. 
However, in few cases, especially in individuals with N279K mutation in which 
parkinsonism is an early feature, asymmetrical resting tremor has been observed with 
responsiveness to levodopa (Tsuboi et al., 2002).  
 In the MAPT gene, more than 50 pathogenic mutations have been identified (figure 
2.5), of which the most common include exonic mutations N279K and P301L, and +16 in 
intron 10 (Ghetti et al., 2015). Most of the mutations that occur in the coding region of the 
gene are predominantly located in the MBRD, which further deteriorate the ability of tau 
to maintain its normal function in MT-dynamics due to reduced MT-interaction 
(Hasegawa et al., 1998; Hong 1998). Moreover, these exonic mutations are missense, 
deletion or silent and occur in exons 1, 9-13, from which missense mutations in exons 1, 
9, 11, 12 and 13 affect all human tau isoforms (Ghetti et al., 2015). The majority of 
intronic mutations are localized in a cluster in the 5’-splice site of the intron that is 
following exon 10. Together with some missense and silent mutations in exon 10, these 
intronic mutations have an impact on alternative mRNA splicing of exon 10 resulting in 
altered isoform ratios of 4R- and 3R-tau by increasing the amount of 4R-tau (D'Souza et 
al., 1999; Clark et al., 1998; Spillantini et al., 1998b; Hutton et al., 1998). More 
specifically, exonic mutations S305I, S305N and S305S, and, intronic mutations +3, +4, 
+11, +12, +13, +14 and +16 are responsible for destabilizing the stem-loop structure 
leading to increased inclusion of exon 10. The destabilizing effect of these mutations to a 
stem-loop structure at exon 10 5’-splice site intron junction was hypothesized upon the 
identification of the first MAPT mutations (Spillantini et al., 1998b; Hutton et al., 1998). 
The existence of the stem-loop structure, i.e. a structure that is suggested to sequester 5’-
splice sites resulting in alternative 5’-splice site usage (Eperon et al., 1988) in tau has been 
further supported by additional studies (Varani et al., 1999; Grover et al., 1999; Jiang et 
al., 2000; Donahue et al., 2006). Moreover, exon 10 mutations occurring outside the stem-
loop may enhance the splicing of exon 10, which can be regulated by either strengthened 
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exon splicing enhancers or weakened exon splicing silencers (D'Souza & Schellenberg 
2002; D'Souza et al., 1999).  
Figure 2.5. MAPT gene mutations associated with frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17). Schematic representation of MAPT 
gene regions of exons and introns (exons are numbered), where known mutations have 
been found. Currently, more than 50 pathological MAPT mutations have been identified. 
Modified from Ghetti et al., 2015. 
 
 
The effect of coding region mutations may at least partially explain the loss-of-function of 
tau (Ghetti et al., 2015). The combined impact of mutations primarily affecting the RNA 
level is the excess production of 4R-tau, which exceeds the MT-binding affinity and the 
rate of MT-assembly over 3R-tau (Goedert & Jakes 1990). However, some of the exon 10 
mutations, such as P301L, P301S and P301T, occur approximately in only a quarter of all 
tau molecules with rest being wild-type, which strongly emphasize that tau loss-of-
function is not merely adequate in explaining the tau-driven neurodegeneration (Ghetti et 
al., 2015). Importantly, the overproduction of exon 10 may also lead to disequilibrium of 
the amount of possible binding sites in MTs in relation to 4R-tau, which may subsequently 
lead to enrichment of unbound cytoplasmic 4R-tau and eventually promote tau 
accumulation and aggregation. Given that the normal ratio of 4R-tau to 3R-tau isoforms in 
healthy human brain is approximately equimolar (Hong 1998), the disturbed balance of 
this ratio may directly promote tau aggregation (Gong et al., 2005). Although the FTDP-
17 MAPT mutations have not been directly shown to influence tau phosphorylation, it has 
been suggested that certain missense mutations (G272V, P301L, V337M and R406W) can 
result in tau protein that is a better substrate for phosphorylation, which may occur faster 
and with higher extent by kinases compared to wild-type tau in vitro (Alonso Adel et al., 
2004). Also, the conformational change induced by these mutations promotes the 
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sequestration of wild-type tau. Furthermore, the filament formation of tau has been 
reported to be reduced in the presence both 4R- and 3R-tau isoforms when compared to 
cases where only 4R-tau is present (Adams et al., 2010).  
 Unlike tauopathies, which are divided either in 4R-, 3R- or 4R- and 3R-tauopathies, 
FTDP-17 MAPT can present all different isoforms depending on the mutation (Ghetti et 
al., 2015). Nevertheless, as in tauopathies generally, the presence of neuronal or glial tau 
inclusions is invariably a neuropathological hallmark for also FTDP-17 MAPT. 
Noteworthy, tau deposits can be found in neurons or in both neurons and glia whereas 
glia-only deposits have not been observed. Furthermore, there is substantial variability in 
the structure of tau inclusion depending on the specific mutation. Tau deposits 
characterized with mutations V337M in exon 12 and R406W in exon 13 display high 
similarity to inclusions seen in AD whereas some mutations in exons 9, 11, 12, 13 present 
Pick body-like morphology with straight and twisted filament formations mostly 
composed of 3R-tau but also containing variable amounts of 4R-tau, which is the case 
with G389R. Additionally, prominent differences are observed in various mutations 
resulting in presence of variable portions of 4R- and 3R-tau in tau inclusions, e.g. V337M 
inclusions contain both 4R- and 3R-tau, G389R inclusions contain predominantly 3R-tau, 
P301L inclusions contain mostly 4R-tau with occasionally small amount of 3R-tau (figure 
2.6) and mutation +3 in intron 10 contains predominantly 4R-tau. Intriguingly, various 
mutations may also dictate in which cell type tau inclusions are the most prominent. In 
particular, mutations in exons 9, 11, 12 and 13 for the most part result in tau inclusions in 
neurons whereas exon 1 and 10 mutations together with mutations in introns 9 and 10 
mostly lead to tau deposits in both neurons and glia. In cases where glial pathology is 
present, tufted astrocytes and astrocytic plaques with oligodendroglial coiled bodies are 
normally seen. The glial depositions in FTDP-17 MAPT are very similar or identical to 
hallmark features of both PSP and CBD.  
 Similarly to the effect of different mutations that affect the composition variation of 
4R- and 3R-tau depositions, the anatomical distribution of tau inclusions has been 
reported to vary in relation to specific mutations (Ghetti et al., 2015). However, due to 
lack of knowledge in early neuropathological disease progression, most of the available 
data concerning the distribution of tau inclusions comes from the intermediate and late 
stage FTDP-17 MAPT patients. Although the histopathological alterations characteristic to 
FTDP-17 MAPT in cerebral cortex, white matter and subcortical nuclei are visible in the 
intermediate disease stage, the atrophy of cerebral hemispheres may be relatively subtle. 
Later, in more advanced stage of disease progression, brain atrophy in different regions 
may be variable: prominent atrophy is usually present throughout temporal and frontal 
lobes and in amygdala, hippocampus and hypothalamus in addition to some other 
subcortical areas. Moreover, the total atrophy in temporal and frontal lobes may be 
asymmetrical and in the most severe cases the gyri may present in so called knife-edge 
appearance, i.e. the atrophy in the brain gyri is so severe that their appearance is starting to 
resemble sharp blade -like structures in addition to significantly enlarged lateral and third 
ventricles. Conversely, parietal and occipital lobes are usually not affected or at least 
much lesser extent of atrophy is detected. Taken together, FTDP-17 MAPT is highly 
heterogenous disorder with insidious onset that presents in multiple phenotypes and 
clinical symptoms, which complicates the diagnosis particularly in the early disease stage. 
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Figure 2.6. Tau pathology of a patient carrying P301L MAPT mutation. AT8 
(hyperphosphorylated tau at Ser202 and Thr205) immunoreactivity at the dentate gyrus of 
the hippocampus (a). No staining is seen when labeled with 3R-tau isoform specific 
antibody (b) (occasional 3R-tau staining may be seen in patients with P301L mutation), 
whereas 4R-tau isoform specific antibody shows immunoreactivity (c). Coronal T1-
weighted magnetic resonance image from a 62 year-old female with a severe behavioural 
variant frontotemporal dementia (d). Symptoms of the patient evolved in a period of six 
years. Striking bilateral atrophy is evident in the prefrontal and anterior temporal lobes 
and also white matter changes. Modified from Ghetti et al., 2015. 
 
2.6 Alzheimer’s disease   
 
Alzheimer’s disease (AD) is the most common form of NDD causing dementia in the 
elderly and estimated to cover approximately 50-75% of all dementia cases (World 
Alzheimer report, Alzheimer’s international, 2015). AD mainly affects the elderly given 
that only small proportion (2-10%) of all cases is predicted to show clinical symptoms 
before the age of 65 years. After the age of 65 years, the increase in the prevalence and 
incidence of AD doubles with each 5-year age increment. It is estimated that there is 47 
million people suffering from AD today, and due to demographic aging of developed 
societies, it is projected to rise to 74 million by the year 2030 and to reach roughly 130 
million people by the year 2050, manifesting even more severe socio-economic burden 
that it already is today (World Alzheimer report, Alzheimer’s international, 2015). 
However, there are recent reports suggesting that in developed countries the population 
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dementia risk may decline due to e.g. increased level of education and increasing success 
in treating the cardiovascular risk factors including e.g. hypercholesterolemia and 
hypertension (Wu et al., 2015; Langa 2015).   
 Clinical characterization of AD, which has a gradual disease onset, includes a wide 
variety of symptoms that include progressive impairment of memory and deterioration of 
cognition, behavioral changes, depression and apathy, loss of various daily functions such 
as perception, language and judgment, and, also physical functioning during the late 
stages of the disease. Although there is a strong genetic component, aging is still by far 
the most important risk factor for AD. Currently, there is no cure or even ways to halt the 
disease progression and only symptomatic treatments are available with rather mild 
clinical benefits. Moreover, regardless of intensive studies there are no preventive clinical 
methods available for AD. Notably, unambiguous diagnosis of AD is possible only post 
mortem combined with the assessment of the clinical picture of the disease progression, 
which strongly emphasizes the need for improvement of the possibility for early diagnosis 
although there has been some great advances in this field, e.g. brain imaging techniques, 
for the past few years.   
 There are two neuropathological hallmarks that characterize AD; extracellular amyloid 
plaques mainly composed of A? peptide aggregates and intraneuronal neurofibrillary 
tangles (NFTs) that are predominantly composed of hyperphosphorylated tau protein 
(figure 2.7) (Terry & Katzman 1983). Clinically, AD is divided into pre-clinical mild 
cognitive impairment (MCI) and mild-, moderate- and severe AD. Actually, MCI is not 
considered as a stage of AD but more as a pre-AD since all patients with MCI do not 
convert to AD. Furthermore, additional pathological assessment of the disease progression 
is used based on the neuroanatomical distribution of NFT-pathology within the brain 
called Braak staging, which are considered the lesions correlating with the severity of 
cognitive decline and dementia in AD (Braak & Braak 1991). The progressive loss of 
synapses and cholinergic neurons in the basal forebrain usually first appears in the 
entorhinal cortex and hippocampal areas subsequently spreading to cortical areas resulting 
in severe brain atrophy particularly affecting the temporal lobes. Importantly, AD can be 
classified into two distinct types based on the age of the symptom onset and familial 
history. These are familial early-onset AD (EOAD), in which the symptoms start before 
the age of 65 years and sporadic late-onset AD (LOAD), where the symptom onset usually 
occurs after the age of 65 years. Noteworthy, EOAD is estimated to represent only 1-5% 
of all AD cases.    
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Figure 2.7. Neuropathological hallmarks of Alzheimer’s disease (AD). Cortical 
extracellular deposits of amyloid-? (senile plaques) (a) and intraneuronal tau inclusions 
called neurofibrillary tangles (b) are characteristic findings in post mortem examination of 
AD patients. Scale bars 50 ?m (a) and 20 ?m (b). Comparison of a healthy human brain 
and severe AD brain (c). Due to a massive neuronal loss and gliosis, there is a substantial 
atrophy in the frontotemporal cortical areas and some white matter changes. Also, 
ventricles are significantly enlarged. (a) and (b) modified from Jucker & Walker 2013.   
 
2.6.1 Early-onset Alzheimer’s disease 
 
Early-onset Alzheimer’s disease (EOAD) is characterized by the onset of symptoms 
before the age of 60-65 years, strong familial background and is inherited mostly by 
dominant autosomal Mendelian transmission. EOAD is almost invariably caused by very 
rare mutations in three distinct genes, APP, PSEN1 and PSEN2, which encode the proteins 
amyloid-? precursor protein, presenilin 1 and presenilin 2, respectively. Mutations in 
these genes are highly penetrant and nearly always result in development of early onset 
AD. Previously, before the identification of causative AD mutations, the presence of A? 
plaques in both AD and Down syndrome (DS) brain were discovered and further purified 
and characterized (Glenner & Wong 1984b; Glenner & Wong 1984a). Given that a 
trisomy of chromosome 21 is the cause of DS, in which almost all carriers develop AD 
with highly increasing incidence when reaching 40 years of age, lead to a hypothesis that 
mutations in genes that are located in this particular chromosome may cause AD in the 
absense of DS (Glenner & Wong 1984a). This suggested hypothesis was later confirmed 
to be correct by linkage analysis, which had been a crucially important approach in 
causative AD gene identification. 
 Linkage analyses method aims for identifying loci in which the transmission is not 
actually independent but seem to be more often associated with a disease than only 
probability would predict (e.g. Chouraki & Seshadri 2014). Specifically, linkage analysis 
approach utilizes the joint segregation of a specific disease and genetic markers within 
families or in population level. In case a genetic marker is identified in a close proximity 
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with causal variant(s) of a specific disease, the inheritance is preferential along with the 
disease at least within larger families.  
 After the identification of association of chromosome 21 with some forms of familial 
EOAD (St George-Hyslop et al., 1987), the APP gene was suggested as a novel candidate 
gene that was located in this locus (Tanzi et al., 1987; Goldgaber et al., 1987; Robakis et 
al., 1987; Kang et al., 1987). These results were further confirmed upon identification of 
association of specific APP mutations in different families with EOAD (Murrell et al., 
1991; Mullan et al., 1992; Goate et al., 1991; Chartier-Harlin et al., 1991). Although the 
discovered linkage peak on chromosome 21 was verified via findings of APP mutations, 
these mutations did not sufficiently manage to completely explain all the familial EOAD 
cases. These doubts were confirmed by the discovery that EOAD is not genetically 
homogenous disorder (St George-Hyslop et al., 1990; Schellenberg et al., 1988) and 
further resulted in the identification of additional linkage peaks in chromosome 14 
(Schellenberg et al., 1992) and chromosome 1 (Levy-Lahad et al., 1995b). Subsequently, 
the causative EOAD mutations were identified in the corresponding genes PSEN1 and 
PSEN2 on chromosomes 14 (Sherrington et al., 1995) and 1 (Levy-Lahad et al., 1995a), 
respectively.  
 These pivotal discoveries in EOAD genetics resulted in the formulation of a hypothesis 
called amyloid cascade -hypothesis stating that A? accumulation is the primary cause of 
progressive AD pathogenesis in the brain (Hardy & Higgins 1992; Hardy & Allsop 1991), 
which has been modified and specified over the years (Hardy & Selkoe 2002). Regardless 
of the ongoing debate whether the amyloid cascade -hypothesis is the leading pathogenic 
mechanism in AD, it has been a foundation for numerous attempts for improved 
diagnostics and targeted therapeutics in AD.  
 A? peptides are proteolytic cleavage products of APP protein, a type I transmembrane 
protein with incompletely understood physiological functions (Haass et al., 2012). 
Proteolytic processing of APP can occur via two competing physiological pathways: non-
amyloidogenic pathway and amyloidogenic pathway. Firstly, in the non-amyloidogenic 
pathway, APP is cleaved by ?-secretases (Sisodia et al., 1990; Esch et al., 1990) resulting 
in soluble APP fragment (sAPP?) and truncated C-terminal APP fragment (?CTF, also 
called C83) followed by an intramembrane cleavege by ?-secretase that generates APP 
intracellular domain (AICD) (Sastre et al., 2001; Gu et al., 2001) and p3 peptide (Haass et 
al., 1993). ?-secretase is a large intramembrane protease complex that consists of four 
distinct subunits including presenilin 1 (PS1) or presenilin 2 (PS2), which are the catalytic 
subunits, nicastrin (NCT), anterior pharynx defective 1 (APH-1) and PS enhancer 2 (PEN-
2) (Wolfe et al., 1999; Francis et al., 2002; Yu et al., 2000), which all are essential 
components of full enzymatic activity of ?-secretase (Bai et al., 2015; Edbauer et al., 
2003). In a competing pathway, the ectodomain of APP is first cleaved by ?-secretase, 
mostly by BACE1 (Vassar et al., 1999) generating a soluble APP fragment (sAPP?) and a 
C-terminal fragment ?CTF (also known as C99). This is followed by ?-secretase cleavage, 
which liberates A? peptide that can vary in length and biochemical properties due to a 
variation in ?-cleavage cleavage site, from which the most frequent species are A?40 and 
the more toxic, aggregation prone A?42 (Benilova et al., 2012). Unexpectedly, a novel 
physiological APP processing pathway was recently identified (Willem et al., 2015). 
Specifically, the generation and enrichment of ?-secretase mediated C-terminal APP 
fragment ? (?CTF) is capable to inhibit neuronal activity in hippocampus. Moreover, an 
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increase of ?CTFs was observed in close proximity with neuritic plaques in dystrophic 
neurites in both mouse model of AD and in AD human brain suggesting that physiological 
?-secretase activity may be altered in AD pathogenesis.      
 Most of the mutations in APP, PSEN1 and PSEN2 genes promote amyloidogenic 
processing of APP resulting in relative increase in A?42 formation and the possible 
subsequent generation of neurotoxic A? oligomers (Citron et al., 1992; Scheuner et al., 
1996). As postulated in the amyloid cascade -hypothesis, this observed increase of A?42 
caused by either increased A? generation, which seem to be the case in EOAD mutations, 
or by decreased A? clearance and degradation is the trigger for consequent cascade in AD 
pathogenesis, including tau hyperphosphorylation and NFT formation, neuronal death and 
eventually leading to progressive brain atrophy and dementia (e.g. Hardy & Selkoe 2002). 
However, although the A? plaque pathology seems to precede NFT pathology, it is widely 
established that NFTs are the primary lesions that correlate with the severity of cognitive 
decline and rate of dementia in AD (Buee et al., 2000; Wang & Liu 2008). Taken 
together, 40 mutations in APP, 197 in PSEN1 and 25 in PSEN2 genes have been reported 
to date with all showing autosomal dominant inheritance and complete penetrance 
(Chouraki & Seshadri 2014), except for one recessive APP mutation (Di Fede et al., 
2009). Importantly, no mutations outside these genes have been found in EOAD, whereas 
any mutations in these genes have not been associated with late-onset AD. The only 
exception responsible here is by a single APP coding mutation (A673T) identified in the 
Icelandic population that was found to be protective against AD (Jonsson et al., 2012).      
2.6.2 Late-onset Alzheimer’s disease 
 
Late-onset Alzheimer’s disease (LOAD) is a complex NDD with exponentially increasing 
incidence after the age of 65 years and the leading cause of dementia in the elderly. In 
LOAD, neuropathological findings including senile plaques and NFTs are highly similar 
to EOAD. After aging, APOE, specifically the ?4 allele of APOE, is the strongest risk 
factor and simultaneously the most important genetic risk factor for LOAD (APOE 
chapter 2.6.3.2.1) (Bettens et al., 2013). Besides aging and genetic risk factors, a large 
variety of other risk factors have been suggested to contribute to pathogenesis of LOAD, 
including cardiovascular factors such as hypertension and hypercholesterolemia, history 
of head trauma, neuroinflammation and type II diabetes mellitus (Whalley et al., 2006). 
Conversely, some simple lifestyle choices, such as diet, physical and social activity and 
stimulation of cognition are associated with decreased incidence of LOAD. Recently, it 
was suggested that people who were overweight in midlife develop LOAD at earlier age 
and were associated with increased AD neuropathology (Chuang et al., 2015). Although 
both genetic and environmental factors contribute in the aetiology of LOAD, the exact 
mechanism(s) how these factors are interconnected remain poorly understood. However, it 
is well established that LOAD brain pathology precedes the onset of clinical symptoms by 
years or even decades, which underlines the importance of early diagnosis in order to 
initiate possible therapeutic measures in the very early stage of the disease.  
 The first implications of participation of APOE to AD came from the observations that 
APOE per se is the protein shown to be expressed upon injury and repair of neuronal 
damage (Ignatius et al., 1987; Ignatius et al., 1986). This was followed by studies 
reporting APOE overexpression in AD (Diedrich et al., 1991) and a discovery of a linkage 
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peak on chromosome 19 associated in families with history of LOAD (Pericak-Vance et 
al., 1991). Furthermore, APOE protein was found to colocalize with both amyloid plaques 
and NFTs in AD (Wisniewski & Frangione 1992; Namba et al., 1991). Subsequently, the 
association of ?4 allele of APOE with both LOAD and EOAD was reported by first 
showing the direct high affinity binding of APOE to A? and the more frequent presence of 
?4 in LOAD with familial background (Strittmatter et al., 1993). Secondly, the results that 
APOE ?4 allele is in fact involved in both sporadic and familial LOAD was confirmed 
(Saunders et al., 1993). Thirdly, the gene dosage of APOE ?4 in LOAD families was 
established and suggested that APOE ?4 carriers manifest an earlier disease onset and 
dementia than non-carriers (Corder et al., 1993), which was further confirmed in a case-
control study of sporadic form of LOAD (Poirier et al., 1993). Conversely, the reduced 
frequency of APOE ?2 allele in AD was reported suggesting a protective role of ?2 allele 
against LOAD (Corder et al., 1994). Importantly, unlike causative mutations in APP, 
PSEN1 and PSEN2 in familial EOAD, APOE ?4 allele is a risk factor for LOAD, which is 
not capable alone causing the disease. In contrast, APOE ?4 is not a prerequisite for 
developing AD since approximately half of the people with AD are APOE ?4 non-carriers. 
Hence, APOE ?4 has been defined as a moderately penetrant genetic factor with a semi-
dominant inheritance (Genin et al., 2011). Furthermore, the APOE genotype-dependent 
lifetime risks of developing AD have been estimated in non-carrier, heterozygote and 
homozygote in 85 year-old women to be 30%, 51% and 60%, respectively. The 
corresponding values in 85 year-old men are 11%, 14% and 23%, respectively. Both 
estimations are calculated based on current average lifetime expectancies and may be 
subject to change in time. 
 The discovery of association of APOE and LOAD launched a tremendous number of 
candidate-gene-based studies (over 1000 studies in less than 10 years) in order to identify 
additional risk genes for AD (Bettens et al., 2013; Chouraki & Seshadri 2014). The genes 
selected for a candidate gene study were usually based either on their assumed or 
predicted role in AD pathophysiology or linkage study-based localization within a linkage 
peak according to AD. Although multiple mutations in genes involved in various AD-
related pathways were assessed, unfortunately these findings were rarely successfully 
replicated, which is most likely due to an inadequate sample size resulting in initial false-
positive findings. Another shortcoming in candidate-gene-based studies capable of 
creating further inconsistencies in the results is the associations that are located in the non-
coding region of a gene, which may by highly important in gene regulatory function but 
are extremely hard to study in biological pathways. However, despite of the mostly 
disappointing results obtained from the candidate-gene approach studies, sortilin-related 
receptor LDLR class A repeats (SORL1) gene was identified in addition to APOE 
(Rogaeva et al., 2007). Importantly, the finding has been replicated and confirmed in 
genome-wide association studies (GWAS) (Miyashita et al., 2013; Lambert et al., 2013b).  
2.6.3 Genetic risk factors of late-onset Alzheimer’s disease 
2.6.3.1 Genome-wide association studies 
 
The principle of genome-wide association studies (GWAS) is highly similar to genetic 
association study where frequency of alleles of specific variant are compared in disease 
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case and control populations (Bertram et al., 2010; Chouraki & Seshadri 2014). Unlike the 
genetic association studies, in which the tested variants are selected based on prior 
hypothesis or known pathways of a few candidate genes, the GWAS approach is largely 
hypothesis-free. Importantly, besides focusing on the preconceived hypothesis of certain 
variants and candidate genes associated with the disease, in GWAS the entire genome is 
covered in terms of known polymorphisms. Accordingly, this allows the detection of 
common variants via enhanced resolution and a larger statistical power compared to 
linkage analysis. These advantages make GWAS highly useful and adaptable to study the 
variation of common genes associated with complex disease.  
 Although GWAS has many advantages, the massive number of statistical testing is an 
importantly critical issue, which can increase the risk of false-positive results. In order to 
avoid false-positive GWAS signals, highly stringent criteria have been used for statistical 
significance in order to reproduce the results. Hence, because of the essentiality of 
reproducing the results to verify the observed genome-wide association, GWAS are 
usually organized in two distinct phases (Chouraki & Seshadri 2014). Firstly, in a 
genome-wide discovery stage, in which the p-value threshold is usually set to 5 × 10-8, 
certain associations that reach statistical significance is established (McCarthy et al., 2008; 
Chouraki & Seshadri 2014). Secondly, in a replication stage the associations of selected 
variants are studied by utilizing de novo genotyping methodology in different independent 
populations (Chouraki & Seshadri 2014). To obtain the most novelty in possible 
discoveries from GWAS it would be optimal to include all the GWAS sample data 
available at given time. 
 The two separate GWAS phases can be further divided into multiple steps within the 
process (Hardy & Singleton 2009). In the first step, the single-nucleotide polymorphisms 
(SNPs) are genotyped genome-wide. This is almost exclusively performed on chip-based 
products manufactured by the two leading companies, namely Illumina and Affymetrix. 
Although the genotyping content of these chips differs, there is a possibility of genotype 
imputation1, which may further alleviate the competition between different groups 
utilizing various methods, and, enhance the collaboration and comparison of the data. 
Finding the missing genotypes by imputation, it is crucial for forming a common set of 
genetic SNPs and further performing meta-analyzes when various platforms have been 
used (Zeggini & Ioannidis 2009).  
 After generating the raw SNP data set, the second step includes cleaning procedures 
and quality control of the data (Hardy & Singleton 2009). These procedures (i) ensure that 
the genotyped sex matches the sex reported for each individual sample (X and Y 
genotypes), (ii) measure the sample matching as a group and (iii) identify individual 
outliers. Outlier identification, which is based on patterns of genetic variability, enables 
the sample removal of the ethnically remote subjects, and, also allows the adjustment of 
any kind of systematic variations within or between cohorts. Next, in the third step, all the 
SNPs that survive the cleaning and quality control step are further tested for association 
trait or some specific disease. At this step, to avoid any false-positive signals and because 
                                                       
1 A statistical technique estimating the genotypes that are missing from the specific population by 
comparing different haplotypes of the specific population to populations with denser reference 
panel (i.e. predicting untyped SNPs from those SNPs that have been genotyped) (Marchini & 
Howie 2010; Chouraki & Seshadri 2014) 
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of the massive amount of statistical tests performed, a stringent p-value threshold for 
genome-wide statistical significance is set. Specifically, the most generally studied risk 
models include dominant, recessive, genomic, allelic and additive, which is the most 
commonly tested. The additive model is assuming that when one allele is present it is 
conferring an intermediate risk compared to having no or two alleles. Fourth step 
encompasses the selection of loci or SNPs to be replicated in an independent set of 
samples, which is preferably larger or at least the same size sample set tested in the 
genome-wide association. The selection process of loci may be based either on statistical 
significance, or, on statistical significance and biological plausibility together. Hence, 
depending on the resources available and the original study design, the amount of SNPs 
can vary largely, from as few as 10 to even 20000. Fifth, any combination of following 
three results is obtained from step four: (i) clear and unambiguous association with the 
selected loci with disease, (ii) no association signal is detected at all, or, (iii) association 
with loci and disease is detected but the magnitude of the association is insufficient to pass 
a predetermined threshold of statistical significance.  
 Sixth step, which is the first step of the replication stage of GWAS, independent 
cohorts are used for additional genotyping to ensure the association with disease, i.e. if the 
obtained signals genuinely are valid or not. Lastly, the seventh step includes multiple parts 
starting from data mining, in which unequivocally associated loci unveils transcripts 
located in and near proximity of any specific locus. Additionally, in this part all known 
genetic variation within the specific region are mapped. Next, further locus fine mapping 
is performed in order to discover any possible novel variants and to genotype untyped 
variants, to further validate the significance of the association with the disease. 
Importantly, more specific analysis of the region is performed to specify the most 
essential variants, the gene that is pathophysiologically most relevantly associated to 
disease, and, to possibly interpret the relevance on biologic effect. 
 For the past ten years, GWAS have been truly a major leap forward in identifying a 
vast number of robust genome-wide associations between the specific loci in 
chromosomes and highly complex human disease (Hardy & Singleton 2009; Lord et al., 
2014). Highly reduced expenses and development of arrays of multiplex genotyping and 
whole-genome and -exome sequencing have enabled the advent of completely novel 
hypothesis-free approach to study genetics of human disease (Bertram et al., 2010). The 
revolutionary advances in microarray technology have made it now possible to assess 
hundreds of thousands or even millions of SNPs in a single experiment. The next-
generation sequencing will hopefully further mitigate the huge workload yet ahead to 
more specifically understand and establish the connection of genotype and human disease.  
2.6.3.1.1 Genome-wide association studies in late-onset Alzheimer’s disease 
 
When the first AD GWAS were reported, the results were initially disappointing because 
they only confirmed the association of APOE ? allele to AD (Li et al., 2008; Coon et al., 
2007; Webster et al., 2008; Abraham et al., 2008). However, novel AD associated loci 
were also identified near genes GAB2 and PCDH11X (Carrasquillo et al., 2009; Reiman et 
al., 2007), but these findings have so far turned out to be difficult to replicate in later 
studies (Miar et al., 2011; Wu et al., 2010; Beecham et al., 2010). Difficulties in 
replicating the initial findings may be due to a smaller sample size used in the replication 
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phase compared to the discovery phase, or, they can merely point out to be false-positive 
signals (Chouraki & Seshadri 2014). Additionally, a number of other AD associated loci 
have been reported, e.g. ATXN1 (Bertram et al., 2008), LMNA (Grupe et al., 2007), 
CHRNB2 (Cook et al., 2004) and ACE (Kehoe et al., 1999) that lack conformation by 
replication studies. Albeit the initial AD GWAS results were mainly disappointing they 
rapidly lead to initiation of multiple consortia (Chouraki & Seshadri 2014). Large 
international consortia, such as the European Alzheimer’s Disease Initiative (EADI) and 
the Genetic and Environmental Risk in Alzheimer’s Disease (GERAD), are pooling data 
from several thousands of participants across the globe.  
 The first convincing truly large scale studies were two back-to-back published reports 
in 2009 from two distinct consortia (EADI and GERAD) that showed for the first time AD 
associated variants other than APOE (Harold et al., 2009; Lambert et al., 2009). These 
studies identified three novel AD associated genes, i.e. CLU, CR1 and PICALM. 
Importantly, these reports independently identified genome-wide significant signal in one 
variant of CLU gene. Consequently, these two studies are considered as hallmark 
publications for showing the first susceptibility genes for late-onset Alzheimer’s disease 
beside the APOE. In the following year, a study conducted by the Cohorts for Heart and 
Aging in Genomic Epidemiology (CHARGE) consortium, identified different variants in 
BIN1 associated with AD (Seshadri et al., 2010). These results were obtained by utilizing 
a three-phase approach that combines independent set of GWAS followed by two-stage in 
silico replication process using the GWAS data from previous EADI and GERAD 
consortia results. Next, the results that reached genome-wide significance after the 
replication were de novo genotyped in an independent Spanish cohort. Another gene, 
EPHA1, also reached genome-wide significance although the signal was significant only 
in the first stage of the two-stage in silico replication phase. Interestingly, this was the first 
study to use imputation in AD related GWAS and also the first to report results from 
meta-analyzes of multiple different datasets that have been previously shown to associate 
with AD risk genes.  
 Another collaboration project between three consortia (EADI, CHARGE and GERAD) 
discovered new variants in ABCA7 gene associated with AD (Hollingworth et al., 2011). 
Simultaneously, a GWAS study from the Alzheimer’s Disease Genetics Consortium 
(ADGC) identified association of MS4A gene cluster (e.g. MS4A4A, MS4A6A and 
MS4A6E) with AD (Naj et al., 2011). In addition, by combining their data, the 
collaboration of these two studies from different consortia managed to identify additional 
signal in (or near) genes EPHA1, CD2AP and CD33 (Hollingworth et al., 2011; Naj et al., 
2011). Furthermore, this study replicated the results of previous studies and validated the 
findings of AD associated risk genes, such as CR1, CLU, PICALM and BIN1, thereby 
establishing the status of these genes as AD susceptibility factors (Naj et al., 2011). 
Importantly, most of these associations have been replicated in different population 
cohorts by either using cross-replication approach, or, by utilizing targeted sequencing or 
genotyping of previous and novel loci discovered, thereby validating the identified signals 
(Carrasquillo et al., 2010; Biffi et al., 2010; Lambert et al., 2011). Notwithstanding the 
multiple replication studies, many previous and novel AD GWAS signals, such as 
MTFDH1L (Naj et al., 2010), ATP5H/KCTD2 (Boada et al., 2014), GAB2 (Reiman et al., 
2007) and PCDH11X (Carrasquillo et al., 2009) are lacking verification and yet needs 
consistent replication. 
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 The attempt to diminish or even abolish the constantly growing overlap of the 
individual study participants between the studies and various consortia a new mega 
consortium was initiated (Chouraki & Seshadri 2014). Naturally, another reason to 
establish this new consortium, called the International Genomics of Alzheimer’s Project 
(IGAP), was to further facilitate novel AD GWAS discoveries. The first “mega” meta-
analysis study conducted by IGAP using European cohorts across the ADGC, EADI, 
CHARGE and GERAD populations confirmed all the previous GWAS loci with the 
exception of CD33, which only reached genome-wide significance in the discovery phase 
(Lambert et al., 2013b). Moreover, new loci in or near 11 genes were identified: CASS4, 
CELF1, DSG2, FERMT2, HLA-DRB5/DBR1, INPP5D, MEF2C, NME8, PTK2B, 
SLC24H4-RIN3, SORL1, and ZCWPW1. From these loci, SORL1 has been previously 
discovered and reach genome-wide significance in a different GWAS study with 
participants of European and Asian ancestry (Miyashita et al., 2013). These two separate 
studies thereby confirm the association of SORL1 in AD. Currently, a lot of effort is used 
to trying to replicate these novel AD GWAS signals, and, at least ZCWPW1 has been 
already confirmed to associate with AD in a study of large Spanish sample cohort (Ruiz et 
al., 2014b). Additionally, by using GWAS complementary method called genome-wide 
haplotype association (GWHA) study with three-step approach, genetic association of 
FRMD4A gene with AD was identified (Lambert et al., 2013a). Interestingly, FRMD4A 
expression has also shown to be altered in the disease progression of AD according to 
Braak staging (Martiskainen et al., 2015).  
 Despite of its robust efficacy, AD GWAS has some substantial limitations (Lord et al., 
2014; Chouraki & Seshadri 2014). Firstly, in GWAS, only the signals of truly trait-
associated common variants can be detected. This is mainly due to commonly used 
GWAS genotyping chips including these variants. At this study design, rare variants 
remain poorly targeted. Secondly, despite of myriad of AD associated loci that have been 
discovered, the variants, i.e. SNPs, underpinning these associations are yet largely 
unknown. Specifically, the variants within the specific locus with the strongest association 
usually are located in the intronic, or unfortunately even in the intergenic regions of the 
identified loci. Indeed, this makes interpretation of data highly complex because the 
causality of the factors of specific loci to AD aetiology remains largely unclear. Earlier, a 
theory postulating that the rare causative mutations are the principal source that underlies 
the association of AD GWAS variants has been mostly withered due to difficulty of 
explaining the connection between common coding variability and disease association 
regardless of the large resequencing effort (Guerreiro et al., 2010).      
Regardless of a number of limitations, the advent of GWAS in AD has been a major 
leap forward in AD genetics. Beside APOE, several polymorphisms in or near genes have 
been identified to date by GWAS associated with late-onset AD risk, including ABCA7, 
BIN1, CASS4, CD33, CD2AP, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-
DRB5/DBR1, INPP5D, MS4A, MEF2C, NME8, PICALM, PTK2B, SLC24H4-RIN3, 
SORL1, and ZCWPW1 (figure 2.8) (Medway & Morgan 2014; Calero et al., 2015; Karch 
& Goate 2015). Moreover, the association of FRMD4A (Lambert et al., 2013a) and TRIP4 
(Ruiz et al., 2014b) to AD susceptibility has been reported. Although the effect size of 
these identified common variants conferring to AD risk is small, it has already broadened 
our perspective of how and which pathways and pathophysiological processes are 
involved in risk of developing AD (e.g. Karch & Goate 2015; Chouraki & Seshadri 2014). 
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In contrast to common variants, rare coding variants usually have modest or even large 
effect size on AD risk. In addition to rare coding variants in genes APP, PSEN1 and 
PSEN2 associated to early onset familial form of AD, novel loci have been reported, 
including TREM2 (Jonsson et al., 2013; Guerreiro et al., 2013a) and PLD3 (Cruchaga et 
al., 2014). However, replication study of the PLD3 gene variants failed to show any 
significant association with AD (Hooli et al., 2015). Recently, loss-of-function variants of 
ABCA7 gene were reported to confer risk of AD with fairly high effect size (Steinberg et 
al., 2015).    
 
Figure 2.8. Genetic landscape of late-onset Alzheimer’s disease (LOAD). Multiple 
genome-wide association studies during the past few years have provided an enormous 
amount of data regarding to genetics of LOAD. Unlike the autosomal dominant disease-
causative genes APP, PSEN1 and PSEN2, majority of the identified common LOAD 
susceptibility genes have a very low single contribution to LOAD pathogenesis (bottom 
right). Among common susceptibility genes, APOE ?4 (hetero- and homozygote) increase 
the risk from mild to moderate. Conversely, rare variants such as TREM2 typically 
contribute more strongly to incidence and pathogenesis of the disease. Color-coding (top 
right) of the genes refers to their cellular functions; the main known cellular function is 
indicated with color inside the circles and additional function on the surface of the circle. 
However, for many susceptibility genes, their cellular functions and the possible 
contribution to LOAD pathogenesis is poorly understood and replication studies are 
needed for many genes, e.g. PLD3 to establish the association with LOAD. Modified from 
Karch & Goate 2015. 
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2.6.3.2 Identified late-onset Alzheimer’s disease susceptibility genes  
 
The identified common alleles in genome-wide associated genes associated with AD can 
be classified in three different pathways, including lipid and cholesterol metabolism 
(APOE, CLU, ABCA7 and SORL1), synaptic vesicle recycling and endocytosis (SORL1, 
BIN1, PICALM, CD2AP, EPHA1 and FRMD4A) and immune system function (CR1, 
CD33, CLU, ABCA7, EPHA1, BIN1 and MS4A-cluster) in which some genes are 
overlapping between these pathways (table 2.2) (Jones et al., 2010; Bertram et al., 2008; 
Medway & Morgan 2014; Karch & Goate 2015).  
2.6.3.2.1 APOE 
 
APOE gene encodes apolipoprotein E (APOE) and is located on chromosome 19q13.2 
(Pericak-Vance et al., 1991; Siest et al., 1995). APOE is a highly pleiotropic glycoprotein 
comprised of three different isoforms, which are determined by two different variations in 
amino acid sequence (cysteine-to-arginine substitutions at 112 and 158 positions) and are 
called APOE2 (C112, C158), APOE3 (C112, R158) and APOE4 (R112, R158) with the 
corresponding alleles ?2, ?3 (which is the most common form) and ?4, respectively 
(Zannis et al., 1982; Weisgraber et al., 1981). The principle role of APOE is to participate 
in transport of cholesterol and other lipids both in the periphery and brain (Mahley 1988). 
In the brain, APOE is the predominant lipoprotein and functions as a ligand for low 
density lipoprotein receptors (LDLRs). Additionally, APOE is involved in mediating the 
binding and internalization of lipoproteins in cells. Besides its crucial role in lipid and 
lipoprotein metabolism, APOE has numerous other important roles in the CNS, including 
modulation of neuroinflammation and synaptic plasticity (Kim et al., 2009a).  
 APOE genotype, especially APOE ?4 allele, is the most important genetic risk factor 
that contributes to the pathogenesis of sporadic, non-familial late-onset form of AD 
(Strittmatter et al., 1993; Corder et al., 1993). Although the presence of APOE ?4 allele 
increases the risk of AD from three- to even 15-fold compared to non-carriers depending 
whether the allele is in heterozygosis or in homozygosis, respectively, it is still considered 
as a risk factor, i.e. APOE?4 alone is not sufficient to cause AD unlike APP, PSEN1 and   
-2 mutations (Bertram et al., 2007; Farrer et al., 1997). However, despite of its strong 
contribution for increasing the risk of AD, the presence of APOE ?4 allele is not necessary 
for developing the disease; approximately half of the patients with AD are APOE ?4 non-
carriers. In addition, in families with AD, there is a gene dose association between the ?4 
allele and the age of AD onset (Corder et al., 1993). On the contrary to ?4, ?2 allele has 
been reported to decrease the risk of AD and at least delay the age of onset, almost as it 
has a protective role against developing AD (Corder et al., 1994).   
 Regardless of more than two decades of intense research the exact pathophysiological 
and molecular pathways linking APOE to AD remain partly unknown (Chouraki & 
Seshadri 2014). However, it has been shown that APOE directly binds A? and influence 
its aggregation, and, also facilitates the soluble A? clearance most likely by acting as a 
chaperone protein where ?4 allele has the least efficient role (Castellano et al., 2011; 
Zhong & Weisgraber 2009). The difference in the efficacy of A? clearance is probably 
due to differences in the amino acid structure resulted by arginine-to-cysteine substitutions 
(Castellano et al., 2011). Furthermore, A? metabolism is indirectly regulated by APOE 
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via interaction with receptors such as low-density lipoprotein receptor-related protein 1 
(LRP1), i.e. APOE and A? compete in LRP1-mediated cellular uptake (Verghese et al., 
2013). Also, APOE binds to tau but the functional relevance of this interaction remains 
unknown (Strittmatter et al., 1994). Interestingly, a recent study showed that a complete 
absence of APOE in a patient caused by deletion mutation did not result in neurocognitive 
function defects regardless of the important role of APOE in lipid metabolism (Mak et al., 
2014). Hence, there is an implication that APOE function in the brain may not be essential 
and there may be complementary mechanism(s) to compensate the absence of APOE. 
Taken together, all the genetic, human, animal and cellular studies truly indicate APOE as 
a risk factor for sporadic AD by modifying the disease pathogenesis via, at least partly, an 
APP/A?-dependent manner (Karch & Goate 2015). 
2.6.3.2.2 Clusterin (APOJ) 
 
Clusterin, another apolipoprotein (also called APOJ), is encoded by CLU gene and is 
located on chromosome 8p21-p12 (Jones & Jomary 2002). Clusterin is a stress-activated 
glycoprotein mainly secreted in heterodimeric form and is expressed nearly ubiquitously 
in all tissues and is linked to a wide range of functions, such as lipid transport, apoptosis, 
intercellular interactions and membrane protection. Multiple SNPs in CLU, such as 
rs7012010, rs1113600, rs9331888, rs7982 and rs2279590 have been identified by GWAS 
that seem to have a protective role in AD development (Hollingworth et al., 2011; Naj et 
al., 2011; Harold et al., 2009; Lambert et al., 2009). From these identified SNPs, 
rs9331888 was associated to AD in mega meta-analyzes with more than 74000 individuals 
(Lambert et al., 2013b). Interestingly, clusterin was associated with pathogenesis of AD 
long before the era of GWA studies. It has been shown that clusterin colocalizes with 
amyloid plaques (May et al., 1990; Choi-Miura et al., 1992; Calero et al., 2000) and that 
expression levels of clusterin mRNA in AD brains is elevated (Allen et al., 2012; Karch et 
al., 2012b). Furthermore, the expression of CLU exons 3 and 4 were shown to be 
increased according to increased NFT related AD pathology (i.e. Braak staging) 
(Martiskainen et al., 2015). Thus, similar with APOE, clusterin may participate in A? 
clearance and amyloid aggregation and also in neurotoxicity. Additionally, clusterin is 
associated with the complement system by regulating the membrane attack via inhibition 
of inflammatory responses that are associated with activation of complement system 
(Jones & Jomary 2002). Because of the crucial importance of neuroinflammation in AD 
aetiology, SNPs that may alter the expression level of clusterin or its function as a 
modulator of A? metabolism may either directly or indirectly modulate AD pathogenesis 
and have an influence on downstream effects of the disease progression (Karch & Goate 
2015). 
2.6.3.2.3 ABCA7 
 
ATP-binding cassette transporter A7 (ABCA7) belongs to the ABC transporter 
superfamily and is encoded by ABCA7 located on chromosome 19p13.3 (Ikeda et al., 
2003). Alternative splicing can generate two distinct isoforms called ABCA7 I and II, 
which both are expressed in the brain, mainly in microglia but also in neuronal cells (Kim 
et al., 2006). Furthermore, subcellular localization of these two isoforms differ within the 
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cells while type I is highly detectable on the cell surface and intracellular compartments, 
type II appears to remain merely in the endoplastic reticulum, which may indicate a 
difference in the function of these two ABCA7 isoforms (Ikeda et al., 2003). ABCA7 is a 
multispan transmembrane protein with a significant sequence homology to ABCA1 (54%) 
(Kaminski et al., 2000), suggesting that ABCA7 has a similar role in stimulating the efflux 
of phospholipids and to lesser extent cholesterol from cells (Wang et al., 2003; Quazi & 
Molday 2013). Additionally, ABCA7 has been reported to regulate APP processing, 
which may result in reduced A? production (Chan et al., 2008). Furthermore, ABCA7 
functions as a stimulator of phagocytosis of apoptotic cells via C1q complement pathway 
by facilitating the cell surface localization of LRP1 (Jehle et al., 2006).  
 Several ABCA7 variants that increase the late-onset AD risk have been identified by 
GWAS, including rs3764650 (Hollingworth et al., 2011; Naj et al., 2011; Lambert et al., 
2013b) and rs4147929 (Lambert et al., 2013b). Nonetheless, how these identified SNPs 
contribute to ABCA7 function, AD pathogenesis and disease risk are yet incompletely 
characterized (Vasquez et al., 2013; Karch et al., 2012b). Importantly, a recent study 
reported rare ABCA7 loss-of-function variants in Icelandic, European and American 
population cohorts with a combined OR of 2.03 (Steinberg et al., 2015). This strengthens 
the results from the former studies that ABCA7 gene is associated to pathogenesis of AD. 
2.6.3.2.4 SORL1 
 
Sortilin-related receptor LDLR class A repeats containing (SORL1) is a type I 
transmembrane protein that is a member of the vacuolar protein sorting 10 (VPS10) 
domain receptor family and the low-density lipoprotein receptor (LDLR) family (Yin et 
al., 2015). It is encoded by SORL1 (also known as SORLA or LR11) gene located on 
chromosome 11q23.2-24.2 and is abundant in the brain. Subcellularly, it is predominantly 
localized in the trans-Golgi network (TGN) and in early endosomes (EEs) (Motoi et al., 
1999). SORL1 has multiple physiological functions, including vesicle trafficking, cellular 
cargo transport, signaling and chaperone-like functions (Yin et al., 2015). Additionally, it 
functions as a receptor that binds lipoproteins, such as APOE, and further modulates the 
lipoprotein uptake via endocytic pathways. Furthermore, SORL1 is involved in APP 
processing by direct trafficking of APP to endocytic and recycling pathways. SORL1 also 
plays an important role in production of A? via directly interacting with APP and BACE 
(Spoelgen et al., 2006), regulating the A? generation via SORL1 expression level (Offe et 
al., 2006) and via interaction of adaptor proteins GGA and PACS-1, which participate in 
the antero- and retograde protein transport between TGN and EEs (Schmidt et al., 2007).  
 The association of SORL1 as an AD risk gene was first discovered from candidate gene 
based studies (Lee et al., 2008; Rogaeva et al., 2007). More recently, among other 
discovered SORL1 associated SNPs, variant rs11218343 that is located near SORL1 was 
identified to decrease the risk of AD (Lambert et al., 2013b). Considering the role of 
SORL1 in APP metabolism and APOE uptake, it is an important protein in AD 
pathogenesis and may be a crucial target to novel AD therapies.  
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2.6.3.2.5 BIN1 
 
Bridging integrator 1 (BIN1, or Amphiphysin 2 (AMPH2)) is a ubiquitous protein that is 
most abundantly expressed in the brain and muscle (Wechsler-Reya et al., 1997). BIN1 
protein is encoded by BIN1 located on chromosome 2q14.3 and exists in several 
alternatively spliced variants (Ren et al., 2006). BIN1 directly binds lipid membranes and 
induces memrane curvature via a highly conserved BAR (Bin/amphiphysin/Rvs) domain 
(Peter et al., 2004). Additionally, splice variant of BIN1 that includes the central insert 
domain interacts with clathrin and AP2/?-adaptin (McMahon et al., 1997; Ramjaun & 
McPherson 1998). BIN1 has multiple cellular functions, including endocytosis regulation, 
intracellular trafficking, calcium homeostasis, caspase-independent apoptosis, 
inflammation and interaction with microtubule cytoskeleton (Tan et al., 2013).  
 Variants of BIN1 that increase the LOAD risk have been identified by GWAS, from 
which the most significant SNPs, rs744373 and rs7561528, are located upstream from the 
coding region of the BIN1 gene (Naj et al., 2011; Seshadri et al., 2010; Harold et al., 
2009). Furthermore, GWAS meta-analysis identified an additional SNP rs6733839 
(Lambert et al., 2013b). Additionally, a variant rs59335482, in linkage disequilibrium2 
(LD) with the SNP rs744373, is shown to increase both the mRNA expression of BIN1 
and the risk of LOAD (Chapuis et al., 2013). Conversely, it has been reported in a small 
case-control study that BIN1 expression is decreased in sporadic late-onset AD but not in 
familial AD. Hence, these data requires further confirmation from additional studies.  
 BIN1 and tau were shown to interact in vitro and in mouse brain (Chapuis et al., 2013). 
Interestingly, BIN1 also interacts with another microtubule-associated protein called 
CLIP-170 (Meunier et al., 2009). More importantly, the mentioned linkage disequilibrium 
of SNPs rs59335482 and rs744373 in near BIN1 region is associated with tau loads, but 
not NFTs nor A? loads (Chapuis et al., 2013). Moreover, in Drosophila AD model, BIN1 
knockdown decreases tau-induced toxicity. These data strongly implicates a possible role 
of BIN1 in modulation of tau-related AD pathogenesis. 
2.6.3.2.6 PICALM 
 
Phosphatidylinositol binding clathrin assembly lymphoid myeloid leukemia (PICALM) 
gene encodes a protein that is important in clathrin-mediated endocytosis, internalization 
of cell membrane receptors and mediating intracellular trafficking of endocytic proteins 
(Miller et al., 2011; Tebar et al., 1999; Dreyling et al., 1996). PICALM is located on 
chromosome 11q14 resulting 23 transcripts via alternative splicing. Although PICALM is 
widely expressed in neurons (Treusch et al., 2011; Xiao et al., 2012), it is also highly 
abundant in endothelium of brain capillaries (Baig et al., 2010), i.e. cell population 
responsible of blood-brain barrier (BBB) function. Additionally, PICALM is a crucial 
protein in fusion of synaptic vesicles to the presynaptic membrane via VAMP2 (vesicle-
associated membrane protein 2, also called as synaptobrevin 2) trafficking (Harel et al., 
                                                       
2 Linkage disequilibrium is the non-random occurrence of some allele combinations in the 
population, i.e. the presence of associations of various loci alleles that are more often or more less 
often expected from a random formation based on their individual allele sequences (Tan et al., 
2013). 
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2008) and in recruiting clathrin and adaptor complex 2 (AP2) to the cell membrane (Baig 
et al., 2010).  
 SNPs rs3851179, rs541458 and rs10792832 at or near the PICALM locus were 
identified by GWAS and were associated with decreased AD risk (Harold et al., 2009; 
Lambert et al., 2013b). The possible functional effect of these variants is yet to be 
elucidated. Interestingly, in vitro and in vivo modulation of PICALM expression has been 
reported to affect A? production, and, APP and PICALM colocalization is shown to occur 
in encocytic vesicles in neurons (Xiao et al., 2012). Specifically, it has been reported that 
APP and PICALM are part of a complex with AP2 that could be recognized by 
autophagosomes and further directing APP-containing vesicles to autophagic degradation 
pathway (Tian et al., 2013), suggesting a role for PICALM in A? clearance and 
generation. Importantly, a recent study showed that reduced PICALM expression in AD 
brain endothelium correlated with A? pathology and cognitive impairment (Zhao et al., 
2015b). Furthermore, in PICALM deficient mice, A? clearance across the BBB was 
decreased resulting in increased brain deposition of A?. This process was shown to be 
reversed by re-expressing endothelial PICALM. In addition, by utilizing in vitro human 
endothelial monolayer mimicking BBB, PICALM was found to regulate the binding of 
A? to LRP1. This enhanced PICALM binding was then showed to initiate 
PICALM/clathrin-dependent endocytosis of A?-LRP1-PICALM complex, and after 
internalization, directed A? to Rab5- and Rab11-positive endocytic vesicles leading to 
BBB transcytosis of A? (Zhao et al., 2015b). Moreover, the protective SNP rs3851179 
expressing iPSCs (inducible pluripotent stem cells) from human endothelial cells showed 
clearly increased PICALM mRNA and protein levels and increased A? clearance. Hence, 
these data reinforces PICALM as a potential target for novel AD therapies. 
2.6.3.2.7 CD2AP 
 
CD2-associated protein (CD2AP) is a scaffolding protein interacting directly and with 
proteins involved in the organization of actin cytoskeleton and affect cytoskeleton polarity 
(Dustin et al., 1998; Lehtonen et al., 2002). Additionally, CD2AP has a function in 
synapse formation (Dustin et al., 1998), cell-to-cell interactions (Wolf & Stahl 2003) and 
role in endocytosis (Cormont et al., 2003). CD2AP protein is encoded by gene CD2AP 
located on chromosome 6p12. Regarding AD, SNPs rs9296559 and rs9349407 in CD2AP 
are associated with increased risk of AD by GWAS (Hollingworth et al., 2011; Naj et al., 
2011), from which the latter SNP is linked to increased neuritic plaque burden in AD 
brain (Shulman et al., 2013), although alterations in CD2AP mRNA expression in AD 
brain have not been observed (Karch et al., 2012b). However, in a functional screen that 
was performed by using a Drosophila model of AD, the knockdown of fly ortholog of 
CD2AP resulted in increased tau-mediated toxicity (Shulman et al., 2014). Recently, 
CD2AP was associated with maintenance of BBB integrity (Cochran et al., 2015).  
2.6.3.2.8 EPHA1 
 
EPHA1 is member of the ephrin receptor subfamily of the receptor tyrosine kinase family. 
EPHA1 protein binds to membrane-bound ephrin-A ligands, which further lead to contact-
dependent signaling to adjacent cells (Yamazaki et al., 2009). Additionally, they 
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participate in axonal guidance and synaptic plasticity both during development and in 
adults (Gerlai 2001; Lai & Ip 2009; Martinez et al., 2005). EPHA1 gene is located on 
chromosome 7q34 that encodes the protein ephrin type-A receptor 1, which is expressed 
by CD4-positive T lymphocytes and monocytes (Sakamoto et al., 2011). It is also 
expressed in epithelial tissues where it regulates cell motility and morphology (Coulthard 
et al., 2001; Yamazaki et al., 2009). With regards to AD, SNPs rs11767557 and 
rs11771145 near EPHA1 locus have been identified by GWAS and both are associated 
with decreased risk of LOAD (Hollingworth et al., 2011; Naj et al., 2011; Lambert et al., 
2013b). 
2.6.3.2.9 FRMD4A 
 
FERM domain containing 4A (FRMD4A) gene is located on chromosome 10p13.  It is a 
member of FERM superfamily but the function of FRMD4A protein in animal cells is yet 
unclear (Tepass 2009). FERM super-family proteins include ubiquitous cytocortex 
components that participate in cellular structure, signaling and transport. Moreover, 
FRMD4A has been reported to function as a scaffolding protein in a Par-
3/FRMD4A/cytohesin-1 complex, which activates Arf6 (Ikenouchi & Umeda 2010). This 
activation is suggested to regulate epithelial cell polarity. Interestingly, ADP ribosylation 
factor 6 (Arf6), which is a key molecule in membrane trafficking, actin cytoskeleton 
dynamics and dendritic branching in neurons (Hernandez-Deviez et al., 2002), was shown 
to control APP processing via endosomal sorting of BACE1 (Sannerud et al., 2011). Thus, 
these data may implicate a similar role for FRMD4A in APP metabolism. According to 
AD, multiple SNPs at the FRMD4A locus were idenfied in a study using GWAS 
complementary method called genome-wide haplotype association (GWHA) approach to 
correlate with plasma levels of A?40 and A?42 (Lambert et al., 2013a). Interestingly, 
FRMD4A expression was shown to decrease in relation to increasing AD-related 
neurofibrillary pathology, i.e. Braak staging (Martiskainen et al., 2015). Additionally, 
down-regulation of FRMD4A functionally affects both the amyloidogenic and tau-
regulating pathways in vitro.  
2.6.3.2.10 CR1 
 
CR1 gene is located on chromosome 1q32, which is a cluster of complement related 
proteins and encodes the complement receptor 1 protein (Weis et al., 1987). Four different 
co-dominant alleles in the gene resulting in four isoforms that differs in size are due to 
genetic deletions and duplications (Krych-Goldberg et al., 2002). CR1 protein functions as 
a receptor for complement protein fragments C3b and C4b, and is widely expressed on the 
surface of different blood cells, including erythrocytes, monocytes, macrophages, B-
lymphocytes and neutrophils (Klickstein et al., 1988), and, can also be found in the blood 
plasma as a dissociated soluble form (Yoon & Fearon 1985).  
 Multiple SNPs in CR1 were identified to associate with LOAD by GWAS 
(Hollingworth et al., 2011; Naj et al., 2011; Lambert et al., 2009; Lambert et al., 2013b), 
from which the SNP rs6656401 showed the highest association conferring AD risk 
(Lambert et al., 2009). Another SNP, rs3818361, was shown to associate with LOAD risk 
only in the APOE ?4 carriers (Lambert et al., 2009). Additionally, variants identified in 
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the CR1 locus are associated with neuritic plaque burden (Shulman et al., 2013) and in 
brain imaging studies in AD patients (Biffi et al., 2010). Furthermore, altered CR1 mRNA 
expression in AD brain is associated with AD disease status (Karch et al., 2012b). 
Interestingly, the expression of complement factors is shown to be upregulated in specific 
affected regions in AD brain (Shen et al., 1997; Eikelenboom & Stam 1982) and both glial 
cells and neurons are reported to express proteins of classical complement pathway 
(Gasque et al., 1993; Terai et al., 1997). Moreover, the isolated material from NFTs and 
A? plaques is shown to lead to activation of the complement system (Shen et al., 2001; 
McGeer et al., 1989). Finally, an association with CR1 and A? clearance has been 
proposed to function via binding of C3b and C4b to A?, which is likely mediated by the 
copy number variation of two CR1 isoforms (CR1-F and CR1-S) (Rogers et al., 2006; 
Hazrati et al., 2012; Brouwers et al., 2012).  
2.6.3.2.11 CD33 
  
CD33 is a type I transmembrane protein, which belongs to the sialic acid-binding 
immunoglobulin-like lectin (Siglec) family of cell surface receptors (Crocker et al., 1998; 
Jiang et al., 2014). CD33 gene is located on chromosome19q13.33 and in mammals CD33 
protein is expressed on the surface of phagocytic and hematopoietic cells, such as 
hematopoietic progenitors, myelomonocytic precursors, monocytes, dendritic cells, 
macrophages and microglia (Crocker et al., 2007; Griciuc et al., 2013). CD33 participates 
in adhesion processes of primary immune cells in humans by binding to sialoglycans on 
target cells thereby mediating interaction between the cells (Jandus et al., 2011). In 
addition, CD33 is an important molecule in inhibiting immune cell functions, for example 
in inhibition of pro-inflammatory cytokine production in human monocytes (Crocker & 
Redelinghuys 2008). Specifically, CD33 activation by binding of sialic acid further leads 
to monocyte inhibition via cytosolic immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs) (Jiang et al., 2014). Furthermore, a role of CD33 in clathrin-independent receptor 
mediated endocytosis has been reported (Walter et al., 2008).  
 GWAS identified SNPs near CD33 are associated with reduced LOAD risk (Bertram et 
al., 2008; Hollingworth et al., 2011; Naj et al., 2011). The SNP rs3865444 (located in the 
CD33 promoter region) is associated with increased expression of CD33 that lacks exon 2, 
which encodes the V-set domain that mediates sialic acid binding (Malik et al., 2013). 
Moreover, rs3865444 is reported to associate with CD33 surface expression on monocytes 
(Bradshaw et al., 2013), larger expression of the V-set domain containing CD33 isoform 
(Raj et al., 2014; Malik et al., 2013) and reduced levels of both CD33 mRNA expression 
and insoluble A?42 in AD brain (Griciuc et al., 2013). Another SNP, rs12459419, which 
is in strong LD with rs3865444, modulates the splicing efficiency of exon 2 (Malik et al., 
2013). Overall, splicing modulates the ability of CD33 to regulate the inhibition of 
microglial activation. In addition, elevated CD33 expression is associated with AD status 
and more severe clinical dementia (Griciuc et al., 2013; Karch et al., 2012b). Although 
SNP rs3865444 failed to reach genome-wide significance in large meta-analyzes, the 
additional data highly support its role in AD pathogenesis (Lambert et al., 2013b).  
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2.6.3.2.12 MS4A -cluster  
 
Membrane-spanning 4-domains subfamily A (MS4A) gene cluster, a locus containing 
several genes that are implicated in the inflammatory response, such as MS4A4A, 
MS4A4E, MS4A6A and MS4A6E, is located on chromosome 11q12 and consists of at least 
16 genes in human and mouse with variable expression (Liang & Tedder 2001; Liang et 
al., 2001; Ishibashi et al., 2001). Overall, MS4A gene cluster is poorly characterized but it 
is known to have structural similarity with CD20 protein, which is calcium influx 
regulator in B-cell antigen receptor activation (Bubien et al., 1993). MS4A gene cluster 
genes are widely expressed in hematopoietic cells (Liang et al., 2001).  
 Variants near MS4A4E (rs670139) and MS4A6A (rs983392) were identified by GWAS 
associated to increased and decreased LOAD risk, respectively (Hollingworth et al., 2011; 
Naj et al., 2011; Lambert et al., 2013b). Importantly, altered expression levels of MS4A6A 
in AD brain and blood have been reported (Proitsi et al., 2014; Karch et al., 2012b; 
Martiskainen et al., 2015). Furthermore, SNPs rs2304933 and rs2304935 in the MS4A4A 
locus are also associated with altered MS4A4A expression in LOAD brain (Allen et al., 
2012).  
2.6.3.2.13 Other known susceptibility genes 
 
Very little is known about the function of the novel 11 AD susceptibility loci (CASS4, 
CELF1, DSG2, FERMT2, HLA-DRB5/DRB1, INPP5D, MEF2C, NME8, PTK2B, 
SLC24H4-RIN3, SORL1, and ZCWPW1) that were identified in the largest AD GWAS 
study to date (Lambert et al., 2013b). Nonetheless, some of these genes are known to 
participate in pathways related to AD aetiology, including immune response (HLA-
DRB5/DRB1, INPP5D and MEF2C), synaptic function (PTK2B and MEF2C), axonal 
transport and function of cytoskeleton (CASS4, CELF1 and NME8) and implicated in tau 
(CASS4 and FERMT2) and APP (CASS4) metabolism. Importantly, the association of 
these loci with AD risk needs further verification in future studies.  
 Taken together, most of the identified AD associated loci have been discovered by 
using statistical methodology to test the association between a set of SNPs, which are 
usually proxies, i.e. located in the proximity of the gene of interest, and disease risk 
(Chouraki & Seshadri 2014). In a general praxis where genetic variants that reach 
genome-wide significance are linked to the closest gene at a specific locus may 
complicate the data interpretation because several genes of interest are usually located 
near or at the same locus. Hence, the next objective after identification of a novel 
candidate locus is to try to search the functional variant(s) within that locus and study their 
effects on a gene or a set of genes. Finally, it is of importance to study how these effects 
might be related to known pathways associated with the pathophysiology and 
pathogenesis of LOAD.           
2.6.3.3 Rare variants in Alzheimer’s disease 
 
The design of GWAS typically aims to identify frequent variants associated with complex 
disease, with a minor allele frequency (MAF) more than 5% (Chouraki & Seshadri 2014). 
Different techniques, such as next generation whole exome and whole genome sequencing 
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are utilized in order to identify less frequent (1-5% MAF) or even rare (<1% MAF) 
variants. With constantly decreasing costs and increasing speed of these emerging 
sequencing techniques, attempts to characterize every single base pair of an individual’s 
genome has become more and more efficient. Conversely to common frequency low 
penetrance variants, rare variants usually have larger effect size on disease pathogenesis 
and are predominantly located in exons, i.e. coding regions of genes.   
2.6.3.3.1 TREM2 
 
TREM2 gene was among the first rare AD associated variants reported simultaneously by 
two distinct studies that used advanced sequencing technologies (Jonsson et al., 2013) and 
candidate gene approach (Guerreiro et al., 2013a). The identified rare missense variant in 
TREM2, rs75932628, results in an arginine-to-histidine substitution at position 47 (R47H) 
and confers an elevated risk and earlier age of disease onset (Jonsson et al., 2013; 
Guerreiro et al., 2013a). After these initial reports on Icelandic and American populations 
with odds ratios (OR) of 2.92 and 4.5, respectively, the role of R47H involvement in AD 
risk has been replicated and verified in numerous population cohorts, including a French 
population (Pottier et al., 2013), an American Spanish population (Benitez et al., 2013), a 
Spanish/Catalan study (Ruiz et al., 2014a), the Cache County study (Gonzalez Murcia et 
al., 2013), a Belgian study (Cuyvers et al., 2014), an African-American sample cohort 
(Reitz & Mayeux 2013) and a Columbian family study with frontotemporal and AD 
dementia (Giraldo et al., 2013). However, in two Han Chinese populations (Yu et al., 
2014; Jiao et al., 2014) and in one Japanese population (Miyashita et al., 2014) the R47H 
was not present or no association with AD was detected, respectively. In a recent study, 
the R47H mutation was connected to impairment of TREM2 to recognize lipid ligands in 
vitro (Wang et al., 2015). Interestingly, it remains yet to be seen whether there are other 
TREM2 variants in these populations that may affect the risk of AD. 
 The triggering receptor expressed on myeloid cells 2 (TREM2) is mainly expressed in 
migroglial cells and functions in stimulation of phagocytosis and in suppression of 
inflammation (Rohn 2013). TREM2 gene is located on chromosome 6q21.1 and exists in 
three alternatively spliced transcripts, from which the longest form encodes a 
transmembrane protein that is further trafficked to membrane surface where it binds to 
several ligands and interacts with DAP12 (also known as TYROPB) (Colonna 2003). 
DAP12 is a key signaling molecule for TREM2 and is a crucial modulator in a gene 
module involved in phagocytosis of pathogens (Zhang et al., 2013). The two shorter 
transcripts of TREM2 lack the transmembrane domain yet still they are predicted to 
secrete from the cell (Colonna 2003). Moreover, after being trafficked to cell surface, 
TREM2 is further cleaved by ?-secretase hereby linking two AD associated molecules in a 
single pathway (Wunderlich et al., 2013).  
AD patients who carry a TREM2 mutation are reported to have more extensive and 
more rapidly progressing brain atrophy compared to non-carrier AD patients (Rajagopalan 
et al., 2013). Interestingly, SNPs in the TREM2 gene cluster are associated with increased 
CSF levels of both phosphorylated and total tau levels (Cruchaga et al., 2013). Moreover, 
increased expression level of TREM2 exons 3 and 4 in AD brain has been observed in 
accordance to more advanced Braak staging (Martiskainen et al., 2015). Recently, it was 
reported that TREM2 deficiency increases accumulation of A? and loss of neurons in a 
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mouse model of AD via dysfunctional response of microglia to senile plaques (Wang et 
al., 2015). However, another study showed that inflammation and both tau and A? 
pathologies were reduced in AD mouse model (APPPS1) with TREM2 deficiency 
occurring most likely via elimination of TREM2 positive inflammatory macrophages (Jay 
et al., 2015).    
 In addition to AD risk, homozygous TREM2 mutations are associated with Nasu-
Hakola disease, a recessive early onset form of dementia with bone cysts and fractures 
(Paloneva et al., 2002). Furthermore, autosomal recessive TREM2 mutations have been 
identified in a family with FTD-like syndrome that lacked the bone derived aspects 
(Guerreiro et al., 2013b). Generally, these data suggest that TREM2 probably plays an 
important role in modulation of neurodegeneration in general via its role in clearance of 
extracellular debris and protein aggregates, and, by modulating neuroinflammation.   
2.6.3.3.2 PLD3 
 
Another rare coding variant associated with AD risk was recently reported. Phospholipase 
D3 (PLD3) was identified in a family-based study design with additional genotyping as a 
risk factor for increased AD incidence (Cruchaga et al., 2014). Identified SNP, 
rs145999145, which results in a valine-to-methionine substitution at location 232 
(V232M), has been suggested to increase the AD risk 2- to 3-fold. However, this finding 
has proved to be really difficult to replicate although there has been a lot of effort from 
various groups with different experimental settings and population cohorts (van der Lee et 
al., 2015; Heilmann et al., 2015; Lambert et al., 2015; Jiao et al., 2014; Hooli et al., 2015). 
Hence, additional experimental data will be required to further verify if rare variants in 
PLD3 have any role in AD risk.  
 PLD3 gene is located on chromosome 19q13.2 and is expressed in as many as 25 
alternatively spliced transcripts (Karch & Goate 2015). PLD3 is a non-classical member 
of a superfamily of PLD proteins with a poorly characterized function(s) (Cruchaga et al., 
2014). PLD1 and PLD2, which are the classical phospholipases, catalyze the hydrolysis of 
phosphodiester bond of a glycerolipid phosphatidylcholine resulting in phosphatidic acid 
and free choline (Jenkins & Frohman 2005). Furthermore, the activity of phospholipase 
enzymes regulates the organization of actin cytoskeleton, modulate vesicle trafficking for 
endocytosis and secretion and participate in receptor signaling. Intriguingly, these proteins 
have been previously associated with APP-trafficking thereby playing a possible role in 
AD pathogenesis (Oliveira et al., 2010; Jin et al., 2007; Cai et al., 2006a; Cai et al., 
2006b).  
2.6.3.3.3 Other rare variants 
 
Other AD-associated rare variants have been proposed with either protective or disease 
driving roles. These include e.g. genes ADAM10 (an ?-secretase) (Cai et al., 2012; Kim et 
al., 2009b), ABCA1 (ATP-binding cassette transporter 1) (Lupton et al., 2014) and a 
protective variant of APP (aa substitution A637T; so called arctic mutation) (Jonsson et 
al., 2012). These recently discovered AD associated rare variants are currently undergoing 
replication studies in order to establish the accuracy of the findings. Altogether, the 
studies on rare AD-associated variants underline the importance of population 
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stratification because of its possible impact on initial and replication results (e.g. Lord et 
al., 2014). Moreover, to distinguish if a failure of replication is caused by a lack of 
statistical power or a lack of association per se large cohort sample size is a prerequisite. 
Additionally, the differences in the disease aetiology between the discovery and 
replication cohorts emphasize the replication phases to be executed both in the same and 
in alternative populations at the gene level.   
2.6.3.4 Missing heritability 
  
The disease-causing APP, PSEN1 and PSEN2 mutations in EOAD and the association of 
APOE with AD that were all identified more than two decades ago initiated an era of 
pursuing to understand AD through genetic perspective. These discoveries built the 
foundation for drug development and multiple clinical trials driven by the amyloid 
cascade -hypothesis, which, unfortunately, have not resulted in any improvement in the 
treatment of AD (Bettens et al., 2013). Furthermore, in the advent of GWASs, this new 
approach was anticipated to elaborate the highly complex aetiology of LOAD, in which it 
at least partly has succeeded. However, the functional relevance of these newly identified 
susceptibility genes to LOAD pathogenesis and pathophysiology yet remains largely 
unknown. Indeed, within the past few years GWASs have resulted in more novel genetic 
information than probably could have been imagined regardless of the mostly subtle 
effects of individual genes conferring to the overall risk of LOAD. In particular, after the 
semi-stagnated period in LOAD genetics that was between the discovery of APOE-
association and before the beginning of GWASs, these novel data has presented numerous 
previously uncertain or unknown common genetic variants in LOAD. Besides causative-
mutations and GWAS susceptibility genes, however, there is still a substantial proportion 
of the genetic disease risk yet to be explained. It has been estimated that all the genetic 
factors combined accounts for approximately 61% of the population attributable risk 
(PAR) of LOAD (Medway & Morgan 2014). Hence, there is a missing heritability -
component (Manolio et al., 2009), which needs to be uncovered in order to gain more 
general view on the LOAD aetiology. 
 Besides the low increment of the each locus that confer to disease risk identified by 
GWAS, additional limiting factor is the invariably increasing sample size needed to detect 
the increasingly minute impact on LOAD risk that is provided by each GWAS loci (Lord 
et al., 2014). Consequently, in the case of highly complex disease, such as AD, this 
missing heritability is very unlikely to be resolved with GWAS or any single methodology 
but will require a combination of complementary approaches. Interestingly, possible 
suggestions and models that might explain the missing heritability have been proposed 
including (i) the possibility of vast number of variants with smaller effect size is still 
undiscovered, (ii) identification of additional rare variants with moderate to high effect 
size (which are difficult to detect with methods like GWAS but may become less arduous 
and cost-effective upon the improvement of next generation sequencing (NGS) methods) 
and (iii) the poor existing capacity to detect genotype-by-genotype interactions by existing 
arrays and (iiii) genotype-by-environment interactions (Gibson 2011; Manolio et al., 
2009). Noteworthy, particularly in the case of large amount of small effect variant -
methods such as GWAS, the term ‘missing’ heritability may be misleading since the 
heritability is rather hidden than missing (Gibson 2010), which is a concept that can be 
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generally extrapolated to the entire field of natural sciences: nothing is missing per se but 
(almost) all the components are already there just waiting to be discovered.  
 In addition to the proposed explanations for missing heritability, epigenetic 
modifications, i.e. alterations in gene regulation by modification of DNA or chromatin-
associated proteins without any changes in the DNA sequence, or more specifically a 
novel field of epigenome-wide association studies (EWAS) have been suggested to have 
an effect on the risk of LOAD. Recently, two distinct studies showed overlapping 
alteration in DNA methylation in various loci in AD brain (De Jager et al., 2014; Lunnon 
et al., 2014). Furthermore, the methylation changes in different regions were observed in 
the brain areas that are usually affected in AD according to Braak stagining with both, in 
samples of cognitively normal and in samples of symptomatic patients. This finding raises 
the question whether this dysregulation of methylation is caused by early 
neuropathological changes or if the methylation changes are responsible for triggering 
neurodegeneration (Lord & Cruchaga 2014). Nevertheless, the novel EWAS approach is 
an important additional tool to study the epigenetic modifications that may confer the risk 
for LOAD.   
2.7 Protein spreading in neurodegenerative diseases 
2.7.1 Prion-like spreading – common hypothesis  
 
Neurodegenerative diseases, as a group of CNS disorders without any disease-modifying 
treatment currently available, present remarkable variety both in clinical and 
neuropathological phenotypes (Brettschneider et al., 2015; Guo & Lee 2014; Jucker & 
Walker 2013). However, majority of NDDs share a common hallmark feature, which is 
the cerebral intracellular or extracellular accumulation of disease-specific proteins into 
insoluble aggregates. These characteristic accumulating proteins include A? in senile 
plaques of AD (Glenner & Wong 1984b), tau in NFTs and neuropil threads of AD and 
other tauopathies (Kosik et al., 1986; Lee et al., 2001), ?-synuclein (?-syn) in Lewy 
bodies and in Lewy neurites of idiopathic PD and PD with dementia and Lewy body 
dementia (Spillantini et al., 1998a), TDP-43 aggregates in FLTD-TDP43 and amyotrophic 
lateral sclerosis (ALS) (Neumann et al., 2006), prion plaque formations in Creutzfeldt-
Jacob disease (CJD) (Bolton et al., 1982) and inclusions of  polyglutamine-rich huntingtin 
protein in Huntington’s disease (DiFiglia et al., 1997) (table 2.3).  
 The transition of the disease-related proteins from their normal functional 
conformation into oligomeric or multimeric fibrillar species typically results in decreased 
clearance and degradation leading to aggregation (Jucker & Walker 2013). The aggregates 
that are composed of misfolded proteins are usually referred to as amyloid, which are 
thermodynamically highly stable structures. Each twisted unbranched amyloid filament is 
composed of ?-sheets (cross-? quaternary structure), which in turn is composed of ?-
strands. In all amyloidoses, such as tauopathies, aggregates of misfolded protein can be 
pathogenic by either directly causing damage within residing cell, tissue or organs, or, the 
aggregated protein in amyloid structures loses their ability to maintain its physiological 
function (Eisenberg & Jucker 2012; Blancas-Mejia & Ramirez-Alvarado 2013). In the 
process of amyloidogenesis, smaller intermediate assemblies, i.e. protein species known 
as soluble protofibrils and oligomers exist and appear to be even more toxic than mature  
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Table 2.3. Examples of neurodegenerative diseases involving protein misfolding. Letter 
“F” (familial) indicates that the disease is caused by an inherited dominant mutation(s) in 
the particular gene encoding the protein or gene multiplications. Combination “F/S” 
indicates that in some cases the disease is inherited and caused by mutation(s) or 
multiplications of the gene encoding the misfolded protein. “S” (sporadic) indicates that 
known cases of the disease are not caused by any dominant mutation(s) in the gene or 
multiplications of the gene that encodes the misfolded protein. * formerly called also as 
tangle-only dementia. Modified from Goedert at al., 2010. 
Misfolded 
protein 
Human disease Familial / 
Sporadic 
Kuru S 
Creutzfeldt-Jakob disease (different variants) F/S 
Gerstmann–Sträussler–Scheinker disease F 
Prion protein 
Fatal familial insomnia F/S 
Alzheimer’s disease S 
Gerstmann–Sträussler–Scheinker disease S 
British dementia S 
Danish dementia S 
Pick’s disease F/S 
Progressive supranuclear palsy F/S 
Corticobasal degeneration F/S 
Argyrophilic grain disease F/S 
Guam Parkinsonism-dementia complex S 
Primary age-related tauopathy*  S 
Globular glial tauopathy F/S 
Frontotemporal dementia and Parkinsonism linked to 
chromosome 17 
F 
Tau 
Progressive subcortical gliosis F/S 
?-Amyloid Alzheimer’s disease F/S 
British dementia F BRI2 
Danish dementia F 
Parkinson’s disease F/S 
Dementia with Lewy bodies F/S 
Multiple system atrophy S 
Pure autonomic failure S 
?-Synuclein 
Lewy body dysphagia S 
Superoxide 
dismutase 1 
Amyotrophic lateral sclerosis 
 
F/S 
Amyotrophic lateral sclerosis 
 
F/S TAR DNA-
binding protein 
43 Frontotemporal dementia F/S 
Amyotrophic lateral sclerosis F/S Fused in sarcoma 
Frontotemporal dementia S 
Huntingtin Huntington’s disease F 
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fibril formations (Mucke & Selkoe 2012; Haass & Selkoe 2007). Although various 
disease-related oligomers and protofibrils have been isolated in vitro, it is very difficult to 
observe or isolate these protein species in human brains, which hinder the establishment 
of a direct connection of the function of protofibrils and oligomers in disease pathogenesis 
(Guo & Lee 2014). 
 Molecular mechanism in prion diseases (also known as transmissible spongiform 
encephalopathies) is defined by conversion of normal cellular prion protein (PrPC) into 
conformationally altered, misfolded prion protein (PrPSc), which is an unconvential 
infectious agent with ability to recruit and induce (“agitate”) the conformational switch in 
their normal counterparts (PrPC) leading to aggregation of pathological PrPSc (Prusiner 
1982; Aguzzi 2009; Aguzzi et al., 2008). Thus, PrPSc acts as a corruptive template, or 
seed, thereby initiating a process that resembles a chain-reaction resulting in further 
misfolding of PrPC and progressive aggregation. Regardless that the trigger responsible for 
initiation of soluble native protein into misfolded conformation is yet unknown, it is 
suggested that once seeded aggregation is started it will progress persistently. As prion 
aggregates grow, they also fragment and spread thereby producing new seeds 
subsequently resulting in additional aggregate formation by newly generated seeds. 
Although this self-perpetuating process was thought to be specific only for prions, in the 
past few years there have been numerous convincing studies presenting evidence that the 
‘prion-like’ self-propagating mechanism may also be plausible for non-prion NDD-
specific proteins (Brettschneider et al., 2015; Guo & Lee 2014). Indeed, lysates that 
contain aggregates and/or fibrils assembled from recombinant proteins of amyloidogenic 
proteins A?, tau, ?-syn, huntingtin, superoxidase dismutase 1 and TDP-43, have been 
reported to act as seeds capable of recruiting and inducing the soluble form of same 
protein into progressively growing fibrils both in vitro and in vivo, in some studies even 
without overexpression of protein in question in recipient cells or animals (Luk et al., 
2012a; Volpicelli-Daley et al., 2011). Of note, TDP-43 differs from other amyloidogenic 
proteins by presenting mainly as inclusions comprised predominantly from granular non-
amyloid fibrils (Thorpe et al., 2008). Importantly, upon in vivo administration of 
aggregate-containing inoculums, the resulted pathology was not restricted to the site or its 
close proximity but additionally lead to an invariable spreading of the specific pathology 
to synaptically interconnected brain areas in a time-dependent manner (Stohr et al., 2012; 
Masuda-Suzukake et al., 2013; Luk et al., 2012b; Luk et al., 2012a; Volpicelli-Daley et 
al., 2011; Iba et al., 2013; Clavaguera et al., 2009).  
 Besides prion-like spreading, another feature shared by amyloidogenic proteins is their 
ability to form fibrils that are structurally diverse protein aggregates that are 
conformationally distinct from each other collectively referred as strains (Aguzzi et al., 
2007). The most studied example of conformational variants, or strains, is PrPSc, which is 
found to exhibit different strains characterized by specific clinical phenotypes and 
pathological lesion patterns. Importantly, the phenotypic variations are able to propagate 
in vivo without any alterations in phenotype in subsequently infected animals after serial 
passage. Similarly to prion strains, assembly of polymorphic fibrils of other pathological 
protein aggregates of the same protein with single amino acid substitutions have been 
reported. Additionally, this has been also shown for proteins having identical primary 
structures under altered fibrillization conditions. Nonetheless, regardless of the structure, 
these aggregates are able to propagate through seeding fibrillization both in vitro and in 
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vivo (Heilbronner et al., 2013; Nekooki-Machida et al., 2009; Petkova et al., 2005; 
Furukawa et al., 2010; Yonetani et al., 2009; Aoyagi et al., 2007; Guo et al., 2013). 
Interestingly, different strains of a single protein may display different biological 
activities.  
 Like prion diseases, each disease class of non-prion proteinopathies exhibits wide 
range of heterogeneity (Brettschneider et al., 2015). Concomitantly, significant overlap is 
present between distinct categories of proteinopathies, in both clinical manifestations 
(Morris et al., 1989; Mayeux et al., 1992) and neuropathologies, in which aggregates 
consisting of different pathological proteins such as NFTs and Lewy bodies, are not 
uncommon co-inclusions in the brains of disease-affected individuals (Galpern & Lang 
2006). Actually, mixed disease pathologies are fairly common among NDDs and only 
rarely cases with stringently “pure” AD or PD neuropathology is observed. Given the 
aspects of prion diseases and non-prion proteinopathies, it has been suggested that various 
protein aggregate strains may possibly explain the differences and similarities of NDDs 
(Brettschneider et al., 2015). Specifically, transmission of fibrillar protein aggregates 
composed of different conformational strains may present significantly differential kinetic 
properties in seeded fibrillization subsequently leading to variable rates of progression of 
specific diseases. Consequently, the development of pathology and progression into 
various brain regions in addition to their ability to induce cross-seeding of other 
amyloidogenic proteins may vary substantially. Hence, besides the potential effect of 
strains on remarkable heterogeneity among NDDs with the same predominant protein 
depositions, they could offer an explanation to rather frequent occurrence of coincidental 
deposition of different protein inclusion. Notably, upon propagation from one cell to 
another with an involvement of templated fibrillization, the strain may convert into 
different conformational strain, which has been shown to occur at least for synthetic fibrils 
of ?-syn (Guo et al., 2013).  
 The concept of prion-like spreading of non-prion proteins is rather novel and although 
it could probably deliver a unifying pathophysiological model of NDDs, there are some 
critical aspects yet to be elucidated. Among others, one highly important aspect according 
to describing the various processes of prion-like spreading is semantics; it is essential to 
establish uniform and consistent nomenclature, i.e. to clearly distinguish which biological 
phenomena are referred to various terms. For instance, the crucial differences in terms 
cell-to-cell/intercellular transmission or propagation compared to transcellular propagation 
where the first process merely includes the cellular release and subsequent cellular uptake 
of a protein whereas transcellular propagation in addition to former includes the passage 
of the protein or aggregate throughout the cell (i.e. release-uptake-intracellular 
propagation-release). Moreover, terms like transmission or transmissable and spreading of 
proteins should be used in their correct context. Furthermore, nomenclature is not a 
specific problem for terminology used in the literature but also concerns laboratory 
practices, for example when using synthetic fibrils or seeds, it is essential for the 
repeatability and confirmation of the previous results to specifically describe the exact 
nature of the fibrils used. Notably, synthetic fibril variants may not be identical, or could 
even display quite significant differences to those formed in the human brain 
(Brettschneider et al., 2015). However, human brain is highly complex related to artificial 
fibrillization conditions and the probability to generate diverse strains in disease-affected 
brain is therefore high. Importantly, more studies are required to convincingly confirm the 
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existence of various strains in non-prion disease groups and their possible impact on 
phenotypic manifestation of the disease. Few recent studies, however, have presented 
some evidence on the existence of pathological strains of tau, ?-syn and A? in the human 
brains (Clavaguera et al., 2013a; Lu et al., 2013; Guo et al., 2013).  
 The most important aspect, however, is the proper definition regarding prions and 
pathological non-prion proteins. By definition, prions are ‘proteinacious infectious 
particles’ (Prusiner 1982), that are capable of infecting other organisms upon the transfer 
from one to another. Owing to this, infectivity is one of the most important features in the 
characterization of prions and distinguishing them from other amyloidogenic proteins. 
Accordingly, the term prionoids has been coined to specifically differentiate bona fide 
prions from other disease-associated proteins that seemingly are able to spread from one 
cell to another to emphasize the similarities of prions with other amylodogenic proteins 
the term prion-like protein is suitable, whereas if pointing out the differences of these two 
group of proteins the term non-prion protein is considered more descriptive (Aguzzi & 
Rajendran 2009). Hence, until now, only bona fide prions have been referred as prions and 
other pathological proteins with variable nomenclature. Unexpectedly, a very recent study 
suggested that ?-syn fibrils are true prions in multiple system atrophy (MSA), which is a 
NDD defined by progressive deterioration of autonomic nervous system function with 
usual signs of parkinsonism and neuropathological hallmark presenting as cytoplasmic 
glial ?-syn filament inclusions (Prusiner et al., 2015). Intriguingly, the ?-syn isolated 
from the brains of MSA patients but not from PD patients induced aggregation of ?-syn in 
cells overexpressing mutant A53T ?-syn and in TgM83+/- mice heterozygous for the same 
mutant suggesting that ?-syn strain causing MSA is different from the ?-syn in PD. 
Importantly, these findings have been supported with additional evidence provided by a 
follow-up study presenting similar data using partially enriched ?-syn strains by selective 
precipitation and reported the existence of at least three different ?-syn strains capable of 
causing MSA (Woerman et al., 2015) Hence, the MSA ?-syn strain is now suggested to 
be the first transmissible human prion since the discovery of CJD. However, of now, there 
is no clinical evidence of transmission of MSA from one person to another. Additionally, 
recent autopsy study revealed the co-existence of A? pathology in the brain of patients 
deceased for iatrogenic CJD (Jaunmuktane et al., 2015), which is a form of CJD caused by 
transmission via contaminated surgical equipment, medical procedures or ritualistic 
cannibalism in Kuru disease (Collinge et al., 2006; Collinge 2001). Specifically, in four 
out of eight individuals (aged 36-51 years) for all of whom had received prion-
contaminated human cadaveric pituitary-derived growth hormone (Brown et al., 2012; 
Swerdlow et al., 2003), showed moderate to severe vascular and grey matter A? 
pathology, which were typical to ones seen in the blood vessel walls of cerebral amyloid 
angiopathy and in grey matter of AD, respectively. Moreover, another recent study 
provided results on the persistence of A? in the brain (Ye et al., 2015). Interestingly, it 
was reported that A? seeds inoculated into APP null mice did not induce further ?-
amyloidosis unlike in the APP transgenic mice. However, in subsequent secondary 
transmission, intracerebral injections containing the brain extracts of A? seed inoculated 
APP null mice induced ?-amyloidosis in APP transgenic mice. Hence, these data suggests 
that A? pathology may be transmissible e.g. by iatrogenic routes and underline the 
longevity and existence of A? seeds in the brain that could at least partially explain the 
long preclinical phase and delay before the onset of dementia in AD (Jaunmuktane et al., 
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2015; Ye et al., 2015). However, it should be emphasized that this evidence of spreading 
of A? pathology by no means equals contagiousness of AD; the presence of NFTs have 
not been reported to co-deposit with A? in any of these cases with iatrogenic CJD 
(Jaunmuktane et al., 2015).  
2.7.2 Propagation of tau pathology 
 
The observed spreading of tau pathology in various tauopathies, as shown by Braak 
staging in AD for example, strongly implicates that cell-to-cell transfer of tau aggregates 
occurs during the clinical progression of the disease (Braak & Braak 1991). The mounting 
experimental evidence within a past few years have strongly supported the theory of cell-
to-cell transfer of tau aggregates both in vitro and in vivo building a foundation for a 
novel ‘prion paradigm’ in NDDs. Indeed, results provided by studies conducted on other 
amyloidogenic proteins support the suggested prion paradigm for NDDs. 
 Induction and propagation of tau pathology was first experimentally demonstrated by 
using transgenic mice (ALZ17; human wild-type tau and P301S mutant) and intracerebral 
injections of aggregate-containing P301S mouse brain homogenates into hippocampus and 
cerebral cortex of ALZ17 mice, which resulted in filamentous formations of wild-type tau 
in neurons presenting as NFTs and neuropil threads and oligodendrocytic coiled bodies 
(Clavaguera et al., 2009). Moreover, tau filament formation was observed first to spread to 
areas at close proximity to the site of injection and further into more distant brain regions 
that are synaptically connected to each other. Additionally, this time-dependent 
progression of pathology was shown to completely depend on tau. These results were 
confirmed by showing that intracerebral injection of tau oligomers and PHFs extracted 
from human AD brains into hippocampus of wild-type mice induce filamentous tau 
pathology that spread over time into other brain areas apart from hippocampus such as 
cerebral cortex, corpus callosum and hypothalamus (Lasagna-Reeves et al., 2012). 
Furthermore, two independent studies replicated the results by using mice overexpressing 
human P301L mutant tau, in which the transgene is restricted to entorhinal cortex for 
specific examination of tau spreading between entorhinal cortex and hippocampus (Liu et 
al., 2012; de Calignon et al., 2012). In both studies, time-dependent spreading of tau 
accumulation was observed in the hippocampus besides the initial formation of 
filamentous tau pathology in transgene-containing neurons in the entorhinal cortex, 
strongly implicating neuron-to-neuron propagation of aggregated tau.  
 Intracerebral injections consisting of pure synthetic filaments assembled from human 
mutant recombinant tau protein into presymptomatic mice expressing human P301S 
mutant tau induce the formation of NFT-like tau inclusions in a dose- and time-dependent 
manner (Iba et al., 2013). Consistent with observations from earlier studies, tau pathology 
spread through synaptically interconnected areas; from injected hippocampus to 
contralateral hippocampus and entorhinal cortex. These results are consistent with the 
previous finding demonstrating that the induction and propagation of tau pathology in 
ALZ17 mice inoculated with brain homogenates of P301S mice is predominantly 
responsible by the insoluble fractions of the extracted homogenates (Clavaguera et al., 
2009). Similar findings were presented upon injecting hippocampus and the overlying 
cerebral cortex of young (3 months old) homozygous human P301S mice with heparin-
containing tau filaments assembled from recombinant human P301S mutant tau 
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(Clavaguera et al., 2013b). Notably, tau depositions at the injection sites were apparent 
only 4 weeks post-injection. Comparable results were obtained in an additional 
independent study, in which young presymptomatic P301S mice were injected with brain 
extracts of P301S mice (Ahmed et al., 2014). Specifically, two weeks after unilateral 
injection at different regions, the NFT pathology was visible and was further spreading in 
time-dependent and stereotypical manner, i.e. consistent with the previous findings 
regarding the spreading pattern of tau pathology. Subsequently, contralateral and 
anterior/posterior propagation of tau pathology became evident in various nuclei that were 
connected synaptically to the site of injection. Hence, these results further underline the 
notion that it is not the spatial location or proximity but anatomically connected regions 
that are strongly synaptically interconnected that serve as a tract for spreading of tau 
pathology. Moreover, transsynaptic spreading of tau pathology has also been 
demonstrated by using lentivirus-mediated rat model (Dujardin et al., 2014b). After 5 
months of lentiviral injection into hippocampus, human wild-type tau was detectable in all 
synaptically interconnected brain regions related to injection site, whereas injection with 
lentiviral human P301L mutant tau resulted in strong induction of tau aggregation, which, 
however, mostly remained restricted close to the injection sites. Thus, these data suggest 
the more prone nature of wild-type tau to synaptically spread as compared to mutant tau 
implicating that transgenic mice with tau mutations may not serve as an optimal model of 
sporadic tauopathies. Interestingly, it was recently reported that upon intraperitoneal 
injection of presymptomatic P301S mice with brain extracts isolated from the same 
transgenic mice presenting symptoms, formation of tau inclusions in the brain is increased 
through a yet unknown mechanism (Clavaguera et al., 2014). Expectedly, intraperitoneal 
injection induces less effective tau deposition in the brain than intracerebral injection 
nonetheless providing preliminary evidence that peripherally administered tau aggregates 
are capable of initiating cerebral tau seeding.     
 The formation of both neuronal and glial tau filaments have been shown to occur after 
intracerebral injection with brain homogenates of pathologically confirmed subjects with 
human tauopathies into the ALZ17 mice expressing single isoform of wild-type 4R human 
tau (Clavaguera et al., 2013a). More specifically, tau inclusions formed after injection of 
all cases of various tauopathies (AD, PART, PiD, AGD, PSP and CBD), although disease-
specific lesions similar to those observed in human cases were detected following the 
homogenate injections of AGD (astrocytic tau pathology), PSP (tufted astrocyte -
reminiscent aggregates) and CBD (astrocytic plaque -resembling structures). Moreover, 
time-dependent stereotypical spreading of filamentous tau pathology was observed in all 
cases except after injecting PiD homogenates, where visible filaments were restricted only 
at the injection sites. Interestingly, similar filamentous tau deposits were present after 
identical injections with homogenates of different tauopathies in wild-type mice. 
Additionally, it was reported that brain homogenates from ALZ17 mice, that were injected 
18 months earlier bilaterally with P301S brain homogenates, injected into young (3 
months of age) ALZ17 mice induced tau filament pathology into neurons and 
oligodendroglial cells at the site of injection 12 months later. Similarly, brain 
homogenates of wild-type mice that were injected with brain homogenates of human 
PART and AGD (bilaterally, 18 months earlier), were injected into ALZ17 mice. One 
year following the injections, neuronal tau aggregates and neuropil threads together were 
present at the sites of injections. Importantly, these results have been confirmed and 
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further extended in an independent study, in which conformationally distinct tau strains 
were assembled of tau containing only 4R repeats in HEK293 cells (Sanders et al., 2014). 
Specifically, two different clones (namely clone 9 and clone 10) isolated from cells had 
distinct properties: clone 9 generated small intranuclear aggregates with highly efficient 
seeding property whereas clone 10 resulted in somewhat larger juxtanuclear depositions. 
Through serial passages, these clones maintained the identical conformational strains 
when transferred into naïve cells. Interestingly, cell lysate injection of different clones of 
tau strains into hippocampus of young transgenic human P301S tau mice induced 
pathology identical to the original presentation after serial passage of injections. 
Strikingly, when tau aggregates isolated from the hippocampi of mice after third round of 
injection were introduced to HEK293 cells stably expressing 4R-tau, the seeding of 
aggregates formed inclusions similar to those displayed in the original cells.  
 Taken together, these data collectively and strongly indicate the existence of various 
tau strains, which may be able to induce distinct human tauopathies. Given that multiple 
tau strains capable of self-propagation that is seemingly indefinite and the persistence of 
conformational strains through serial passage it has been suggested that tau would be 
considered as a prion. In fact, data from a very recent study further substantiates the 
notion of tau strains (Woerman et al., 2015). It was reported that tau strains isolated from 
brains of two individuals with pathologically confirmed PSP induce rapid tau aggregation 
in a cell line stably expressing tau 4R-repeats (Woerman et al., 2015). However, 
regardless of the advances in cell-to-cell propagation of tau pathology, the specific 
molecular mechanism underlying cellular tau release and uptake are both poorly 
understood processes.       
2.7.2.1 Cellular tau release 
 
A prerequisite for subsequent internalization by adjacent or connected neurons or glial 
cells, tau must be first translocated from cytoplasm to extracellular space. Previously, it 
was thought that tau found in the cerebrospinal fluid (CSF) was only a result of passive 
release from degenerated axons and dead neurons (Blennow et al., 1995). However, 
besides patients with AD where the levels of tau in the CSF are increased, tau is also 
found in the CSF of healthy individuals (Vigo-Pelfrey et al., 1995; Vandermeeren et al., 
1993; Blennow et al., 1995). Moreover, tau is found to be present in the brain interstitial 
fluid (ISF) of both healthy wild-type mice and in transgenic human tau P301S mutant 
mice (Yamada et al., 2011). It was reported that the total level of ISF-tau was higher than 
CSF-tau, and, that ISF-tau in P301S mice was five fold higher compared to endogenous 
tau. Interestingly, it was shown that there was a significant reduction in the level of 
monomeric ISF-tau upon the initiation of tau aggregation. Thus, there is an inverse 
correlation between the decrease of soluble tau and the increase of insoluble tau in the 
mouse brain homogenates. Hence, these data strongly implicate that tau is secreted from 
cells in an activity-dependent manner without the presence of any signal peptide sequence 
or protein lipidation thereby diminishing the possibility of conventional secretion via 
endoplasmic reticulum-Golgi-pathway (Gendreau & Hall 2013).   
 Induction of neuronal activity and calcium-mediated AMPA-receptor activation are 
both shown to promote tau release from cells in vitro (Pooler et al., 2013). These results 
have been confirmed and partly extended by using in vivo microdialysis showing that 
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induction of neuronal activity increase the steady-state level of ISF tau in both wild-type 
mice and transgenic human tau P301S mutant mice, and that presynaptic glutamate release 
increases the level of ISF-tau, implicating a connection between presynaptic excitatory 
neuronal activity and tau release (Yamada et al., 2014). Recently, it was reported that 
synaptic connections significantly enhance the cell-to-cell propagation of tau pathology in 
co-cultures in artificial neuronal networks created in microfluidic devices (Calafate et al., 
2015). Also, decrease in tau propagation between neurons due to either suppression of the 
activity in the synapse or reduction of synaptic density was demonstrated. In addition, 
nutrient deprivation and lysosomal inhibition or dysfunction, which is an established 
feature of many NDDs, was reported to increase cellular tau release from primary cortical 
neurons (Mohamed et al., 2014). Interestingly, the level of extracellular tau is altered 
relative to changes in tau protein structure (Karch et al., 2012a). More specifically, the 
ratio of extracellular/intracellular tau of 3R- and 4R-tau isoforms lacking N-terminal 
inserts (exons 2 and 3; 0N/3R and 0N/4R) is highly similar when compared to each other 
whereas it is remarkably higher than 2N/4R and significantly lower than ratio of 2N/3R 
isoforms. These results implicate that rate of tau secretion is dependent on tau isoforms 
and that 3R-tau isoforms are more abundant in the extracellular space compared to 4R-tau 
in vitro. Moreover, the impact of different tau mutations to cellular tau release was shown; 
all the mutations tested (P301L, P301S and R406W) in both isoforms 2N/3R (R406W) 
and 2N/4R (P301L, P301S and R406W) significantly reduced the level of extracellular tau 
as compared to wild-type tau without altering intracellular total tau levels suggesting that 
FTDP-17 MAPT mutations regulate the rate of tau secretion in vitro. Another study 
according to structure of tau relative to its cellular release reported that upon C-terminal 
cleavage of tau at D421, which is prefenrential site for caspase 3 -mediated cleavage, tau 
secretion is enhanced in vitro (Plouffe et al., 2012). Furthermore, similar results regarding 
to secretion of C-terminal truncated tau into CSF have been proposed also to occur in vivo 
(Barten et al., 2011). These results have been replicated and extended in a recent study 
suggesting that extracellular tau is predominantly cleaved at the C-terminus (Kanmert et 
al., 2015). Particularly, it was proposed that majority of extracellular tau lacks the MBRD 
and that the minority of extracellular tau with MBRD is originated from dead cells. Due to 
the suggested necessity of MBRD involvement in aggregate formation, it was proposed 
that induction of cell death mechanism is required for initiating extracellular tau 
propagation in vitro.  
 Tau is secreted from cells in a vesicle-free form (Kim et al., 2010a; Chai et al., 2012) 
and by exocytic mechanism either inside or associated with vesicles (Simon et al., 2012; 
Saman et al., 2012). Recently, it was reported that besides vesicle-free and exosome-
associated tau, active tau release is predominantly mediated by ectosomes (Dujardin et al., 
2014a). Ectosomes are plasma membrane-originated vesicles that are larger in size 
compared to exosomes (Dujardin et al., 2014a), which are vesicles released into 
extracellular space when multivesicular endosomes fuse with plasma membrane at cell 
surface (Fevrier & Raposo 2004). Specifically, it was demonstrated by both in vitro and in 
vivo models that in normal physiological conditions tau is secreted by ectosomes and 
upon over-accumulation of tau in cells there is a shift of mechanism toward exosome 
release of tau functioning in concert with ectosomal release. Additionally, by using an 
alternative in situ lamprey model to study tau secretion it was shown that N-terminus of 
tau, which is known to interact with plasma membrane and other membrane-associated 
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proteins, is required for cellular tau release (Kim et al., 2010b). In the lamprey model, tau 
secretion is dependent on whether MBRD is present or not thus representing in two 
distinct patterns; secretion is ‘diffuse-like’ and mostly occurring in soma when lacking the 
MBRD whereas full-length tau is predominantly secreted from dendrites in a more focal 
manner (Kim et al., 2010b). Hence, these patterns suggest an interaction between tau 
MBRD and elements of extracellular matrix that may have an effect on inclusion 
spreading and possible extracellular tau-induced toxicity (Lee et al., 2012). Finally, taken 
together, it is currently not fully understood by which mechanisms under physiological 
and pathophysiological conditions tau is secreted from cells, and, how the altered 
conditions affect the ratio between extracellular vesicle-free and microvesicle-associated 
tau. Accordingly, the excess of vesicle-free tau in extracellular space may also result from 
post-secretional release by microvesicles. Moreover, whether the majority of secreted tau 
is in aggregated (insoluble) or in monomeric or oligomeric (soluble) form relative to 
differential conditions is yet to be elucidated.   
2.7.2.2 Cellular tau uptake 
 
Uptake of tau into cells has been currently characterized even in less detailed manner than 
secretion. Fibrils assembled of recombinant tau, but not monomers, are reported to be 
uptaken by cells (Frost et al., 2009a). Subsequently, internalized aggregates are capable of 
inducing fibrillization of intracellular full-length tau in recipient cells. Upon 
internalization, tau aggregates were shown to co-localize with a marker of fluid-phase 
endocytosis (dextran) rather than lipid raft marker (cholera toxin B), strongly implicating 
the involvement of endocytic processes and not mere penetration of cell membrane. 
Interestingly, the fibrillization of intracellular tau induced by extracellular-originated 
aggregates was transferred to co-cultured cells and also seeded further fibrillization of 
recombinant monomer of tau in vitro. Similar results have been reported when tau seeds 
are introduced to cells with a transfection reagent in vitro (Nonaka et al., 2010). It was 
also reported that protein aggregation is nucleation-dependent as well as isoform- and 
protein-specific since 4R-tau did not induce fibrillization in 3R-tau expressing cells and 
vice versa. Additionally, a distinct study reported the templated transmission of the 
conformational features of fibrils assembled of recombinant tau (Frost et al., 2009b). 
Specifically, fibrils assembled of mutated tau (P301L/V337M) were reported to induce 
fibrillization of wild-type tau monomer, of which both were shown to have distinct 
secondary structures, leading to formation of novel fibrillar tau conformation, which was 
shown to be maintained over multiple rounds of seeding.     
 Before fibril formation, tau misfolds into dimers followed by formation of PHFs, 
which are established as a critical intermediates in aggregate formation, and low 
molecular weight oligomers in a so called nucleation process (Friedhoff et al., 1998; Wu 
et al., 2013). These extracellular low molecular weight oligomers and short fibrils, but not 
long fibrils or monomers, are uptaken by neurons (Wu et al., 2013). More specifically, 
internalization was mediated by bulk-endocytosis and it was shown to be dependent on the 
size and conformation of tau aggregates. Previously, results supporting endocytosis-
mediated tau internalization have been presented (Guo & Lee 2011). Transduction of 
filaments generated from either full-length human tau or truncated tau (containing only 
MBRD) into cells transfected with 2N/4R tau, induced fibrillization and formation of 
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tangle-like aggregates. Interestingly, when cells were incubated in 4°C to block 
endocytosis, the amount of cells containing aggregates was clearly reduced whereas upon 
incubation in normal culture temperature (37°C) aggregate-containing cells were 
increased in number.  
 Macropinocytosis, which is a subtype of bulk endocytosis specialized in internalization 
of fluids and macromolecular structures, has been implicated to be involved in cellular 
uptake of tau fibrils (Holmes et al., 2013). It was demonstrated that extracellular tau fibrils 
promoted the dynamic rearrangement of the plasma membrane inducing the formation of 
endocytic vesicles that were consistent to macropinosomes and further stimulated 
macropinocytosis in a dose-dependent manner. Heparan sulfate proteoglycans (HSPGs) 
on the cell surface participate in a variety of signaling and endocytic functions in cells 
(Bishop et al., 2007). Similar to infectious prion proteins, which have been shown to bind 
HSPGs on the cell surface plasma membrane for propagation of pathological strains 
(Horonchik et al., 2005; Schonberger et al., 2003), binding of tau aggregates to HSPGs 
was shown to be required for macropinocytosis-mediated cellular uptake and subsequent 
seeding of intracellular aggregates (Holmes et al., 2013). HSPG-mediated uptake of tau 
fibrils was reported to significantly decrease in the presence of HSPG inhibitors such as 
soluble heparin (to compete for the binding) in vitro and in vivo (synthetic heparin mimic 
F6). However, it currently remains unclear how tau fibrils or aggregates escape from 
macropinosomes to the cytosol to interact and transduce endogenous tau to pathological 
form. 
 Internalization of PHFs purified from AD-brains have been reported to be mediated by 
an endocytic process and result in formation of aggresome-like bodies in vitro (Santa-
Maria et al., 2012). Aggresomes are perinuclear MT-dependent inclusions containing 
misfolded proteins that have an important function in disposing misfolded proteins upon 
overload of various degradative systems such as ubiquitin-proteosome pathway (Kopito 
2000; Johnston et al., 1998). Indeed, perinuclear aggregates that form following the 
uptake of AD-brain derived PHFs were shown to have aggresome-like resemblence 
(Santa-Maria et al., 2012). In another study, presynaptically released tau dimers were 
shown to be increased in synaptosomes isolated from cryopreserved human post mortem 
AD-brains as compared to healthy controls (Sokolow et al., 2015). Moreover, it was 
shown that quarter or less of tau localized in the synaptosomes contained the C-terminus, 
which consistent with previous results reporting the C-terminally truncated tau being the 
major tau species released from cells. However, recent study reported that tau trimer, but 
not dimer, is the minimum unit capable of propagating and induce subsequent aggregate 
seeding in recipient cells (Mirbaha et al., 2015). Additionally, it was shown that both 
synthetic fibrils of various sizes and aggregates isolated from AD-brains with a minimum 
unit of tau trimer were internalized in an endocytic process mediated by HSPGs. 
 Overall, similar to tau secretion, very little is currently known about the exact 
mechanisms or their resiprocal relations of coincidental in different conditions according 
to cellular uptake of tau. Furthermore, the molecular structure or identity of tau species 
that are predominantly transferring between cells remains unclear. Hence, the 
identification of cellular mechanisms of tau release and uptake and the ratios of vesicle-
free and microvesicle associated tau secretion and internalization under normal and 
pathophysiological conditions is critical to understand the cell-to-cell propagation of tau in 
tauopathies (figure 2.9). Additional mechanism on how tau may transfer from one cell to 
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another could also be discovered beside the pathways that have been already more or less 
established. For example, tunneling nanotubes that connect adjacent cells have been 
proposed to be involved in the cell-to-cell tau propagation although very little is known 
about their functions in disease pathogenesis (Guo & Lee 2014; Clavaguera et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. Putative mechanisms of cell-to-cell transmission of cytosolic tau 
aggregates. Seeding of misfolded tau protein first occurs in the cytoplasm of a releasing 
or ‘donor’ cell. In seeding fibrillization, soluble tau monomers are recruited or sequestered 
into growing intracellular aggregates and subsequent fragmentation or secondary 
nucleation may initiate indefinite prion-like replication of amyloid fibrils. Tau can be 
released from the donor cell into extracellular space either in an unbound vesicle-free 
form (a) or via membrane-bound microvesicles such as exosomes or other microvesicles 
(b). Unbound extracellular tau aggregates may either directly translocate across the 
plasma membrane of a recipient cell via unknown mechanism (1), bind to surface of the 
plasma membrane e.g. via heparan sulfate proteoglycans, which induce macropinocytosis 
(a fluid-phase endocytic process) (2) or enter into recipient cell via receptor-mediated 
endocytosis (3). Extracellular aggregate-containing microvesicles may fuse with the 
plasma membrane of a recipient cell (4). However, the mechanism(s) of tau aggregates 
escaping from the lumen of endosomes/macropinosomes is currently unknown. 
Additionally, tau seeds may be transferred from one cell to another via nanotubes that 
directly connect the cytoplasm of two adjacent cells (5). Modified from Guo & Lee 2014. 
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3  Aims of the study 
 
The general aim of this study was to develop a novel live-cell platform method to 
investigate cellular protein interactions of tau and to further study the effects of genetic 
and pharmacological modulation of its protein-protein interactions, phosphorylation and 
cellular secretion and uptake.  
 
The specific aims of the study were to:  
 
1. Set up and validate a method to study protein-protein interactions of tau in live 
cells and use this assay to perform proof-of-concept screening with a focused 
library of chemical compounds. 
 
2. Explore the functional association of late-onset Alzheimer’s disease susceptibility 
genes with known AD-related pathways by investigating the effect of RNAi-based 
gene silencing on protein-protein interactions, phosphorylation of tau and 
amyloidogenic interactions and proteolytic processing of APP. 
 
3. Study the impact of late-onset Alzheimer’s disease susceptibility gene silencing on 
intracellular dimerization/oligomerization, cellular secretion and uptake of tau in 
live cells.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 69 
4 Materials and methods  
 
More detailed descriptions of used methodology are in the materials and 
methods/experimental procedures -sections of adjoining original publications (I-III).  
4.1 Cell culture and transfections (I, II, III) 
 
Cells were cultured in full Dulbecco’s Modified Eagle Medium (DMEM with 10% (v/v) 
FBS (Gibco, Invitrogen), 1% (v/v) L-Glutamine-Penicillin-Streptomycin solution (Lonza) 
(Neuro2A, HEK293T and CHME-5) or in neurobasal medium containing 2% B27 
supplement, 1% penicillin/streptomycin, and 1% glutamine (primary neurons) at 37°C, 
5% CO2 and water saturated air. Transfection of plasmid DNA and siRNA-DNA 
cotransfection were done using JetPei and Jetprime reagents (Polyplus) according to 
manufacturer’s instructions, respectively. The effect of gene silencing was assessed using 
real time quantative polymerase chain reaction (qPCR, comparative Ct method) to 
measure the relative level of mRNA (table 4.1).  
4.2 Protein-fragment complementation assay (I, II, III) 
 
Protein-fragment complementation assay (PCA) is a method to study protein-protein 
interactions in live cells in their native environment. PCA is based on a reconstitution of 
enzymatic activity of reporter protein fragments (Michnick 2001). In PCA, two 
complementary fragments of reporter protein are fused with proteins of interest. When the 
proteins of interest interact, the reporter fragments fold into their active native 
conformation thereby restoring the enzymatic activity, which can be measured as a 
bioluminescence in the presence of substrate (Michnick et al., 2007). In this study, the 
reporter protein used was split humanized Gaussia princeps luciferase (GLuc, 19.9 kDa, 
185 aa) and native coelenterazine (nCol, NanoLight Technology) was used as a substrate.  
 Briefly, cells were transiently transfected with proteins of interests fused with reporter 
protein fragments (GLuc1 and GLuc2) 24 h postplating on 96-well plates (table 4.2) or 
cotransfected with selected LOAD susceptibility gene siRNAs (table 4.3). Next, cells 
were washed with PBS prior to starting possible treatments and media was changed to 
phenol red-free DMEM (Gibco, Invitrogen) without serum (PRF-DMEM). In case of 
chemical treatment of cells, the chemicals were diluted in phenol red-free DMEM. In all 
experiments, comparisons were done to control conditions, e.g. mock transfection, vehicle 
treatment and positive and negative controls. Bioluminescence was measured 48 h 
posttransfection in the presence of nCol (final concentration of 20 ?M) regardless of 
performed treatments/treatment time by using either Victor3 1420 Multilabel counter 
(PerkinElmer) or Varioskan Flash multiplate reader (Thermo Scientific).  
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Table 4.1. Primers used for qPCR.  
Gene Forward / Reverse Sequence 5’ ?  3’ 
Forward AGACCTTCCCAGCAACTGTG BIN1 
Reverse GATCACCAGCACCACATCAC 
Forward GGTCGCTTTTGGGATTACCT APOE 
Reverse TTCCTCCAGTTCCGATTTGT 
Forward CCAGTGGAAGATGCTCAACA CLU 
Reverse AGCTTCACGACCACCTCAGT 
Forward AGCCCGCAACATCTCAAG ABCA7 
Reverse CTCACGGAAAAGTCCTCCAC 
Forward GCCAGGCCTACCAACCTAAC CR1 
Reverse GCCATTCACAGGATCTGGAG 
Forward ACCCCCTGTAATGGCCTATC PICALM 
Reverse CTCCTGATACAGGGCCAAAG 
Forward GCTCTCTATCAATCGCCACAG MS4A6A 
Reverse ACTGCAGTGAGGCAGGATTT 
Forward GACCAGAGCAGGAGTGGTTC CD33 
Reverse GTGGTAGGGTGGGTGTCATT 
Forward AACCATGCAAGGAATGGAAC MS4A4E 
Reverse TTCCCATGCTAAGGCTCATC 
Forward GGTGGCTGGAAGGAGAACTA CD2AP 
Reverse GTGGATGTGGCTGAATTCCT 
Forward ATCAAGCCCAAAATGTGGAG FRMD4A 
Reverse CTGCAAGGAGTTGCTTCCTC 
Forward TGGCACTCTCACCATTACGC TREM2 
Reverse GAGGCTCCTGGAGATGCTGTG 
 
Table 4.2. GLuc reporter proteins used in the study. 
 
 
Name Insert / Gene Accession number Source of cDNA 
Studies 
used 
tau-GLuc1 Human MAPT (0N4R) BC114948 OpenBioSystems I, II, III 
tau-GLuc2 Human MAPT (0N4R) BC114948 OpenBioSystems I, II, III 
Pin1-GLuc1 Human PIN1 NM_006221 OpenBioSystems I, II, III 
PP2A-GLuc1 Human PPP2R2A (B?) BC041071 OpenBioSystems I 
GSK-3?-GLuc1 Human GSK3B BC000251 OpenBioSystems II 
BACE1-GLuc1 Human BACE1 NM_012104.4 Dr. Oksana 
Berezovska, 
Harvard Medical 
School 
II 
APP-GLuc2 Human APP (695) NM_201414.2 Dr. Dora Kovacs, 
Harvard Medical 
School 
II 
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Table 4.3 List of used human siRNAs (Silencer Select, Ambion, Life Technologies) for 
LOAD risk gene knockdown.  
Gene siRNA ID # Sense sequence (5’ > 3’) 
BIN1 s1340 AGGUUUCAUGUUCAAGGUAtt 
BIN1 s1341 GGAGGUGUAUGAGCCCGAUtt 
BIN1 s1342 AGAUCGCAGAGAACAACGAtt 
APOE s1496 CUAGUUUAAUAAAGAUUCAtt 
APOE s1495 GGAGUUGAAGGCCUACAAAtt 
APOE s194291 GACAAUCACUGAACGCCGAtt 
CLU s3156 GGAAGUAAGUACGUCAAUAtt 
CLU s3157 AGAUAAAGACUCUCAUAGAtt 
CLU s3158 GCUGAGAGGUUGACCAGGAtt 
ABCA7 s20241 CCUUUUACCCGGAAGCUCAtt 
ABCA7 s20239 GAUCUGGUUCAACAACAAAtt 
ABCA7 s20240 CUACAGCGGAGGGAACAAAtt 
CR1 s3471 GUCCUACGAUCCCAAUUAAtt 
CR1 s3472 GGACAUCUUUAAAGUACGAtt 
CR1 s3473 CGAUGAAGGGUUCCGAUUAtt 
PICALM s15799 GGAUAUGACAUGUCUACAUtt 
PICALM s15800 GGCAAGCACUGGUCUAUCUtt 
PICALM s15801 CCACCUAGCAAGUUAGUAUtt 
MS4A6A s224607 GCAUGAUGGUAUUGAGCUUtt 
MS4A6A s34589 CUCUCCAAAUUUUACCCAAtt 
MS4A6A s34587 CUGCUUCCUUCUCUCCAAAtt 
CD33 s2637 CAACUUUCAUGGGAUGAAUtt 
CD33 s2638 CCCAACAACUGGUAUCUUUtt 
CD33 s2636 GCACCAACCUGACCUGUCAtt 
MS4A4E s55398 UGAUGUAUCCUUAUCAGUUtt 
MS4A4E s55399 AUUUAGUUCUUAUGAAGAAtt 
MS4A4E s55397 GACAUAAGUUUUCAACUCAtt 
CD2AP s24192 CUAUGAAGGUACUAAUGAAtt 
CD2AP s24193 CUGGAACAGUGUACCCAAAtt 
CD2AP s24191 CGAACUUAAUGGUAAAGAAtt 
FRMD4A s31260 GGGCUUCGCUGAUCAUAGAtt 
FRMD4A s31261 GGGAGAUUUUUCUAGCAAUtt 
FRMD4A s31262 GGAGUACUUUGGAAUAGCAtt 
TREM2 s28905 GAGGUGGAAUGGGAGCACAtt 
TREM2 s28906 GGAGCCUCUUGGAAGGAGAtt 
TREM2 s28907 CCAUUACGCUGCGGAAUCUtt 
Negative ctrl #1   
Negative ctrl #2   
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4.2.1 High throughput screening (I) 
 
High-throughput screening (HTS) was carried out in cooperation with Dr. Päivi Tammela 
from Centre of Drug Research (CDR, University of Helsinki, Helsinki, Finland) using 
CDR’s libraries of pharmaceutical compounds (PC) and natural compounds (NC), which 
were pre-diluted in dimethyl sulfoxide (DMSO) on 96-well master plates (10 mM and 20 
mM, respectively). The interaction pair selected and used in the HTS was tau-Pin1 and the 
screen was performed using Neuro2A cells. 
 The sample plates were prepared manually from master plates by diluting the pre-
diluted stock solutions to desired concentrations in PRF-DMEM. At the primary screening 
round the concentration used for compounds was 50 ?M and controls (untransfected, 5 
?M Juglone and 25 mM KCl), 4 replicate wells each. The first screening round included 
the whole PC/NC library containing altogether 355 compounds (240 and 115, 
respectively). On the secondary screening round, 5 different concentrations (50 ?M, 25 
?M, 12,5 ?M, 6,25 ?M and 3,125 ?M, 4 replicate wells each) were used for selected 
compounds (15 PCs, freshly dissolved) to verify results from the first round. Based on the 
observations from the second round, the third screening round was performed for further 
selected compounds. 
 The plating of cells (10 000 per well) on 96-well plates and transfections for HTS were 
performed as described. 46 h posttransfection the assay plates were washed once with 
warm PBS followed by addition of compounds from pre-warmed sample plates to assay 
plates. The measurements were performed using Varioskan Flash 48 h posttransfection. 
The luminescence was measured well-by-well immediately after the injection of the 
substrate (final concentration of 20 ?M). 
4.2.2 Tau secretion assay (III) 
 
Coating, plating, transfection of cells and PCA measurement were done as described 
above. In addition to previous protocol, 16 h before measurement, cells were washed once 
with PBS and changed to PRF-DMEM (140 ?l per well). 30 minutes before measurement, 
plate was span at 200-300 × g for 3-5 minutes using a swing bucket rotor and conditioned 
PRF-DMEM was recollected. 75 ?l of this conditioned media was used for measuring 
PCA signal (secreted tau dimers), and 50 ?l was used for lactate dehydrogenase (LDH) 
release measurement (Promega CytoTox 96® Non-Radioactive Cytotoxicity Assay, 
G1781) according to manufacturer’s instructions. After collection of conditioned media, 
the cells were changed to 75 ?l of fresh PRF-DMEM and PCA signal was detected as 
described for a standard PCA (intracellular tau dimers). 
 For RNAi screen of tau secretion, tau-GLuc1, tau-GLuc2 and LOAD risk gene siRNAs 
(at 5 nM) were cotransfected to HEK293T cells as described in the PCA section and 
further followed the tau secretion assay protocol as described above. 
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4.2.3 Assessment of tau uptake (III) 
4.2.3.1 Production of conditioned media 
 
HEK293T cells were plated into poly-L-lysine-coated 100-mm plates at density of 2.0-2.5 
million cells per plate and transiently transfected with tau-GLuc1 and tau-GLuc2 plasmids 
24 h post-plating. 24 h after transfection, cells were washed once with PBS and media 
replaces to PRF-DMEM. Media was conditioned for 24 h, collected and cleared by 
centrifugation at 3,000 × g for 30 min for removal of cell debris. The level of Tau- 
GLuc1/2 dimers in the media was determined by PCA. Additional tau-conditioned media 
characterization was performed using total human Tau ELISA kit (#KHB0041, 
Novex/Life technologies). 
4.2.3.2 Tau uptake assay 
 
Naïve HEK293T cells on 96-well plates were washed once with PBS and changed to 
conditioned media containing Tau-Gluc1/2. After 4 h incubation, media was completely 
removed by gently pipetting followed by a wash with PBS. Cells were then incubated with 
20 ?g/ml heparin (Sigma) diluted in PRF-DMEM for 5 min to remove cell surface-
associated Tau. Heparin solution was removed, cells were washed with PBS and 75 ?l 
PRF-DMEM was added to the wells and cellular PCA signal was measured as described 
above. 
 For RNAi screen of tau uptake, LOAD risk gene siRNAs were transfected to 
HEK293T cells using JetPrime, and after 24 h cells were changed to fully supplemented 
DMEM. Next, 44 h post-plating the media was replaced with tau-GLuc1/2 conditioned 
media and incubated for 4 h. Cells were washed and processed for PCA detection as 
described above. 
4.3 Western blotting (I, II, III) 
 
Cells were washed twice with ice-cold PBS 48 h posttransfection, and extracted with 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 6.8, 150 mM NaCl, 1% Triton X-100, 0.25% 
Nonidet P-40, Protease and Phosphatase Inhibitor cocktail tablets (Roche Molecular 
Biochemicals), 1 ?M NaF) and incubated on ice for additional 30 minutes. Cell debris was 
removed by centrifuging total lysates at 16,000 × g, and protein concentration was 
determined by BCA protein assay kit (Thermo). Equal amounts of cell lysates were loaded 
per lane on 4-12% gradient Bis-Tris gels (Novex, Invitrogen) and resolved under reducing 
conditions. Proteins were transferred to PVDF membranes (GE Healthcare) by using 
semidry blotting (Bio-Rad). Various antibodies were used for detection of different 
proteins and posttranslational modifications (table 4.4).   
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Table 4.4. List of antibodies used for Western blotting analyses. 
 
4.4 Phosphatase activity assay (I) 
 
The phosphatase activity assay was performed according to manufacturer’s protocol, 
provided in the Serine/Threonine Phosphatase Assay System (V2460, Promega). Briefly, 
cell lysates were prepared from mature (21 days in vitro) rat cortical neurons (2 × 6-well 
plates, 400 000 cells/well). After the cells were washed once with ice-cold phosphatase 
storage buffer (PhSB, 50 mM Tris-HCl pH 7.4, 0.25 M sucrose, 0.1 M EDTA) cells were 
lysed in 75 ?l of ice-cold full PhSB (PhSB including 0.1% ?-mercaptoethanol, protease 
inhibitor cocktail) and collected. Cells from 6-wells were pooled into one sample tube, 
incubated on ice for 20 min and were pulled 10 times through a needle. Pooled samples 
were centrifuged for 1 h at 100 000 × g at +4°C (Beckman TL-100 ultracentrifuge, TLA-
55 rotor) and supernatants were then transferred into fresh tubes on ice. Following the 
stabilization of spin columns, the cell lysates were transferred into the spin columns, 
centrifuged for 5 min at 600 × g at +4°C to remove endogenous free phosphate and pooled 
the lysates resulting one lysate sample. Protein concentration of the cell lysate was further 
determined. 
 The PP2A assay was performed according to manufacturer’s protocol (Phosphatase 
Assay protocol, Promega). The 5 × PPase buffer used was 5 × PP2A buffer (250 mM 
imidazole, 1 mM EGTA, 0.1% ?-mercaptoethanol, 0.5 mg/ml bovine serum albumin). All 
the reactions and proper controls were done in duplicates/triplicates and were incubated at 
37°C for 30 min before stopping the reactions by adding the Molybdate dye/additive 
mixture. After 15 min of incubation in room temperature the PP2A, activity was 
determined by measuring the absorbance (620 nm) of released phosphate-molybdate-
malachite green complex. 
 
 
Antibody Detected epitope Manufacturer Catalog # 
Primary antibodies    
Tau-5 Total Thermo scientific MA5-12808 
AT8 pSer202/pThe205 Thermo scientific MN1020 
PHF13 pSer396 Cell signaling 9632 
PHF-6 pThr231 Millipore MAB5450 
AT100 pThr212/pSer214 Thermo scientific MN1060 
TG3 pThr231/Ser235 gift from Dr. Jing-Jing Pei*  
GSK-3? Total Cell signaling 9315 
phospho-GSK3?  pSer9 Cell signaling 9336 
Pin1 Total Santa Cruz Sc-46660 
GAPDH Total Millipore MAB347 
Secondary antibodies   
HRP-anti-mouse GE Healthcare NA931V 
HRP-anti-rabbit GE Healthcare NA934V 
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4.5 Statistical analysis 
 
A minimum of three independent repetitions were used for each experiment and four 
independent wells was considered as one datapoint in PCA (I, II, III). GraphPad Prism and 
Microsoft Excel software were used for statistical analyses and generation of graphs. 
Statistical significance was evaluated with two-tailed Student’s t-test and two-way 
ANOVA, where appropriate, with the significance threshold set at p < 0.05 (*), and ** = p 
< 0.01 and *** = p < 0.001 (I, III). Detailed statistical methods used in study II are in the 
Methods/statistical analyses -section of original publication II. 
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5 Results 
5.1 Assay development and HTS to identify novel modulators of tau 
phosphorylation (I) 
5.1.1 Assay development and high-throughput screening 
 
Tau phosphorylation is a highly important regulator of its normal functions. In AD and 
related tauopathies, tau phosphorylation is increased resulting in a decrease in its ability to 
bind and stabilize MTs. In order to study protein-protein interactions of tau in live cells 
we developed a protein-fragment complementation assay (PCA) based on split humanized 
Gaussia princeps luciferase (GLuc) (Remy & Michnick 2006). PCA-based assay allows 
detection of direct interaction of proteins of interest fused with complementary reporter 
fragments. Importantly, PCA allows studying protein-protein interactions in their native 
cellular environment without need to lyse or extract cells for analysis.  
 Peptidyl-prolyl isomerase Pin1, which recognizes and catalyzes the cis/trans 
isomerization of phosphorylated serine/threonine-proline sequences, facilitates the PP2A-
mediated dephosphorylation of tau. Hence, as a critical regulator of tau 
dephosphorylation, Pin1 was selected as an interaction partner for development and 
validation of luminescence-based PCA to investigate dynamic protein-protein interaction 
of tau that may serve as a readout of tau phosphostatus in live cells. In addition to Pin1, 
multiple constructs were generated and tested during the set up and validation of PCA 
platform for tau protein-protein interactions (table 5.1). The identity, expression and 
detection of specific interaction of generated tau and Pin1 constructs were assessed (I / 
figures 1A, 1C and 2). Furthermore, localization of tau-GLuc2 construct to neurites and 
cytoskeletal structures suggested that the hGLuc fusion tag did not alter subcellular 
localization and functions of tau (I / figure 1C). Subsequently, the validated Pin1-tau PCA 
was optimized for various parameters in order to perform a screen of a focused library of 
pharmaceutical and natural compounds that may modulate Pin1-tau interaction.  
 The primary screen of Pin1-tau interaction pair resulted in 25 initial hits as detected 
either in increase (21 hits) or in decrease (4 hits) of protein-protein interaction signal (I / 
table 1 and supplemental table 1). From these hit compounds 14 were further selected 
based on their biological relevance for secondary screening and were tested in five 
different concentrations (I / supplemental table 2). Interestingly, sedative-hypnotic 
compounds, including barbiturates and benzodiazepines, were strongly presented among 
the hits of the secondary screening round. The hit compounds butethal and 
desalkylflurazepam, which both are known GABAA receptor activators, from secondary 
round were further selected and confirmed (I / figure 3A). Since GABAA receptor activity 
was not directly linked to tau phosphorylation based on literature, we used muscimol (a 
selective GABAA receptor agonist) and picrotoxin (a noncompetitive GABAA receptor 
antagonist and channel blocker) to confirm that the sedative-induced alteration of Pin1-tau 
interaction is most likely GABAA receptor-mediated (I / figure 3B).  
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Table 5.1. Assay validation criteria used in this study. 
 
5.1.2 GABAA receptor modulation promotes tau phosphorylation in neurons 
 
Given that in the brain of Pin1 deficient mice tau phosphorylation is significantly 
increased (Liou et al., 2003), we tested whether our screen-identified sedatives affect the 
phosphorylation of tau in mature (21 days in vitro) primary cortical rat neurons. After 6 h 
treatment with either butethal or desalkylflurazepam, there was a dose-dependent increase 
in tau phosphorylation at the AT8, a phosphoepitope with pathophysiological importance 
(I / figures 4A and B). Furthermore, to assess the stability of observed increase in tau 
phosphorylation, which is naturally transient, induced by GABAA receptor activators, a 
washout experiment was performed. Primary rat cortical neurons were incubated for 24 h 
with either butethal or desalkylflurazepam, which was followed by a wash-out period of 
24 h, showed that tau phosphorylation remained increased at an elevated level after 24 h 
washout period as compared to vehicle treated control (I / figure 4C). These data suggest 
that pharmacological GABAA receptor activation enhances tau phosphorylation in a way 
that is rather persistent in vitro at least for 24 h after washout of sedatives.    
5.1.3 Pharmacological modulators of GABAA receptor reduce tau-PP2A interaction 
 
Increased tau phosphorylation is typically a result from increased protein kinase activity 
and/or decreased protein phosphatase activity. Moreover, barbiturates have been shown to 
directly inhibit phosphatases such as PP2B/calcineurin (Humar et al., 2004) and there are 
reports indicating an association between anesthesia and increased tau 
hyperphosphorylation mediated by decreased PP2A activity (Planel et al., 2007). Since 
PP2A is known to be the phosphatase that predominantly dephosphorylate tau, we tested 
whether butethal and desalkylflurazepam directly alter the activity of PP2A in a cell-free 
PP2A assay in vitro. No effect was detected with either sedative whereas significant 
calyculin A (PP2A inhibitor) -mediated decrease in PP2A activity was observed (I / figure 
5A). 
Test Acceptance criteria Notes and corrective actions 
Intra-plate tests Z’ ? 0.2, CV% ? 20% For a transient transfection-based assay Z’ 
? 0.2 was considered acceptable (? 0.5 
would be optimal), four replicate wells 
used per data point, comparisons made to 
reference samples per each plate 
Inter-day tests Normalized average mid-
signal should not translate 
into a fold shift within > 2 
experiments 
Observed variations (day-to-day) caused 
by cell number and transfection efficiency 
differences, comparisons made to 
reference samples per each plate 
Material plate tests  Edge or drift effects not 
accepted 
Due to observed minor edge effects, empty 
wells left on all edges of the 96-well plate 
DMSO 
compatibility 
> 0.1% (v/v) 0.1-1.0% (v/v) tolerated well; maximum of 
1.0% (v/v) DMSO to be used 
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 To investigate the effect of sedatives on direct protein-protein interaction of tau-PP2A, 
GLuc-PP2A construct was generated using the regulatory B? subunit of PP2A. 
Pharmacological validation of this interaction by using Juglone (Pin1 inhibitor) resulted in 
dose-dependent decrease in tau-PP2A interaction (I / figure 5B), which was expected as 
reduced Pin1 activity was previously reported to decrease tau-PP2A interaction in cells 
(Galas et al., 2006; Landrieu et al., 2011; Zhou et al., 2000). Butethal and 
desalkylflurazepam treatment of cells expressing tau and PP2A PCA reporters 
significantly decreased (approximately 50%) tau-PP2A interaction (I / figure 5C). Hence, 
despite the unaltered activity of PP2A in cell-free system by these sedatives, tau-PP2A 
protein-protein interaction is reduced upon butethal and desalkylflurazepam treatments 
suggesting that increased tau phosphorylation is a resulted by decreased tau-PP2A 
interaction.       
5.1.4 GABAA receptor activity-induced tau phosphorylation is mediated by CDK5 
 
Multiple kinases contribute to tau phosphorylation by either directly phosphorylating tau 
or acting as a priming kinase. Of tau kinases, GSK-3? and CDK5 are considered as the 
main kinases that phosphorylate tau at multiple disease-associated proline-directed 
serine/threonine sites. To test whether GABAA receptor activity-induced aberrant tau 
phosphorylation was associated with GSK-3? or CDK5, we used kinase inhibitors 
SB216763 and roscovitine, respectively, together with desalkylflurazepam on primary rat 
cortical neurons. SB216763 had no effect while roscovitine effectively decreased 
desalkylflurazepam-induced abnormal tau phosphorylation at AT8 epitope (I / figure 6A). 
This indicates a role for CDK5 but not GSK-3? activity in GABAA receptor activity-
mediated tau phosphorylation.  
 In order to confirm the contribution of CDK5 in GABAA receptor activity-induced tau 
phosphorylation, we modulated CDK5 activity by overexpressing p35, which is a 
regulatory subunit of CDK5 kinase strongly expressed in neurons (Tsai et al., 1994; 
Spillantini et al., 1998b). Expectedly, functional validation performed by simultaneous 
expression of tau and Pin1 PCA reporters and p35 resulted in increased Pin1-tau 
interaction, which was significantly inhibited upon treatment with roscovitine (I / figure 
6B). Interestingly, when p35 was overexpressed with Pin1 and tau PCA reporters, 
treatment of desalkylflurazepam increased Pin1-tau interaction approximately 3-fold 
compared to mock/Pin1-tau PCA reporter-transfected cells (I / figure 6C).  
 Taken together, these data suggest that GLuc-based PCA is a sensitive and dynamic 
assay to measure protein-protein interactions of tau in live cells and to identify novel 
modulators of tau phosphorylation by using screening methodology. Moreover, our 
chemical biology approach identified a novel connection between GABAA receptor 
activity and tau phosphorylation, likely mediated by CDK5 and PP2A.  
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5.2 Expression profiles and functional association of LOAD susceptibility genes (II) 
5.2.1 Characterization of sample cohort 
 
Since the advent of genome-wide association studies (GWAS) in late-onset Alzheimer’s 
disease (LOAD) several novel susceptibility genes with rather small effect size have been 
identified. Although many of the identified genes pinpoints them into different subgroups 
regarding to their suggested functions on a more general level, such as endocytic 
trafficking, cholesterol metabolism and inflammatory pathway, the exact mechanism of 
these genes to underlying disease pathogenesis and progression remain largely unknown. 
Accordingly, to assess possible pathophysiological roles of LOAD-associated 
susceptibility genes, two distinct approaches were utilized: analysis of the expression and 
splicing status of these genes in post mortem AD brain, and, a functional study of the 
effect of these genes in previously established AD pathogenesis-related pathways.  
 Thorough characterization of post mortem brain sample set of 60 individuals that were 
previously assessed at the memory clinic was performed. 41 individuals of this cohort 
were diagnosed as probable AD. The brain sample set was classified according to Braak 
staging (I-VI), which is based on the anatomical distribution of neurofibrillary pathology 
in AD brain (chapter 2.5.1.1) (Braak & Braak 1991), and further subdivided into 3 distinct 
groups: Braak 0-II, Braak III-IV and Braak V-VI (II / table 1). Results from the 
biochemical assessment of the extracts of the brain sample set of inferior temporal cortex 
showed significantly increased level of soluble A?42 in the Braak V-VI group as 
compared to Braak 0-II (II / figure 1A), and increased ?-secretase activity in both Braak 
III-IV and V-VI groups as compared to Braak 0-II group (II / figure 1B), which also had 
strong correlation with ?-secretase activity (II / figure 1C). Subsequently, CSF 
measurements of A?42, total tau and phopsho tau (p-tau) were performed. CSF levels of 
A?42 were significantly decreased in Braak groups III-IV and V-VI as compared to Braak 
0-II (A?42 CSF samples available form 22 individuals) (II / figure 1D) and both total- and 
p-tau CSF levels were both increased in Braak V-VI group as compared to Braak 0-II (tau 
CSF samples available form 21 individuals) (II / figure 1E and F). These biochemical 
assessments, additional characterization of the sample set (II / table 2 and 3) and Braak 
staging confirmed this as an AD cohort that is applicable for further examination. Notably, 
no change in MAPT expression and splicing status were observed in relation to increasing 
neurofibrillary pathology in this cohort.     
5.2.2 Expression of LOAD susceptibility genes in relation to Braak staging in AD 
 
Before assessing the expression level of LOAD susceptibility genes APOE, BIN1, CLU, 
ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, CD2AP, FRMD4A and TREM2, the 
single-nucleotide polymorphisms (SNPs) associated with AD risk of our sample cohort 
were genotyped (II / table 2). Expression analysis revealed a linear increase in MS4A6A 
expression and decrease in FRMD4A expression in relation to increasing AD-related 
neurofibrillary pathology (both normalized to Braak 0-II) (II / figure 2A and B). 
Additionally, normalization of the expression of both MS4A6A and FRMD4A to the 
expression of neuronal, astrocytic and microglial genes was performed. There was a 
significant reduction in FRMD4A expression when normalized to astrocytic marker for 
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glial fibrillary acidic protein gene GFAP expression and positive correlation between 
MS4A6A expression normalized to microglial marker for allograft inflammatory factor 1 
gene AIF-1 (or Iba-1) expression. This positive correlation may implicate a role for 
MS4A6A in microglial function. The overall expression of neuronal marker genes was 
decreased and astrocytic marker gene expression was increased in our neuropathological 
cohort related to increasing neurofibrillary pathology (II / supplemental figure 3). 
Furthermore, exon level linear analysis resulted in significant increase in expression of 
exon 3 and exon 4 of both CLU and TREM2 genes according to increased severity of 
Braak staging (II / figure 2C and D).    
5.2.3 Expression of LOAD susceptibility genes in normal pressure hydrocephalus 
 
In addition to our neuropathologically confirmed AD cohort, biopsies were obtained from 
22 individuals with shunt-responding idiopathic normal pressure hydrocephalus (NPH) 
during life. The right frontal cortical samples from individuals with NPH were obtained 
during cranial shunt implantation followed by histological analyzes.  
 In some NPH cases pathogenesis may share similar features as AD and some 
individuals with NPH are prone to develop AD during life (Leinonen et al., 2012). Since 
A?-pathology is present in 22%-42% of NPH cases samples were divided into A?-
negative and A?-positive subgroups (II / supplemental table 1). The expression and 
splicing status of LOAD susceptibility genes were examined in NPH cohort to assess 
whether these genes are associated in NPH pathogenesis. Both the expression and splicing 
status of studied genes were not significantly altered neither in A?-negative nor A?-
positive subgroups of NPH patients, suggesting that investigated LOAD-related genes are 
not associated with NPH pathogenesis but are specifically associated with development of 
LOAD pathology.      
5.2.4 Functional association of FRMD4A with APP and tau pathways 
 
Potential functional association of LOAD susceptibility genes with established major 
cellular pathways involved in AD pathogenesis were assessed utilizing PCA methodology 
combined with siRNA-mediated gene silencing. Knockdown efficiency of 3 separate 
siRNAs per gene was first performed (II / figure 3A). Due to the low level of expression 
of both MS4A4E and MS4A6A in HEK293T cells, these genes were excluded from 
subsequent experiments. Three distinct protein-protein interaction pairs were used in 
PCA-gene knockdown experiments: BACE1-GLuc1 / APP-GLuc2, Pin1-GLuc1 / tau-
GLuc2 and GSK-3?-GLuc1 / tau-GLuc2. One by one silencing of LOAD genes upon 
studying BACE1-APP interaction revealed that knockdown of CLU, ABCA7, CD2AP and 
FRMD4A significantly increased this protein-protein interaction (II /figure 3B and 4A). 
Moreover, when ABCA7 and FRMD4A were silenced a corresponding increase in A?40 
secretion was observed (II / figure 4B). By monitoring the changes in intracellular Pin1-
tau interaction, siRNA knockdown of ABCA7 and FRMD4A resulted in enhanced 
interaction (II / figure 3C and 4C). Furthermore, an increase in GSK-3?-tau interaction 
resulted from reduced expression of ABCA7, CD2AP and FRMD4A genes (II / figure 3D 
and 4D).  
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 To examine the possible effect of LOAD susceptibility genes on tau phosphorylation 
the assessment of phosphorylation status of 4 specific disease-associated phosphoepitopes 
(AT8, AT100, PHF-6 and PHF13) were performed using Western blot analysis. These 
experiments showed an altered phosphorylation status of tau at phosphoepitopes PHF-6 
and PHF13 when FRMD4A expression was reduced (II / figure 4E, F, G and H). 
 Taken together, the assessment of the expression and splicing status of LOAD 
susceptibility genes in AD brain according to increasing severity of AD-related 
neurofibrillary pathology revealed increased expression of MS4A6A and reduction in 
FRMD4A expression. Additionally, the results from exon-level linear analysis showed 
increased expression of exons 3 and 4 of both CLU and TREM2 genes in our 
neuropathologically confirmed AD cohort. The expression and splicing status of LOAD 
genes examined in patients with NPH did not show any significant changes suggesting 
that these genes are specifically associated with development of LOAD pathology. 
Furthermore, functional association studies using a PCA-based in vitro pathway analysis 
platform showed that altered expression of FRMD4A is involved in both amyloidogenic 
APP processing and tau-regulation pathways. 
5.3 Impact of LOAD susceptibility genes to cell-to-cell propagation of tau (III) 
5.3.1 Studying cellular tau secretion and uptake in live cells 
 
The concept of prion-like cell-to-cell propagation of tau and other accumulating 
amyloidogenic proteins in neurodegenerative diseases (NDDs) has evolved during the past 
few years as a ‘prion-paradigm’, which could possibly deliver a common 
pathophysiological model for spreading of pathology in NDDs. Despite of emerging 
evidence on cell-to-cell spreading of tau pathology, the exact molecular mechanism on 
cellular secretion and uptake of tau remains poorly characterized.  
 In order to investigate cellular release and uptake of tau, we utilized our PCA-based in 
vitro platform system. To study dimerization of tau, which is known to be the first step in 
rate-limiting nucleation process before the formation of higher order oligomers and 
aggregates (Friedhoff et al., 1998), PCA reporter constructs tau-GLuc1 and tau-GLuc2 
were generated (III / figure 1A). Expectedly, there was a dose-dependent correlation in 
both intracellular tau dimerization and level of secreted tau in conditioned media relative 
to the level of tau-Gluc1/2 expression (the amount of reporter constructs used in 
transfection), which was independent from lactate dehydrogenase (LDH) release (III / 
figure 1B and C). This observation suggests that tau is secreted effectively via 
physiological pathways and is not due to passive leakage or release of tau from apoptotic 
cells. Kinetics of tau secretion into media showed almost a linear increase in the 
observation period of 24 h (III / figure 1D). To study whether the increase of cellular tau 
secretion in relation to intracellular tau dimerization is entirely due to overexpression of 
tau-GLuc1/2 plasmids in HEK293T cells, Pin1-tau interaction was tested. No alteration 
was detected in the ratio of intracellular and secreted Pin1-tau interaction (III / figure 1E), 
i.e. intracellular interaction was highly similar to the signal measured from conditioned 
media suggesting that Pin1-tau complex is not actively secreted from cells.  
 Although PCA is not capable of distinguishing protein complexes larger than dimer, 
i.e. the minimum signal generating unit is dimer, it does not exclude the possibility that 
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detected signal is generated in higher order tau species. Western blot analysis of cell 
lysates and conditioned media (with or without 3-fold concentaration of conditioned 
media and chemical crosslinking) implicated that majority of secreted tau in our cellular 
system is in the form of low molecular weight oligomers or small fibrils, whereas tau in 
cell lysates is predominantly in monomeric form (III / figure 1F). To elucidate the 
proportion of intracellular tau compared to secreted tau, total tau ELISA was used to 
determine tau levels in both conditioned media and cell lysates resulting in a ratio of 
approximately 1:200, respectively, suggesting that less than 0.5% of tau is secreted (III / 
figure 2A). Furthermore, given that tau is suggested to be secreted from the cells in 
exosomes (Saman et al., 2012) and other microvescles such as ectosomes (Dujardin et al., 
2014a), exosome biogenesis was inhibited using GW4869 showing a reduction of more 
than 30% in tau secretion from the cells (III / figure 1G). GW4869 is an inhibitor of 
neutral sphingomyelinase (nSMase) acting via ceramide generation that regulates 
exocytosis (Rohrbough et al., 2004). To further characterize whether tau is secreted 
predominantly in association with microvesicles (either inside or outside of vesicles) or as 
a vesicle-free form, conditioned media was incubated with either trypsin (0.005% v/v) or 
saponin (0,005% v/v) or both. Results from these experiments indicate that vesicle-free 
tau dimers accounts for 99.8%-99.9% of all secreted tau with less than 0.5% being inside 
vesicles (III / figure 2B) in this HEH293T cell-based assay system. Fractionation of tau-
GLuc1/2 conditioned media further revealed that, in our cellular system, the vast majority 
of secreted tau in conditioned media is in vesicle-free form (99.7%), whereas ectosomal 
fraction (0.22%) and exosomal fraction (0.05%) represent only minor portions from the 
extracellular tau (III / figure 2C, D and E). Similar results were obtained from PCA 
analysis performed with fractionated and unfractioned conditioned media (III / figure 2F). 
 To study cellular uptake of tau in our PCA platform, conditioned media containing tau-
GLuc1 and tau-GLuc2 reporter plasmids was produced by conditioning media with cells 
overexpressing the reporter plasmids for 24 h. Immunostaining of naïve cells after 
incubation with tau-conditioned media for 4 h resulted in punctate patterns of tau staining, 
whereas no immunoreactivity for tau was observed when recipient cells were exposed to 
conditioned media generated by mock-transfected cells (III / figure 3A), suggesting 
cellular uptake of tau reporters. Different washes of cells were tested in PCA-uptake 
experiments after incubation with tau-GLuc1/2 containing conditioned media (III / figure 
3B). Consequently, to confirm that the measured signal is generated by internalized tau, 
additional washing step with heparin was included into uptake protocol to remove cell 
surface-bound tau, which significantly reduced the signal as compared to unwashed and 
PBS washed cells. To determine the most optimal time to incubate cells with conditioned 
media to allow the internalization of tau into cells, the rate of uptake were observed for 24 
h. The rate of uptake started to slow down after 4 h incubation suggesting a saturable 
mechanism of tau internalization (III / figure 3C). Furthermore, when GW4896 was added 
to cells 16 h prior to addition of conditioned media (with or without GW4869), the 
detected signal from internalized tau was significantly increased from cells treated with 
GW4869 as compared to control. Hence, there may be rapid resecretion mechanism of 
internalized tau dimers, a process that can be at least partially inhibited by GW4869. 
Additionally, fractionated conditioned media was used to assess whether vesicle-
associated and vesicle-free tau are internalized with varying efficiency by cells. Due to a 
relatively low secretion level of vesicle-associated tau and rather low overall uptake 
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activity of tau, 100-fold concentrated media-resuspended batches of exosome and 
ectosome fractions were used. The comparison of unconcentrated vesicle-free conditioned 
media and concentrated vesicle-associated fractions showed that vesicle-associated 
fractions are internalized relatively more actively (III / figure 3E). However, due to the 
majority of secreted tau being in vesicle-free form, unconcentrated and unfractioned 
conditioned media was used in further experiments.  
5.3.2 Effect of LOAD susceptibility genes on cellular secretion and uptake of tau 
 
To investigate whether LOAD susceptibility genes are functionally associated to either tau 
secretion or uptake, we performed a screen based on RNAi. The siRNAs used for 
knocking down the genes (APOE, BIN1, CLU, ABCA7, CR1, PICALM, CD33, CD2AP, 
FRMD4A and TREM2) in the screen were the same utilized in study II, in which the 
knockdown efficiencies were determined (II / figure 3A and III / figure 4A). 
Cotransfection of PCA reporter constructs tau-GLuc1/2 and siRNAs did not significantly 
alter the intracellular level of tau dimerization in HEK293T cells (III / figure 4B).  
 For studying the impact of RNAi knockdown to tau secretion, conditioned media were 
collected from reporter plasmid-siRNA transfected cells and tau dimer content was 
measured by PCA. Reduction of LDH-normalized tau dimer signal in the conditioned 
media was shown in cells upon knockdown of TREM2 (55%), CD33 (27%), CD2AP 
(23%) and FRMD4A (19%) (III / figure 4C). Values are average of cells transfected with 
two independent siRNAs per target gene. Since TREM2 and CD33 are predominantly 
expressed in myelomonocytic cells and their expression level in HEK293T cells is 
relatively low, the effect of gene knockdown to secretion level of tau was tested in more 
physiological context. In fetal human microglial CHME-5 cells, cotransfection of tau-
GLuc1/2 and TREM2/CD33 siRNAs did not result in changes of either intracellular tau 
dimerization or the signal level of secreted tau dimer in conditioned media (III / figure 
4E). 
 For investigating internalization of tau, recipient cells were transfected with the panel 
of LOAD susceptibility siRNAs followed by an exposure of tau-GLuc1/2 conditioned 
media for 4h. Knockdown of APOE was the only gene to significantly affect the uptake of 
tau, which was observed as a 29% increase in intracellular tau dimer signal as compared 
to control (III / figure 4D).   
5.3.3 Regulation of cellular tau secretion by FRMD4A-cytohesin signaling 
 
Our previous results from study II showed decreased FRMD4A expression in the brain of 
LOAD patients and its functional association with tau. Since the current data implicated 
an involvement of FRMD4A in cellular tau secretion, we studied the possible mechanism 
of this phenomenon. Immunostaining of cells expressing FRMD4A-GFP showed 
cytosolic localization of FRMD4A in structures resembling vesicles (III / figure 5A, left) 
suggesting a functional interaction with vesicle membrane-associated proteins. 
Coexpression of FRMD4A-GFP and tau-GLuc2 did not show significant colocalization 
although they both occasionally localized in same regions close to plasma membrane in 
HEK293T cells (III / figure 5A, right). PCA measurements of cells coexpressing tau-
GLuc1/2 reporter plasmids and FRMD4A showed a significant dose-dependent increase 
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in tau secretion in conditioned media relative to FRMD4A expression, whereas 
intracellular tau dimerization remained almost unchanged (III / figure 5B). Moreover, 
FRMD4A-induced increase in tau secretion seems to be at least partially dependent on 
ceramide signaling, since GW4869 decreased the tau secretion signal by nearly 30% (III / 
figure 5C). However, the effect of GW4869 on tau secretion may be more general and not 
necessarily specific to effect of FRMD4A-related secretion.  
 Although very little is known about FRMD4A function in mammalian cells, in 
epithelial cells it has been shown to function as a scaffolding protein in the interplay of 
Par3/Par6 cell polarity complex and Arf6 signaling via cytohesin-1, which is a guanine-
nucleotide exchange factor (GEF) (Ikenouchi & Umeda 2010). FRMD4A overexpression-
induced tau secretion was decreased and intracellular tau dimerization was increased when 
cells were treated with SecinH3 (III / figure 5D), a small molecule cytohesin/Sec-7 GEF 
activity antagonist (Hafner et al., 2006). Moreover, in cells expressing only endogenous 
FRMD4A intracellular tau dimerization was increased whereas level of tau secretion to 
media was almost unchanged (III / figure 5E). Given that FRMD4A-cytohesin signaling is 
known to induce translocation of active Arf6 to the plasma membrane (Ashery et al., 
1999; Hafner et al., 2006; Ikenouchi & Umeda 2010), we co-overexpressed Arf6 and tau-
GLuc1/2 in cells to study whether it produces a similar response as FRMD4A to level of 
tau secretion. Overexpression of wild-type Arf6 induced 34-fold increase in tau secretion 
as compared to endogenous Arf6 levels, which was almost completely suppressed by Arf6 
siRNA coexpression (III / figure 5F). However, SecinH3 did not have any effect on Arf6-
induced tau secretion suggesting that Arf6 overexpression robustly increases the activity 
of Arf6, which seems to be independent of cytohesin GEF activity.  
 To further elucidate the mechanism involved in tau secretion, the co-overexpression of 
tau-GLuc1/2 and atypical protein kinase C subtype ? (aPKC?) was studied using PCA 
approach. As a part of Par polarity signaling complex, ceramide-binding protein aPKC? 
regulates multiple membrane trafficking events and is also associated with exocytosis 
(Wang et al., 2009; Horikoshi et al., 2009; Joberty et al., 2000). The resulted significant 
increase in tau secretion upon aPKC? overexpression was comparable to FRMD4A-
induced effect (III / figure 6A). No significant effect was observed when cells were 
overexpressed with C-terminal ceramide-binding region of aPKC? (C20?) (Wang et al., 
2009) instead of full aPKC?. Interestingly, coexpression of aPKC? and C20? decreased 
aPKC?-induced tau secretion suggesting that ceramide-binding is important for this 
activity of aPKC?. Since Par6 is known to connect aPKC? to Par3 (Joberty et al., 2000), 
which further activates Arf6 via FRMD4A (Ikenouchi & Umeda 2010), we explored the 
impact of Par6 to tau secretion. Wild-type Par6 expression enhanced tau secretion 7-fold 
as compared to control, whereas expression of Par6(S345A), an inactive mutant that is not 
aPKC?-phosphorylated (Gunaratne et al., 2013), had only subtle effect on tau secretion 
(III / figure 6C). Neither wild-type Par6 nor Par6(S345A) mutant altered intracellular tau 
dimerization. Finally, SecinH3 had no effect on aPKC? and Par6 expression-induced tau 
secretion (III / figure 6B and D) implicating that aPKC?/Par6 complex functions 
independently of cytohesin GEF activity, possibly as a downstream component in the 
FRMD4A/cytohesin-signaling pathway. 
 Taken together, according to these data, PCA-based assay is a sensitive, cost-effective 
and dynamic method to investigate cellular tau uptake and secretion in live cells. 
Furthermore, PCA method combined with siRNA-mediated knockdown of LOAD 
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susceptibility genes is an effective approach to study the association of these genes to 
known pathophysiological pathways connected to cell-to-cell propagation of tau in AD 
and related tauopathies. We identified a novel pathway related to the LOAD susceptibility 
gene FRMD4A, that regulates tau secretion. Specifically, aPKC?/Par6-FRMD4A-
cytohesin-Arf6 signaling pathway is connected to cellular secretion of tau. 
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6 Discussion 
6.1 Cellular physiology and cell-to-cell propagation of tau (I, III) 
 
Tau undergoes various posttranslational modifications (PTMs) in normal physiological 
conditions to maintain and regulate its functions. The impact of tightly controlled 
regulation of tau phosphorylation and dephosphorylation alone, which is by far the most 
widely studied PTM, is essential for its major cellular function in stabilizing and 
promoting assembly and disassembly of MTs. The central role of phosphorylation in 
regulation of MT interaction highlights the importance of tau PTMs in its protein-protein 
interactions and cellular functions. The amount of putative serine and threonine 
phosphorylation sites (approximately 80 Ser/Thr sites) in relation to total number of 
amino acids in the longest human tau isoform (441 aa) provides a vast variety in 
combinations and patterns of tau phosphorylation. Although all of the nearly 80 sites have 
not been shown to be phosphorylated in vivo, proper regulation of phosphorylation 
equilibrium of tau is critical even without the involvement other PTMs.  
Relatively recent discoveries of novel tau PTMs, such as methylation (Thomas et al., 
2012; Funk et al., 2014), as well as confirmation and possible exclusion or critical 
reviewing of previously suggested PTMs have been established mainly by using mass 
spectrometry approach (Morris et al., 2015). Nonetheless, as additional PTMs are 
emerging, their effect on tau function in both physiological and pathophysological context 
remains to be defined. Since a wide number of PTMs may affect practically all six 
splicing isoforms of tau, the pool of differentially modified tau species in cells is 
enormously diverse. Hence, despite of rigorous studies conducted over the past few 
decades, the complexity of physiological tau pool may at least partly explain the observed 
difficulties in examining the role of pathophysiological tau in disease pathogenesis of AD 
and other tauopathies, in which there is typically a disequilibrium in normally highly 
regulated PTMs.  
Recently, however, a study showed that tau acetylated at lysine 174 (K174) is an early 
change in both human AD brain and in a mouse model of FTD (PS19) (Min et al., 2015). 
Furthermore, it was reported that inhibition of acyltransferase p300-induced acetylation of 
tau by salsalate, a prodrug of salicylate that has been used in treatment of rheumatoid 
arthritis, significantly reduced the level of both total and acetylated tau at K174 in PS19 
mouse. Interestingly, administration of salsalate after disease onset in PS19 mice was also 
shown to ameliorate the memory deficits and rescue from hippocampal atrophy as 
compared to control-treated mice thereby providing a novel candidate for 
neurodegeneration therapeutics. Moreover, considering the reported substantial overlap of 
various competitive PTMs toward lysine residues including methylation, acetylation and 
ubiquitination, it is an intriguing question how these PTMs affect normal conventional tau 
functions or e.g. the recently suggested tau (mis)localization to dendritic postsynapse 
contributing to A?-NMDA receptor-mediated excitotoxicity (Ittner et al., 2010). 
Accordingly, the interactions of tau with proteins regulating its PTMs collectively 
determine not only the physiological or pathophysiological nature of a single tau molecule 
but may affect the entire pool of tau in specific cellular compartments owing to its ability 
to sequester additional physiological tau.  
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 Photoprotein-based protein-fragment complementation assays (PCA) are highly useful 
and widely utilized for studying protein-protein interactions (Tannous et al., 2005). 
Diverse properties of various photoproteins such as fluorescent (e.g. green fluorescent 
protein, GFP) and bioluminescent proteins (various luciferases) allow detection of 
differential phenomena in live cells. In fluorescent proteins the refolding of split reporter 
protein is an irreversible process enabling the examination of more rarely occurring 
protein interactions or complex formations, and generally localize cellular protein 
interactions and relocalization of possible complexes using small molecules that may 
disturb their normal balance (Hu et al., 2002; Michnick et al., 2007). Conversely, 
bioluminescence-based PCAs are suitable for studying dynamics and kinetics of protein-
protein interactions due to the mostly reversible nature of reporter protein refolding 
preventing the trapping of proteins in a complex (Remy & Michnick 2006). Multiple 
beneficial properties including reversibility, sensitive and real-time quantification and 
investigation of dynamics of protein-protein interactions and modulation of interactions 
by pharmacological and genetic methods, underline the suitability of luminescence-based 
PCA for high-throughput screening (HTS) purposes (Michnick et al., 2007). However, 
overexpression of reporter protein constructs and addition of substrate are required to 
obtain an active luminescence generating reaction in luminescence-PCA methods. Our 
assay validation work and proof-of-concept small molecule library screen using split 
Gaussia princeps luciferase (GLuc) PCA with a focus on Pin1-tau interaction pair 
revealed the suitability of this approach for studying tau protein interactions in live cells. 
Interestingly, the screen identified several sedative-hypnotic class compounds 
(benzodiazepines and barbiturates) commonly considered to have positive allosteric 
modulator activity on ?-aminobutyric acid type A (GABAA) receptor, as regulators of 
Pin1-tau interaction. Furthermore, an association of GABAA receptor modulation with 
increased tau phosphorylation was found in primary rat cortical neurons. 
 GABAA receptors belong to the superfamily of ligand-gated ion-channels and mediate 
most of the fast inhibitory neurotransmission in the mammalian brain (Jacob et al., 2008; 
Luscher et al., 2011). Moreover, GABAA receptors are clinically significant targets for 
multiple CNS active drugs such as anxiolytics, anti-convulsants and sedative-hypnotics. 
Beside the abundant expression in CNS, GABAA receptors are functionally expressed also 
in Neuro2A cells (Baraldi et al., 1979) that were utilized in our screen and further 
mechanistic studies. Different subunit composition of pentameric GABAA receptors result 
in varying expression, cellular localization and sensitivity of pharmacological and 
physiological properties, for example benzodiazepine-sensitive GABAA receptors are 
mostly located in the synapse while other types, such as GABAA receptors mediating tonic 
inhibition, are predominantly extrasynaptic, i.e. not located at synaptic sites (Brunig et al., 
2002). Hence, according to our data, benzodiazepine-induced increase was observed in tau 
phosphorylation at the AT8 phosphoepitope. Observed increase of tau phosphorylation 
remained at elevated level 24 h after washout of the drug in mature synaptically connected 
cortical neurons, an effect which appears to be predominantly mediated by synaptic 
GABAA receptors. Furhermore, the major inhibitory synapse scaffolding protein gephyrin 
is known to associate with synaptic GABAA receptors and microtubules (Prior et al., 1992; 
Essrich et al., 1998). Since stabilizing and regulating MT dynamics is a predominant tau 
function, this may implicate a function for tau in dynamic regulation of clustering or 
trafficking of GABAA receptors and could be also a modulation target of GABAergic 
 88 
synaptic signaling. Interestingly, it has been reported that GSK-3?-mediated regulation of 
GABAergic synapse formation occurs via gephyrin phosphorylation (Tyagarajan et al., 
2011). Importantly, a role for CDK5 in gephyrin-mediated stabilization of GABAA 
receptor clustering was recently reported (Kalbouneh et al., 2014). In hippocampal 
neurons, it was shown that shRNA-mediated knockdown and pharmacological inhibition 
of CDK5 significantly decreased phosphorylated gephyrin clusters and postsynaptic 
GABAA receptors. Also, site-directed mutagenesis and dephosphorylation by PP1/PP2A 
of gephyrin at Ser270 residue reduced CDK5-induced phosphorylation implicating Ser270 
as target site for CDK5 phosphorylation (Kalbouneh et al., 2014), which is the same site 
suggested to be phosphorylated by GSK-3? (Tyagarajan et al., 2011). In further 
examination of the effects of screen-identified GABAA receptor activators, our data 
suggest a mechanism involving CDK5 kinase but not GSK-3? in observed increase of tau 
phosphorylation.  
 Phosphorylation of GABAA receptor subunit ?3 is reported to play an important role in 
the regulation of GABAA receptor function, and, ?3 associates and is dephosphorylated by 
PP2A (Jovanovic et al., 2004). Our data suggest that increased GABAA receptor activity 
decreases PP2A-tau interaction without reduction of PP2A enzyme activity. Decrease in 
PP2A-tau interaction upon treatment of GABAA-active sedatives may result from 
compartment-specific expression variations of PP2A. Subsequently, a possible 
recruitment of PP2A for GABAA receptor ?3 subunit dephosphorylation and 
desensitization induced by persistent and strong GABAA receptor activation may further 
reduce the availability of PP2A to interact and dephosphorylate tau. Additionally, 
association of synaptic activity and PP2A with tau phosphorylation has been reported 
(Sun et al., 2012). Specifically, zinc released from synaptic terminal was suggested to 
result in tau hyperphosphorylation via inhibition of PP2A, which was reversed by zinc 
chelators. However, whether the level of synaptic activity contributes to regulation of tau 
phosphorylation remains to be elucidated.  
 Phosphorylation of multiple proline-directed serine and threonine residues located in 
the proline-rich region flanking the MBRD is a central mechanism regulating tau 
functions. Pin1 binds and facilitates dephosphorylation of tau by PP2A (Liou et al., 2003). 
Specifically, Pin1 acts on phosphorylated Thr231-Pro-motif of tau and catalyzes the 
cis/trans isomerization of peptidyl-prolyl bond (Lu et al., 1999). This isomerization 
facilitates the binding of PP2A to tau since PP2A is Pro-directed conformation-specific 
phosphatase (Zhou et al., 2000). Importantly, PP2A interacts with and deposphorylates 
trans isoforms of its target proteins, such as tau, which emphasizes the importance of 
Pin1-mediated cis/trans conversion of tau and subsequent restoration of its cellular 
functions via PP2A dephosphorylation. Additionally, Pin1 acts on phosphorylated Pro-
directed gephyrin sites and isomerizes its cis/trans conversion, which is suggested as an 
important mechanism of gephyrin-mediated regulation of glycine receptor function (Zita 
et al., 2007). Among the numerous cellular functions of Pin1, it has been suggested to act 
as a molecular timer in order to modulate the duration and amplitude of different cellular 
processes including e.g. cell signaling and neuronal function (Lu et al., 2007). Based on 
these observations and our data, Pin1-mediated prolyl isomerization of both tau and the 
scaffolding protein gephyrin may together regulate the duration and timing of GABAA 
receptor trafficking signals in the inhibitory synapse. Overall, GSK-3?, CDK5 and PP2A 
all have an essential role in both regulation of tau phosphorylation and GABAA receptor 
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clustering and trafficking. Both tau and gephyrin are tightly connected to MTs, which 
raises intriguing questions whether also tau has a role in GABAA receptor modulation or if 
regulation of tau phosphorylation is affected by activation and trafficking of GABAA 
receptors or MT-mediated cytoskeletal changes. Hence, studying the interaction of tau and 
gephyrin could provide novel insights on clustering and trafficking of GABAA receptors. 
However, whether there is a direct or indirect interaction between these proteins is yet to 
be established.  
 Tau phosphorylated at Thr231 has been described to appear early in human AD, 
particularly in cells containing pre-tangles (Luna-Munoz et al., 2007), and its CSF levels 
was reported to correlate with memory deficits in mild cognitive impairment (MCI) and 
AD (Hampel et al., 2010). Moreover, by using a specific antibody that is able to 
distinguish between cis and trans isoforms of Thr231 phosphorylated tau, cis isomer was 
observed early in human MCI and reported to accumulate in degenerating neurons and 
localize into dystrophic neurites (Nakamura et al., 2012). Additionally, tau in cis 
conformation at Thr231 site is unable to regulate MT dynamics and becomes increasingly 
resistant to dephosphorylation and protein degradation, which, in turn, leads to cellular 
conditions in which tau is more prone to aggregate. Interestingly, a recent study showed 
that initiation and possible progression of AD-like tau pathology could be prevented after 
traumatic brain injury (TBI) using a monoclonal antibody specific for cis-isoform, Thr231 
phosphorylated tau (cis mAb) (Kondo et al., 2015). TBI may cause acute neurological 
dysfunction and occasionally lead to development of more long-lasting events, such as 
chronic traumatic encephalopathy (CTE)  (e.g. Blennow et al., 2012; Smith et al., 2013; 
McKee et al., 2013) and is also considered as risk factor for AD (e.g. Guo et al., 2000; 
Mortimer et al., 1991). Acute production of Thr231 phosphorylated cis tau in neurons 
after TBI in mice and after stress in vitro was shown to result in disrupted MT networks, 
altered mitochondrial transport, interneuronal spreading and eventual apoptosis, a process 
termed ‘cistauosis’ that precede other markers of tauopathy (Kondo et al., 2015). 
Importantly, treatment of TBI mice with cis mAb inhibited cistauosis and halted the 
development and spreading of further tauopathy, and, also rescued multiple functional and 
structural TBI-related dysfunctions. These data strongly suggest cistauosis as an early 
disease process of TBI, CTE and AD, and that cis mAb may be an effective tool to 
diagnose and halt the spreading of tau pathology in the early stage of disease 
pathogenesis. The Pin1-tau PCA tool developed in this study provides an effective in vitro 
tool for studying cellular regulation and mechanisms that underlie accumulation of cis-tau 
in cells.    
 Emerging evidence of prion-like spreading of conformationally distinct protein 
aggregates, or ‘strains’, in various NDDs suggest a common mechanism for spreading of 
non-prion amyloidogenic proteins such as tau. Regardless of the mounting evidence of 
transcellular tau propagation in mouse models and human brain in anatomically 
interconnected areas, several questions according to exact mechanisms of cell-to-cell 
propagation still remain unanswered. Particularly, the molecular mechanisms of cellular 
tau secretion and uptake are poorly understood. Although a few intriguing mechanistic 
studies have reported how tau is translocated from intracellular to extracellular 
compartment by associating with various microvesicles and how tau is internalized into 
cells, the tau species predominantly involved in these processes still remains poorly 
characterized. Moreover, whether cell-to-cell propagation of tau in physiological and 
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pathophysiological conditions occurs via differential mechanisms is yet to be clarified. A 
novel PCA-based assay system for investigation of cellular secretion and uptake of 
soluble tau was developed in this study. The assay allows detection of secreted and 
internalized tau dimers. Dimerization is a fundamental step for further formation of higher 
order fibrils and aggregates (Friedhoff et al., 1998), and likely oligomers. Accordingly, in 
our split GLuc-based assay tau dimer is the minimal signal generating unit due to a 
refolding of complementary reporter protein fragments. However, PCA is incapable of 
distinguishing whether the detected signal is generated by tau dimers or higher order 
oligomers. Regardless of common limitations of the assay set up in relation to generally 
utilized cellular models, such as requirement of overexpression of reporter plasmids and 
C-terminally tagged tau, thorough assay validation for multiple critical parameters 
resulted in reliable approach to study cellular secretion and uptake of tau in live cells. 
Furthermore, Western blot analysis suggested spontaneous assembly of reporter-tagged 
tau into higher molecular weight and/or oligomeric species implicating that detected 
luminescence signal may be also originated from tau species larger than dimer.    
 Cellular secretion of tau to extracellular space is suggested to occur in association with 
microvesicles such as exosomes and ectosomes and in vesicle-free form (Barten et al., 
2011; Kim et al., 2010b; Chai et al., 2012; Dujardin et al., 2014a; Saman et al., 2012). In 
our system the portion of vesicle-associated tau secretion was less than 1% and more than 
99% of secreted tau was in vesicle-free form. Although it is possible that post-secretional 
release of tau from the microvesicles via unknown mechanism contributes to this balance, 
it seems that vast majority of tau released in our system is vesicle-free. Notably though, 
the internalization of vesicle-associated tau was slightly more active as compared to 
vesicle-free tau. Binding of extracellular, vesicle-free tau with cell surface HSPGs is 
reported to mediate tau internalization most like occurring via macropinocytosis (Holmes 
et al., 2013), a bulk fluid-phase endocytic mechanism. Additionally, it has been recently 
reported that trimer is the minimal propagating tau unit that is spontaneously uptaken into 
cells and capable to induce further seeding (Mirbaha et al., 2015). Internalization of 
different tau species via different mechanisms may result in various outcomes according 
to compartmentalization and cellular fate, such as degradation or rapid re-secretion of 
uptaken tau. The levels of tau uptake in our assay system were relatively low, which could 
be at least partially explained by re-secretion of tau following the uptake, a process typical 
to macropinosomes that undergo a rapid exocytosis resulting in bidirectional trafficking 
regulated by collective endocytic and exocytic coordination (Falcone et al., 2006). Based 
on our data, inhibition of ceramide generation by neutral sphingomyelinase, a main 
regulator of exosome biogenesis (Trajkovic et al., 2008), increased cellular levels of 
uptaken tau while it decreased the secretion of tau.  
 We performed an siRNA-based screen using 12 LOAD associated risk genes to study 
their potential functional link to cellular tau secretion and uptake. Knockdown of genes 
TREM2, CD33, CD2AP and FRMD4A showed significant decrease in tau secretion 
whereas only APOE gene affected tau uptake by increasing the signal in recipient cells. 
Since TREM2 and CD33 are predominantly expressed in microglial cells, we tested the 
knockdown effect of these genes on tau secretion in human fetal microglial cell line. The 
decrease upon siRNA-mediated gene knockdown observed in HEK293T cells was not 
recapitulated in microglial cells suggesting an off-target effect of used siRNAs rather than 
an effect targeted on TREM2 and CD33 expression and function. Interestingly, a recent 
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study reported that depletion of microglia significantly reduce tau propagation in vivo 
(Asai et al., 2015). Exosome-mediated tau spreading by microglia was suppressed by 
genetic and pharmacological inhibition of exosome synthesis both in vitro and in vivo 
suggesting a new role for microglia in propagation of tau pathology. These data strongly 
emphasize the importance of studying non-transsynaptic tau propagation mechanisms in 
addition those focusing on transsynaptic propagation. The finding that neither of the genes 
with proven functional roles in endocytosis, PICALM (Miller et al., 2011; Tebar et al., 
1999) and BIN1 (McMahon et al., 1997; Tan et al., 2013), had any effect on tau uptake 
was surprising and may indicate that cellular uptake of tau does not rely on receptor-
mediated endocytic mechanisms, such as clathrin-mediated endocytosis, but may be 
related to fluid-phase endocytosis mechanisms, specifically macropinocytosis, as has been 
suggested recently (Holmes et al., 2013). It should also be noted that different cell types 
may internalize tau using different mechanisms and at specific times. For example, due to 
extensive membrane turnover associated with macropinocytosis, neurons may perform 
macropinocytosis only during axonal development and remodeling  
 Based on the observations that FRMD4A expression is decreased in AD brain in 
relation to increasing disease severity according to increasing neurofibrillary degeneration 
and functional association to tau phosphorylation (II), we further examined the 
mechanistic basis of the FRMD4A-tau secretion finding. Our results clearly indicate that 
decreased expression level of FRMD4A reduce cellular tau secretion whereas 
overexpression significantly increase tau release.   
 Although very little is known about its function in mammalian cells, FRMD4A is 
involved in regulation of epithelial cell polarity in association with the Par polarity 
complex (Ikenouchi & Umeda 2010). FRMD4A connects Par3/Par6/aPKC? complex to 
Arf6 activation via cytohesins, a family of Arf6 guanine-nucleotide exchange factors 
(GEF). Signaling of Par polarity complex is essential in neuronal polarization (Insolera et 
al., 2011) and in various cellular membrane trafficking events such as vesicular secretion 
(Balklava et al., 2007). Recently, tau release from neurons was suggested to associate with 
plasma membrane fusion of presynaptic vesicles regulated by neuronal activity (Pooler et 
al., 2013; Yamada et al., 2014). Hence, considering that facilitation of synaptic 
transmission by direct interaction of cytohesin-1/mSec7 and Munc13-1, which is most 
likely resulting in increasing reserve of presynaptic vesicles ready to fuse with plasma 
membrane (Neeb et al., 1999; Ashery et al., 1999), the levels and activity of FRMD4A 
and cytohesins may correlate with the level of tau secretion. Interestingly, cellular tau 
secretion is suggested to increase A? generation in a process most likely regulated by 
neuronal hyperactivity (Bright et al., 2015). Additionally, since increase in extracellular 
level of A? is known to promote neuronal hyperactivity (Fogel et al., 2014; Busche et al., 
2008) and enhanced glutamatergic synaptic activity is reported to promote tau secretion 
from neurons (Yamada et al., 2014), these observation collectively suggest an existence of 
a feedback loop between A? production and tau secretion in pathogenesis and progression 
of AD. Also, considering our results suggesting an increase in tau phosphorylation by 
GABAA receptor activation, it remains to be seen whether GABAA receptor activation has 
an impact on tau secretion and uptake.     
 Extensive amount of evidence has been presented to support the prion-like propagation 
of amyloidogenic proteins in NDDs. Nonetheless, various discrepancies are observed 
when comparing data from mouse models of non-prion protein transmission and human 
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brain such as different time course of spreading and onset of pathology (Guo & Lee 
2014). Some of the inconsistencies could be explained for example by the size difference 
between mouse and human brain, the rate-limiting step of protein nucleation phase 
(Friedhoff et al., 1998) and utilization of overexpression mouse models (Guo & Lee 
2014). Hence, multiple concerns still exist before the suggested prion paradigm can be 
fully established. Nevertheless, strong evidence point toward a paradigm shift in 
neurodegenerative non-prion proteinopathies, such as co-transmission of A?-pathology 
after iatrogenic CJD-contaminated human growth hormone treatment (Jaunmuktane et al., 
2015) and the propagation of specific ?-syn prion strains from human MSA brain into 
transgenic mouse causing the disease (Woerman et al., 2015; Prusiner et al., 2015).   
 Taken together, our results identify a novel connection between GABAA receptor 
activation and tau phosphorylation, and, cell polarity complex signaling and tau secretion. 
Given the importance of polarized protein delivery into various plasma membrane 
subdomains for physiological functioning of cells, it is fundamental to further establish the 
exact molecular mechanisms of how synaptic activity and cell polarity complex may be 
involved in cell-to-cell propagation of tau in AD and related tauopathies.       
6.2 New insights into functional association of GWAS identified LOAD 
susceptibility genes with disease pathogenesis (II, III) 
 
The association of APOE with AD was discovered nearly three decades ago and was 
further confirmed as a genetic risk factor using candidate gene approach (Saunders et al., 
1993; Ignatius et al., 1987; Ignatius et al., 1986; Strittmatter et al., 1993; Corder et al., 
1993). Currently, besides aging, APOE is the strongest risk factor contributing to onset 
and pathogenesis of LOAD (Bettens et al., 2013). In the last ten years, a major 
technological advances such as large-scale genome-wide association studies (GWAS) 
allowing identification of millions of genetic variations covering the whole genome in a 
largely hypothesis-free experimental approach has produced tremendous amount of data 
improving knowledge of the genetic landscape of LOAD. Since there are currently 
approximately 700 AD-associated susceptibility genes, we focused on the top 10 genes 
presented in AlzGene database compiled from meta-analyses of published AD GWASs 
(Bertram et al., 2007) and two additional recently identified genes FRMD4A (Lambert et 
al., 2013a) and TREM2 (Jonsson et al., 2013; Guerreiro et al., 2013a). 
 Regardless of persistently growing number of possible novel LOAD-related 
susceptibility genes, the functional association and expression in relation to disease 
pathogenesis and progression are poorly understood. Although the exact cellular functions 
and direct association to established pathophysiological AD pathways of identified LOAD 
susceptibility genes are yet to be clarified, these genes can be classified in three distinct 
pathways, including lipid and cholesterol metabolism, immune system function and 
vesicle recycling and endocytosis with some overlap of genes between the classes (Jones 
et al., 2010; Bertram et al., 2008; Medway & Morgan 2014; Karch & Goate 2015). Of the 
10 LOAD genes studied, APOE and CLU (APOJ) are brain lipoproteins, BIN1 and 
PICALM are intracellular proteins associated with endocytic machinery and CD33, CR1 
and MS4A proteins are associated with immune and complement systems. Also, ABCA7 
is suggested to function in cholesterol and lipid metabolism, and, CD2AP in regulation of 
actin cytoskeleton reorganization. In our neuropathologically validated AD cohort the 
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expression of FRMD4A was decreased and the expression of MS4A6A was increased 
according to increasing AD-related neurofibrillary pathology.  
  FRMD4A has been associated as a susceptibility gene for LOAD (Lambert et al., 
2013a). The function and expression of FRMD4A in mammalian cells is in general poorly 
understood and its connection to AD pathogenesis is currently unknown. Interestingly, a 
homozygous coding region FRMD4A mutation was recently associated with autosomal 
recessive congenital microcephaly and intellectual disability, disturbed genesis of corpus 
callosum and dysmorphism in a Bedouin kindred (Fine et al., 2014). Specifically, the 
frame shift mutation resulting in truncation is located in the domain of FRMD4A that 
interact with Par3 (Fine et al., 2014), which is essential for regulation of cell polarity 
(Ikenouchi & Umeda 2010). We showed that siRNA-mediated genetic knockdown of 
FRMD4A is functionally associated with increased interaction of APP and BACE1 and 
corresponding increase of secreted A?40. Furthermore, decreased expression of FRMD4A 
increased the interaction of tau with both Pin1 and GSK-3? and was associated with 
altered phosphorylation status of tau. By studying the effect of LOAD susceptibility genes 
on cell-to-cell propagation of tau, we showed significant changes in tau secretion in 
relation to expression level of FRMD4A. Further mechanistic experiments confirmed the 
association of tau secretion with cell polarity complex signaling pathway. Activity of 
cytohesins, which play a crucial part in cell polarity signaling (Ikenouchi & Umeda 2010), 
and are also involved in synaptic transmission (Neeb et al., 1999; Ashery et al., 1999), 
were recently shown to be associated with ALS (Zhai et al., 2015). More specifically, 
pharmacological and genetic inhibition of cytohesins was shown to protect motor neurons 
and rescue locomotor defects in vitro and in C. elegans model of ALS, respectively. 
Complex formation of mutant superoxidase dismutase 1 (SOD1), a causal factor of 
familial ALS, and cytohesins was not associated with alterations in either activity of GEF 
or ARF activation. However, mutant SOD1-induced ER stress was mitigated upon 
decreased cytohesin activity resulting in reduced mutant SOD1-driven protein toxicity and 
enhanced autophagic flux. These observations in concert with our data suggest that 
FRMD4A-cytohesin-ARF signaling may have a significant role in neuronal protein 
homeostasis in general and possibly contribute to pathogenesis of several NDDs.       
 The amount of information regarding to impact of LOAD susceptibility genes to 
cellular secretion and uptake of tau is limited. Since tau is known to interact with some of 
the proteins encoded by LOAD susceptibility genes (APOE, BIN1, CLU and PICALM), it 
has been suggested that these genes may have a potential effect on cell-to-cell propagation 
of tau (Avila et al., 2015). Based on our data, gene silencing of APOE increased the 
internalization of tau, which may relate to previously reported property of tau to bind 
APOE (Fleming et al., 1996; Strittmatter et al., 1994). In addition to FRMD4A, our results 
showed that knockdown of CD2AP decreased cellular tau secretion and was associated 
with increased BACE1-APP and GSK-3?-tau interactions in the PCA-based in vitro 
platform. Also, reduced level of CD2AP expression altered tau phosphorylation. 
Interestingly, novel function for CD2AP in maintaining blood-brain barrier (BBB) 
integrity was recently reported suggesting a cerebrovascular role for CD2AP (Cochran et 
al., 2015) in addition to its roles in signaling between T cells and antigen presenting cells 
(Dustin et al., 1998) and in cell junction signaling in the kidney slit diaphragm (Shih et al., 
1999). Intriguingly, a recent study showed that depletion of tau in a tauopathy mouse 
model prevents progressive BBB damage (Blair et al., 2015). Given that tau-mediated 
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toxicity is reported to exacerbate upon CD2AP deficiency in Drosophila model of AD 
(Shulman et al., 2014), these data collectively implicate the involvement of both tau and 
CD2AP in regulation of BBB integrity, which may affect the late-stage AD-related 
vascular changes contributing to cognitive impairment and dementia. However, whether 
CD2AP-mediated BBB dysregulation is a cause or a consequence of pathological tau or 
how CD2AP deficiency may affect cell-to-cell propagation of tau is a subject of future 
studies.   
 Conversely to common identified variants, novel emerging sequencing techniques such 
as whole exome and whole genome sequencing have facilitated the discovery of 
additional rare coding mutations, e.g. in genes CD2AP, EPHA1, ABCA7 and BIN1 
(Vardarajan et al., 2015; Steinberg et al., 2015). Moreover, whether these novel and 
previously identified rare AD risk increasing variants such as TREM2 (Jonsson et al., 
2013; Guerreiro et al., 2013a) are connected to tau propagation is currently unknown. In 
our AD cohort, the expression of exons 3 and 4 of both genes TREM2 and CLU were 
increased related to increasing AD severity according to Braak staging. It was recently 
reported in a large meta-analysis that carriers of TREM2 SNP rs75932628 present 
significant increase in the level of CSF total-tau as compared to non-carriers suggesting 
that role of TREM2 in AD could be related to tau dysfunction (Lill et al., 2015). 
Furthermore, it was recently reported that microglial TREM2 is upregulated during 
disease progression in P301S mice and gene silencing of TREM2 in P301S mice brain 
exacerbated tau pathology (Jiang et al., 2015). More specifically, it was suggested that 
TREM2 silencing-induced increase of tau pathology and learning deficits may result from 
loss of ability of TREM2 to attenuate activity of tau related kinases. Additionally, a novel 
locus near MAPT gene encoding tau protein was identified to associate with LOAD 
particularly in patients lacking APOE ?4 allele (Jun et al., 2015). Hence, it will be 
interesting to see whether TREM2 is functionally connected to tau-related pathways in AD 
and if this is possibly mediated by differential APOE genotype. We observed an increase 
in expression level of MS4A6A in relation to increasing Braak stage severity in AD. In 
particular, there was a significant positive correlation between MS4A6A expression and 
microglial AIF-1 (encoding microglial marker Iba-1) gene expression, which is consistent 
with the previous finding (Karch et al., 2012b) further corroborating the suggestion that 
genes of MS4A -cluster are involved in immune system function (Ishibashi et al., 2001). 
Recently, MS4A gene cluster has been specifically associated with LOAD patients who 
are APOE ?4 non-carriers (Jun et al., 2015). In our APOE ?4-stratified cohort (36 carriers; 
24 non-carriers), we were unable to show this since majority of the patients in Braak 
group V-VI were APOE ?4 carriers whereas in Braak group 0-II, in which the expression 
level was normalized to, the majority were non-carriers. This inconsistency may be at 
least partially due to a small sample size of our cohort (n=60). 
 Level of ABCA7 expression was clearly indicated to associate with established 
pathophysiological pathways related to AD in our in vitro platform. Specifically, siRNA-
mediated gene silencing of ABCA7 resulted in increased BACE1-APP interaction and 
corresponding elevation of A?40 level. Furthermore, down regulation of ABCA7 was 
associated with increased tau interaction with both GSK-3? and Pin1. Interestingly, rare 
ABCA7 loss-of-function mutations were shown increase the risk of AD (Steinberg et al., 
2015). Recently, it was shown that ABCA7 loss-of-function mutations and decreased 
expression promote amyloidogenic APP processing in vitro and in vivo (Satoh et al., 
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2015). This is consistent with a previous study reporting that deletion of ABCA7 
significantly increased the amount of cerebral accumulation of A? in a mouse model of 
AD (Kim et al., 2013). These data strongly implicate an important role for ABCA7 in A? 
production. However, whether ABCA7 loss-of-function or depletion contributes to A? 
clearance remains to be elucidated.  
 Each individual common LOAD susceptibility gene identified to date has only a minor 
addition on conferring the overall risk of disease incidence strongly implicating the 
existence of missing, or more precisely hidden heriditary component (Lord et al., 2014). 
According to highly complex disease aetiologies of NDDs, such as LOAD, it is unlikely 
that this hidden genetic component will be discovered using a single methodology such as 
GWAS but requires combinations of various approaches complementing each other. 
Hence, epigenetics and epigenome-wide association studies (EWAS) among others could 
provide an additional tool to accompany the more established methodologies in order to 
reveal possible genotype-by-environment interactions, such as DNA methylation (Gibson 
2011; De Jager et al., 2014; Lunnon et al., 2014; Lord et al., 2014). Furthermore, large 
portion of the known LOAD associated SNPs are located in the non-coding regions of 
genes, which is significantly complicating functional studies of the impact of these 
variants to disease pathogenesis and pathophysiology. Moreover, considering the non-
coding region located SNPs and the subtle effect of each gene to disease onset, functional 
association studies are highly challenging and novel methodology is sorely needed to 
address this issue. Moreover, single gene silencing approach may not be able to detect 
epistatic interactions between LOAD genes. Indeed, one possible approach could be 
targeting the LOAD susceptibility genes in clusters, i.e. since some identified genes can 
be classified for e.g. involving endocytosis and vesicle transport, it may prove efficient to 
investigate a cluster of genes associated to particular cellular phenomenon with varying 
endpoint measurements.          
 Overall, in our study combining the expression and splicing status of LOAD 
susceptibility genes in AD brain and functional association of disease pathogenesis in 
established pathways in vitro, we show the differential expression of MS4A6A, FRMD4A, 
TREM2 and CLU during progression of AD-related neurofibrillary pathology. 
Furthermore, FRMD4A, CD2AP and ABCA7 are associated with both amyloidogenic APP 
processing and altered tau phosphorylation in vitro. Moreover, the expression level of 
FRMD4A and CD2AP modulates the cellular secretion of tau. Finally, our mechanistic 
studies on FRMD4A suggest that tau secretion may be affected more generally by cell 
polarity complex Par3/Par6/aPKC? signaling via cytohesin-mediated Arf6 activation.   
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7 Concluding remarks and future prospects 
 
Microtubule-associated protein tau is an essential regulator of cellular and particularly 
neuronal function via modulation of microtubule integrity and dynamics. Abnormal tau 
function upon disequilibrium in various posttranslational modifications such as 
phosphorylation, contribute to detachment from MTs, aggregation and to cell-to-cell 
spreading of tau pathology and subsequent neurofibrillary degeneration in numerous 
neurodegenerative diseases (NDDs), including Alzheimer’s disease (AD) and other 
tauopathies. This thesis provides new insights into cellular tau physiology and suggests a 
novel mechanism regulating cellular secretion of tau.  
 Firstly, we have developed and validated a novel method based on protein-fragment 
complementation assay (PCA) to study protein-protein interactions of tau in live cells (I, 
II, III). Moreover, PCA-based in vitro platform is suitable for investigating dynamic 
changes upon pharmacological and genetic modulation of protein-protein interactions of 
tau and other established pathogenic protein pathways in AD (I, II). Additionally, we have 
further validated these assays to effectively examine cellular secretion and internalization 
of tau in live cells (III). 
 Secondly, our proof-of-concept chemical library screen identified GABAA receptor 
modulators, such as benzodiazepines, as novel modulators of tau phosphorylation (I). 
Accordingly, the increased tau phosphorylation at the AT8 phosphoepitope, which is 
aberrantly phosphorylated in AD and related tauopathies, is most likely a result of reduced 
tau binding with protein phosphatase 2A and dependent on CDK5 protein kinase. 
 Thirdly, we show that the expression of LOAD susceptibility genes MS4A6A is 
increased and the expression of FRMD4A is decreased in regards to increasing AD-related 
neurofibrillary pathology in temporal cortex of post mortem patient samples of our 
neuropathologically validated AD cohort (II). Based on our in vitro data, FRMD4A is 
functionally associated with both established pathogenic AD-pathways: amyloidogenic 
APP processing and increased tau phosphorylation. 
 Finally, we showed that the expression level of FRMD4A modulates cellular tau 
secretion (III). Based on our mechanistic studies, we revealed a novel connection between 
cell polarity complex Par6/aPKC?-FRMD4A-cytohesin-Arf6 signaling pathway and 
cellular tau secretion hereby for the first time, implicating a functional association 
between a LOAD susceptibility gene and a central pathological spreading mechanism of 
the disease.  
 The constantly growing list of disappointing outcomes of clinical trials assessing 
potential therapies for AD and other NDDs strongly emphasizes the urgent need for better 
understanding of the risk factors and aetiology of these disease, hopefully leading to 
development of disease-modufying treatments and more effective preventive measures in 
the future. Owing to this, it is initially crucial to investigate and establish the exact 
molecular mechanism(s) how amyloidogenic proteins such as tau are posttranslationally 
modified and how these modifications further affect the secretion and internalization of 
misfolded and aggregated proteins by cells. Answering these fundamental mechanistical 
questions regarding NDD pathogenesis and pathophysiology is expected to provide a 
major leap toward the development of strategies to halt the progression of disease-specific 
pathology.    
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